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ABSTRACT

PARP PET IMAGING AGENTS
by
Brandon Carney

Advisor: Professor Lynn C. Francesconi & Professor Thomas Reiner

The poly (adenosine-diphosphate (ADP) ribose) polymerase (PARP) family of enzymes has
been of interest to researchers and clinicians for over fifty years, especially the first member of
the family, PARP1. This enzyme has become a target for cancer therapeutics due the reliance
of highly proliferating cells on PARP1 for genomic maintenance. In the coming age of
individualized medicine, however, highly specific therapeutic agents like PARP inhibitors are in
need of similarly highly specific companion diagnostic agents. These kind of agents have been
made possible with the quickly progressing field of molecular imaging. Specifically, positron
emission tomography (PET) has enabled the clinician to observe functional information about
patients at a whole body level, and non-invasively. Our goal was to develop and validate an
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labeled PARP-targeted molecular imaging agent with the ultimate goal of translation to the
clinical setting. To that end, we have developed [18F]PARPi and tested it in animal models of
many different kinds of disease. Over and over again, we see that [18F]PARPi uptake clearly
and specifically reveals information about PARP1 expression and therapeutic target
engagement. This information could serve a crucial role in patient stratification and treatment
monitoring where PARP targeted therapeutics are being considered. In addition, PARP targeted
PET imaging provides a new diagnostic and prognostic tool for diseases that currently lack good
options for this purpose. In summary, these investigations serve as preclinical validation of
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[18F]PARPi, and serve as the basis for future preclinical and clinical exploration of the
possibilities of PARP PET imaging in conjunction with PARP targeted therapies.!
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CHAPTER 1: PARP BIOLOGY AND THE DEVELOPMENT OF PARP
INHIBITORS

1.1:

Introduction

The poly (adenosine-diphosphate (ADP) ribose) polymerase (PARP) group of proteins is a 17
member family of enzymes that share a similar catalytic domain1. PARP biology and PARP
inhibitor technology has been widely studied and it is beyond the scope of this chapter to
present a thorough review of the literature on this topic, about which an entire book of reviews
has been written2. However, it is essential to present at least a brief overview of the PARP
biology to understand the potential utility and limitations of PARP imaging agents, as well as the
structural requirements of these agents.
The PARP family of enzymes, sometimes referred to as ADP-ribosyltransferases (ARTs), plays
many roles in the DNA repair process (Figure 1.1.1). The first enzyme discovered in this family,
PARP1#

Ionizing#
Radia/on#

UV#

PARP1#

ROS#

PARP1#

Alkyla/ng#
Agents#

DNA#Repair#
Enzymes#

DAMAGE#
PARP1#

DNA#Repair#
NAD+/ATP#

CELL#RECOVERY#

DNA#Degrada/on#

NECROSIS#

APOPTOSIS#
Figure 1.1.1. Overview of PARP1 as a DNA repair enzyme.
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PARP1, is the most studied, but there is an increasing interest in other members of this family3,4.
Only 6 members are thought to actually produce poly (ADP-ribose) (PAR) chains, and only 3
PARPs (PARP1, PARP2, and PARP3) can bind to DNA. Interestingly, knockout mice can
survive in the absence of PARP1 or PARP2, but not when both are deleted5. The same has
been shown for PARP5A and PARP5B (also referred to as the tankyrase enzymes, TNKS1 and
TNKS2)6. PARP1 is overexpressed (expression raised above that in the healthy cells of the
analogous organ, e.g. breast cancer compared to normal breast tissue) in many cancer types,
but the same has not been found for other PARP enzymes, including PARP27. Therefore,
PARP1 is most relevant member of the PARP family for imaging applications and was the focus
of all studies described in this work.
1.2:

PARP1 in the DNA Repair Response

Figure 1.2.1. Biological function of PARP1. PARP1 detects and binds to sites of DNA damage.
PAR chain formation causes the unwinding of DNA from the histones and also recruits other
DNA damage repair proteins to the damage site. Modified and reprinted from Ferraris. J Med
Chem, 2010.
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DNA endures thousands of lesions everyday from sources such as ionizing radiation and
ultraviolet light and also through the normal process of proliferation. There are many proteins
involved in the DNA damage response (DDR) with a wide range of functions that together serve
to repair the DNA so that the cells can remain viable and functional (Figure 1.1.1). PARP1 has
been shown to be especially important with concern to single strand breaks (SSBs) by being a
critical factor in base excision repair (BER)8,9, although it also plays a role in other repair
pathways such as homologous recombination repair (HR)10, non-homologous end joining
(NHEJ)11 and nucleotide excision repair (NER)12. One major mechanism by which PARP1 aids
in DNA repair is through the nicotinamide adenine dinucleotide (NAD) dependent ADPribosylation of the histones or other chromatin proteins. The negatively charged polymers relax
the tertiary structure of the chromatin which causes the DNA to unwind and allows other DNA
repair factors access to the damage site13,14 (Figure 1.2.1).
In addition to histone ribosylation, PARP1 aides in recruitment of other DNA factors through the
high affinity of these factors to either PARP1 itself (e.g. TDP115) or to the PAR chains it creates
(e.g. XRCC116). The subsequent dissociation of PARP1 from the DNA is also important to the
repair process, without which other repair factors cannot access the damage site17. This is
especially relevant to a recently discovered mechanism of PARP inhibitor induced cell killing,
called PARP trapping18, which will elaborated upon in section 1.7 below.
1.3:

Two Enzymatic Conformations

PARP1 is a 1014 amino acid, 113 kDa enzyme that can be thought of as consisting of seven
discrete domains. Three zinc finger domains (Zn1-3) are responsible for detecting and binding
to DNA damage sites19. These are attached to the catalytic subdomains through the BRCA1
C-terminus domain (BRCT) and the tryptophan-glycine-arginine (WGR) domain. The BRCT
domain serves as the primary target for automodification (also called autoPARylation)20, which
will be discussed in section 1.4 below. The WGR domain has the primary function of
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Figure 1.3.1. Two enzyme conformations. Upon binding to DNA, PARP adopts a compact
conformation that greatly elevates catalytic activity. Modified and reprinted from Langelier &
Pascal, Curr Opin Struct Biol, 2013.
communicating between the zinc finger domains at the catalytic domain (CAT)21. The catalytic
domain consists of two subdomains, the helical subdomain (HD) and the ADP-ribosyl
transferase subdomain (ART). The HD subdomain is the primary recipient of communication
from the zinc fingers, and is primarily responsible for regulating the catalytic activity, which is
increased when a certain leucine residue is displaced by the WGR domain21. The ART domain
is the site which binds the NAD+ and performs the catalysis22,23. This domain serves as the basis
for the definition of the PARP family, and is therefore conserved across all 17 members.
The PARP1 enzyme exists in one of two different conformational states based on whether or
not it is bound to DNA (Figure 1.3.1)24. While there is some catalytic activity (=PARylation) in the
unbound conformation, binding to DNA causes a shift to a more compact conformation which
increases catalytic activity more than 500-fold. Since the NAD+ substrate can be present in
either of these conformations, nicotinamide mimicking imaging agents cannot differentiate
between the relatively inactive unbound enzyme and the highly active bound enzyme. This is
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important because it means that nicotinamide based tracers can not predict PARylation activity,
but can only predict PARP enzyme expression. In fact, these kinds of tracers have only shown
correlation with PARylation when this also correlated with PARP expression levels25, but not
when these two variables did not correlate26.
1.4:

The Enzymatic Cycle

PARP enzymes form linear or branched polymer chains composed of up to 200 ADP-ribose
units14. By catalyzing the hydrolyzation of the NAD+ substrate, the enzymes are responsible for
the three steps of PAR anabolism (Figure 1.4.1) by attaching a single ADP-ribose unit to either
an acceptor protein (step 1, mono-ADP-ribosylation) or to another ADP-ribose unit (steps 2 & 3,
elongation and branching). Acceptor proteins are modified at charged amino acids within the
protein (lysine, arginine, glutamate or aspartate), and can be the enzyme itself (usually at the

Figure 1.4.1. Chemical function of PARP1. Anabolism shown in red, catabolism shown in
green. Glycosidic cleavage sites indicated by green arrows. Modified and reprinted from
Rouleau et al. J Cell Sci, 2004.
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BRCT domain, termed automodification), histones (especially the linker histone H1 and the core
histones H2A and H2B), or high-mobility group (HMG) proteins. Whether elongation or
branching occurs is based on which of the two ribose units accepts the addition on the acceptor
ADP-ribose unit (Figure 1.4.1). Nicotinamide is produced as a byproduct of the hydrolyzation
reaction and – without ADP-ribose – acts as a mild inhibitor of PARP enzymes (PARP1 Ki = 5.7
µM27) which serves to help regulate the enzymatic process. Branching occurs after 20-50 ADPribose units, but does not occur with all members of the PARP family. Catabolism is performed
by the poly (ADP-ribose) glycohydrolase (PARG) enzyme, which generates both free ADPribose units and free PAR polymers by hydrolyzing glycosidic bonds either at the end of the
polymer chain (exoglycosidic activity) or in the middle (endoglycosidic activity).
1.5:

PARP inhibitors

PARP mediated DNA repair is important for the survival of many cancerous cell types, and
leads to resistance against DNA damaging chemotherapeutics28. Therefore, PARP inhibitors
were developed with the initial goal of working in combination with DNA damaging therapies
such as certain chemotherapeutics and ionizing radiation to increase the DNA damage load
while simultaneously decreasing the ability to repair such damage, eventually leading to cell
death. In addition to combination therapy, by blocking BER, PARP inhibition leads to the
accumulation of unrepaired single-strand DNA breaks (SSBs), which develop into double strand
breaks (DSBs) in replicating cells. These DSBs require HR repair for continued cell survival.
This leads to the possibility that PARP inhibition might be used as a monotherapy in cases
where the cancer cells are deficient in this DNA repair pathways. (e.g. BRCA1/2 mutants29).
This approach has been termed “synthetic lethality”.
The first inhibitors were simple modified benzamides based on the nicotinamide byproduct of
the PAR synthesis, which, as was pointed out before, is itself a mild inhibitor. Benzamides were
preferred for specificity reasons as nicotinamide is involved in a number of other cellular
processes not related to PARP30. It was found that the ring nitrogen was unnecessary for PARP
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Figure 1.5.1. PARP inhibitors. Shown here are the NAD+ natural substrate PARP1 and a
selection of nicotinamide mimicking PARP inhibitors including all of those that have reached
phase 3 clinical trial. Iniparib is included even though it was shown not to be a PARP1 inhibitor
after the unsuccessful conclusion of a phase 3 trial. Also shown are AG14361 and AG14031,
which have inspired some imaging agent analogues, and UPF1069, which is currently the most
selective inhibitor for PARP2. The nicotinamide mimicking moiety in each molecule is
highlighted in blue.
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inhibition, but that without it, the molecule could not be metabolized by NAD-biosynthetic
enzymes. It was further found that the amide moiety was necessary for the inhibitory effect, and
that substitutions were best tolerated at the position -3. It was found that, in particular, hydrogen
bond acceptors or donors at this position improved potency (e.g. Figure 1.5.1: rucaparib,
veliparib and talazoparib). Additional studies showed improved potency when the amide was
fused into a bicyclic31 or pseudo-bicyclic32

(e.g. Figure 1.5.1: veliparib and niraparib) ring

system so that the amide is locked into the best conformation for PARP inhibition. It was also
shown that a heteroatom in position -5 improves potency32 (e.g. Figure 1.5.1: rucaparib and
talazoparib). Cocrystallization studies confirmed all of these findings and revealed a large
hydrophobic

pocket

adjacent

to

the

nicotinamide

binding

site

referred

to

as

the

Figure 1.5.2. Molecular design considerations for PARP inhibitors. (a) Schematic drawing from
cocrystallization studies showing hydrogen bonds (dashed lines) and hydrophobic contacts
(parallel lines). Modified and reprinted from Ruf et al. Biochemistry. 1998. (b) Summary of
inhibitor design principles. Modified and reprinted from Ferraris. J Med Chem, 2010.
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adenine-ribose binding site (Figure 1.5.2a)23. Further development of inhibitors uses this pocket
to add groups to improve potency, solubility, or other properties (Figure 1.5.2b)33.
To date, six PARP inhibitors have reached stage three clinical trials. One of them, iniparib, was
shown to not be a true PARP inhibitor only after it had entered stage three trials. Although
iniparib showed positive results in phase two trials with triple negative breast cancer (TNBS)34,
the drug failed in phase three35. In fact, the failure of iniparib might have been the end of clinical
evaluation of PARP inhibitor therapy in general had it not been discovered that iniparib is in fact
not actually a PARP inhibitor at all36. These studies show the importance of proper preclinical
evaluation of potential therapeutics before they enter clinical trials37. Furthermore this validates
the development of PARP imaging agents insofar as these imaging agents might serve as tools
for evaluating therapeutics before they reach the clinic.
Of the other five inhibitors (Table 1.5.1), three have made it to FDA approval. The first was
olaparib, which was approved in December 2014 for treatment of BRCA mutated advanced
stage ovarian cancer38. Since then, two others, rucaparib in December 201639 and niraparib in
March 201740 have been approved for the same disease. In addition to these successes, there
have been two phase three failures for veliparib, one in non small cell lung cancer (NSCLC) and
the other in TNBS. Unlike iniparib’s failure, it is possible in these cases that failure does not

Table 1.5.1. Properties of PARP inhibitors and summary of trial information.
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mean that veliparib is completely ineffective. For instance, it could be that only a certain patient
subgroup responds and therefore patient selection has to be improved. This is something that
PARP imaging agents could be useful for. There is one other late stage PARP inhibitor,
talazoparib, for which phase three results have not yet been reported, but looks promising in
preclinical studies due to its superior trapping ability.
1.6:

Rucaparib and olaparib

Most of the imaging agents presented in the following sections are based on either rucaparib or
olaparib, both of which have been FDA approved for the treatment of advanced stage ovarian
cancer. As such, it is helpful to provide an overview of the evolution of the chemical structures of
each of these compounds in order to better understand the possibilities each provides for
modification with respect to the introduction of an imaging moiety.
1.6.1

Rucaparib

The development of rucaparib (Figure 1.6.1) began with the identification of benzimidazole
carboxamide as a particularly potent pharmacophore (Ki = 95 nM)41. It was then found that
addition of a benzene ring to position -2 significantly increases potency (Ki = 15 nM with H
instead of OH in Figure 1.6.1). These bicyclic compounds displayed potent in vitro activity but
suffered from problems such as poor specificity, poor physical properties (low solubility, low
melting points), and unfavorable pharmacokinetic profiles, or had in vivo side effects42. These
problems were overcome by locking the benzamide in the s-trans conformation via a ring
connection. The incorporation of ionizable substituents in the benzene ring was mainly to
improve solubility, although an improvement in potency was also noticed. Further optimization
resulted in the eventual clinical candidate43, but the important thing to note here is that the
imaging agents based on rucaparib all sacrifice the ionizable benzene substituents in order to
attach the imaging moiety, hence potentially sacrificing potency and solubility.
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Figure 1.6.1. Evolution of the chemical structure of rucaparib. Modified and reprinted from
Ferraris. J Med Chem, 2010.
1.6.2

Olaparib

The development of olaparib began with the several bicyclic compounds, the most successful of
which was phthalazinone44. As with rucaparib, the addition of a benzene ring improved potency.
The fluoro substitution at the para position on this benzene ring was found to increase cellular
potency more than two-fold45. Further studies showed that a wide variety of substituents were
tolerated at the meta position on the benzene ring46, and this was exploited to introduce a
piperazine, which greatly improved aqueous solubility. However, clinical demand necessitated
further optimization to improve oral availability. It was reasoned that oral availability was
impeded mainly by the high pKa of the secondary amine of the piperazine group, and so several
acyl substitutions were studied, with cyclopropyl methanone chosen in the end because it
showed improved cellular potency compared with methyl and ethyl acyl groups. It is important to
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Figure 1.6.2. Evolution of the chemical structure of olaparib. Modified and reprinted from
Ferraris. J Med Chem, 2010.
highlight that this cyclopropyl had only a modest effect on inhibitory potency, since this group is
replaced in all of the imaging agents based on olaparib.
After it was revealed that olaparib is a P-glycoprotein (P-gp) substrate47,48, which caused drug
resistance by rapid removal of olaparib from the intracellular space, AZD2461 was developed as
a close analogue to olaparib but with lower P-gp affinity49. AZD2461 replaced olaparib’s
1-cyclopropylcarbonyl-piperazine with a 4-methoxy-piperidine. It is notable that, although
PARP1 affinity is unaffected by this substitution, PARP3 affinity is greatly reduced in AZD2461
compared to olaparib50. This is important because all of the imaging agents based on olaparib
also replace the cyclopropyl group, not to decrease P-gp affinity but to add imaging functionality.
The imaging agents that have been examined with regard to PARP3 affinity also show
decreased PARP3 affinity compared to olaparib (see Figure 6.2.1 in chapter 6 below).
1.7

Talazoparib and PARP trapping

Talazoparib plays an important role in the small cell lung cancer (SCLC) studies presented in
chapter 6. This molecule is of particular interest in SCLC due to its superior PARP trapping
properties (Table 1.5.1), which have been found to be especially important for the treatment of
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SCLC in particular51 and could prove to have wide ranging ramifications for PARP treatment in
general. As such, it is useful to here give an overview of this mechanism of action, which is
different from the normal inhibitory mechanism that was the aim of the original development of
the first PARP inhibitors.
PARP trapping is a process where prolonged binding of a PARP inhibitor prevents dissociation
of the PARP enzyme from the damage site on DNA, which prevents DNA replication and
transcription9. While catalytic inhibition blocks BER and leads to synthetic lethality in cells
deficient in HR (see section 1.5), PARP trapping is thought to lead to many different kinds of
damage requiring many different kinds of repair. Mutations affecting these other repair pathways
cause sensitivity to trapping agents such as olaparib and rucaparib, but not to inhibitors showing
poor trapping ability such as veliparib52, which leads to much greater potential for monotherapy
options. The trapping mechanism was demonstrated by detecting PARP DNA complexes in
cells treated with PARP inhibitors52. Trapped PARP–DNA complexes are more cytotoxic than
unrepaired SSBs caused by PARP inactivation, and the mechanism also explains why PARP
inhibitors exhibit significantly greater cytotoxicity than the absence of PARP1 altogether, and
why the cytotoxicity of PARP inhibitors was eliminated by deletion of the PARP1 gene (Figure
1.7.1)52,53. This has lead to the question of whether PARP inhibition could be used by itself as
DNA damaging agent for use as a monotherapy in the treatment of cancer.

Figure 1.7.1. Enzymatic requirements of PARP inhibitor treatment. Modified and reprinted from
Murai et al. Mol Cancer Ther, 2014.
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One important note here is that although the PARP trapping mechanism is not independent of
the catalytic inhibition mechanism of PARP inhibitors, the trapping ability of a PARP inhibitor
does not track with its ability to inhibit PARylation (synthesis of PAR chains)52,54. The trapping
ability has been shown to be dependent on the structure of the molecule, especially that part of
the structure outside of the nicotinamide mimicking moiety. For instance, olaparib and
talazoparib have the same phthalazinone core, but very different trapping properties53.
Talazoparib’s trapping ability is said to be highly dependent on its stereochemistry outside the
phthalazinone core53, although its enantiomer, LT674, is also several orders of magnitude lower
in inhibitory potency (IC50 = 144 nM)55.
The elucidation of the PARP trapping mechanism may revolutionize the development of PARP
inhibitor therapy, although it is important to note that trapping ability also correlates with greater
toxicity to normal tissue54. Dosing limitation due to this toxicity may prove to be proportionally
disadvantageous to the benefit of greater trapping ability. This trapping mechanism is also an
interesting area of exploration for PARP imaging agents as well, and it is even true that since
PARP imaging agents are themselves inhibitors, the imaging agents themselves must also
exhibit this trapping property. However, it remains to be seen whether this property has any
effect on a PARP imaging agent’s utility.
1.8:

Conclusion

The design and scope of PARP imaging research is grounded in the PARP research
accumulated over the past fifty years, and what has been presented here is only a short
summary. Although much progress has been made in this field of study, there are still many
areas that need further exploration, and PARP imaging technologies could prove to be
extremely powerful tools in this area. The ultimate goal, however, of the development of PARP
imaging agents is their clinical translation. PARP inhibition therapy is rapidly being implemented
in the clinic, and it is likely that this kind of therapy will find relevance in a variety of diseases. As
PARP imaging agents begin to enter the clinic, these imaging techniques may begin to play a
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central role in the implementation of PARP targeted therapies. With the recent push towards
personalized medicine56, and the patient stratification and treatment monitoring techniques
offered by highly specific imaging agents, PARP imaging agents have the potential to provide
essential information to the clinicians who are providing PARP targeted therapies. It is with this
motivation in mind that the development of PARP imaging agents progresses.
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CHAPTER 2: PARP IMAGING AGENTS
This chapter is an adaptation of published work, and is reproduced in part, from Carney, B.,
Kossatz, S. & Reiner, T. Molecular Imaging of PARP. J Nucl Med (2017). Copyright

2.1:

Introduction

Biomedical imaging has revolutionized medical science. Preclinically, it has helped to transform
our understanding of biology, and clinically, it has greatly advanced our ability to diagnose and
treat disease. Our goal has been to develop imaging agents based on PARP inhibitor
technology so that we can take advantage of the preclinical and clinical benefits that biomedical
imaging offers. PARP based optical imaging agents could be used for both diagnostic purposes
and to improve surgical procedures through intraoperative imaging. Radiolabeled probes would
allow direct measurement of PARP expression in patients, with the goal of improving patient
stratification, quantification of target engagement of therapeutic inhibitors and non-invasive
treatment monitoring. It is with these goals in mind that we describe the current state of the art
of PARP imaging technology.
2.2:

Fluorescently Labeled PARP Imaging Agents

The development of optical PARP agents is challenged by the intranuclear localization of
PARP1/2. Hence, imaging requires targeting vectors that can freely cross both cell membranes
and the nuclear envelope, and do not lose this ability after their conjugation with a fluorescent
dye.
2.2.1: BODIPY Labeled Compounds
The most published optical PARP reporter, PARPi-FL1–12 (half maximal inhibitory concentration
(IC50)=12.2 nM), is structurally similar to the Food and Drug Administration approved olaparib13
(IC50=5.0 nM14). The fluorescence signal of PARPi-FL stems from the dye BODIPY-FL
(excitation maximum/emission maximum, 503/512 nm), which was covalently linked to the
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Figure 2.2.1. Fluorescent PARP imaging agents. Nicotinamide mimicking benzamide moiety is
highlighted in blue and fluorescent moieties are highlighted in green.

Table 2.2.1. Properties of fluorescent PARP imaging agents.
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olaparib scaffold (Fig. 1)9. High-contrast imaging of PARP1-expressing nuclei in vitro and in vivo
implies high cell permeability and rapid washout of unbound PARPi-FL3,5,7,9,12, indicating that the
dye conjugation and resulting increase in molecular weight (PARPi-FL, 640 g/mol; olaparib, 435
g/mol) do not strongly perturb the molecule’s binding affinity and cell permeability. Uptake
specificity was shown by correlation of PARP1 protein expression and PARPi-FL retention, as
well as by the ability to block PARPi-FL uptake by saturating PARP with olaparib9. One set of
studies3,4 presented PARPi-FL as a tool to measure drug–target interaction in real time at
subcellular resolution in vitro and in vivo using multiphoton fluorescence anisotropy microscopy.
The anisotropy value of an excited fluorophore is linked to its mobility and hence provides
insight into its binding state. The earlier study3 showed anisotropy measurements of PARPi-FL
in vivo using a window chamber model. Later4, an indirect anisotropy approach was used to
measure pharmacodynamic parameters of olaparib, allowing the identification of single cells that
featured a low occupancy despite a high average target engagement.
Another study1 presented an activatable version of PARPi-FL where an inactive, photo-caged
BODIPY dye was conjugated to the olaparib scaffold (PARPi-BODIPYc; IC50=32nM). Ultraviolet
light (350-410 nm) converted it to its fluorescent version, PARPi-BODIPYa (IC50=68nM) by
photolytic cleavage of the 2,6-dinitrobenzyl caging group. Up to 3 hours of washing were
required to receive a crisp nuclear signal of PARPi-BODIPYa, compared to 10 minutes for
PARPi-FL, indicating decreased cell permeability and clearance (Figure 2.2.2a).
PARPi-FL is the only optical PARP imaging agent that has been verified to accumulate in
tumors in vivo. The first study5 to do so used PARPi-FL to image U87 and U251 orthotopic and
subcutaneous glioblastoma xenografts ex vivo and found tumor/brain and tumor/muscle ratios
>10 at 1 hour p.i. (i.v.), suggesting that PARPi-FL could be useful for intraoperative imaging of
glioblastoma. PARPi-FL was also used for imaging of oral squamous cell carcinoma (OSCC).
One study6 found increased PARPi-FL uptake 48 hours after irradiation which correlated with an
increased PARP1 expression, suggesting that tumor response to radiation can be quantified.
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Another study7 showed specific high contrast imaging (tumor to muscle/trachea/tongue ratios
>3) in orthotopic OSCC models 90 min p.i. using clinical imaging instruments including a
fluorescence endomicroscope and a surgical stereoscope (Figure 2.2.2b). This study also
showed the feasibility of topical application of PARPi-FL, which accumulated in OSCC tumors
after a 2 min application interval and reported penetration and nuclear accumulation of
PARPi-FL >250 µm deep into tumor tissue (Figure 2.2.2c).

Figure 2.2.2. Fluorescent PARP imaging agents1,7,12,15. (a) In vitro staining with various
fluorescent PARP inhibitors. (b) In vivo imaging of orthotopic oral squamous cell carcinoma with
PARPi-FL using fluorescence stereoscope, confirmed by histology. (c) In vivo imaging of
orthotopic oral squamous cell carcinoma xenografts after a 2-min topical application of
PARPi-FL. H&E = hematoxylin and eosin.
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2.2.2: Optical imaging of PARP1 in the NIR
PARPi-FL is limited by low tissue penetration of the BODIPY-FL fluorescence (Exmax/Emmax:
502nm/510nm). Imaging in the near infrared (NIR) spectrum (600-900nm) would allow for
improved tissue penetration and therefore higher signal to background. AZD2281-TexasRed16
(IC50=15.4nM;

596nm/615nm),

was

produced

by

bioorthogonal

trans-cycloctene

(TCO)/tetrazine(Tz) cycloaddition. In vitro imaging showed nuclear accumulation after first
adding TexasRed-Tz, followed by AZD2281-TCO (Figure 2.2.2a), while a pre-reacted full-sized
AZD2281-TexasRed (1536 g/mol) showed reduced cell permeation. A study17 that adapted this
modular approach using AZD2281-TCO and Cy5-Tz also showed in vitro nuclear staining, but
did

not

report

IC50

values.

A

labeling

strategy

similar

to

PARPi-FL

produced

Olaparib-BODIPY65012 (IC50=92nM; 646/660nm, 895 g/mol). The increase in size and
hydrophilicity (cLogP of 6.0; PARPi-FL: 4.0) presumably affected permeability and off-target
clearance, requiring in vitro washing intervals of 2 hours to visualize the nuclear staining (Figure
2.2.2a).
Charge was also reported as a significant factor in cellular distribution15. One study labeled
olaparib with a new class of cell permeable silicon containing rhodamines (SiR, 653/670nm).
These SiRs contained either a methyl group (SiR-Me) or a carboxyl group conjugated directly
(SiR-COOH) or via a short aliphatic spacer (SiR-spacer-COOH). Olaparib-SiR-Me (IC50=99nM;
MW=792 g/mol; cLogP=4.23) was cell permeable but only accumulated in mitochondria. The
negatively charged Olaparib-SiR-COOH (IC50=100nM; MW=822 g/mol; cLogP=3.74) showed
cytoplasmic staining, comparable to Olaparib-BODIPY 650. However, Olaparib-spacer-SiRCOOH (IC50=112nM; MW=978 g/mol; cLogP=3.59) allowed imaging of nuclear PARP1,
following a standard PARPi-FL staining protocol with a short wash (Figure 2.2.2a). This
indicates that neutralization of the negative charge of SiR-COOH and increased hydrophobicity
introduced by the spacer outweighed the handicap of the higher molecular weight.
In conclusion, retention of fast cell permeation and rapid clearance of optical PARPi is most
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essential for their performance. Although in vitro PARP1 staining has been shown for the NIR
probes AZD2281-TexasRed and Olaparib-spacer-SiR-COOH, their in vivo performance remains
unknown. Despite the general trend to move toward the NIR for optical imaging, in the specific
case of PARP1 imaging, BODIPY-FL labeling currently remains the most promising approach.
Its brightness, resulting from a high maximum absorption and high quantum yield, could even
prove advantageous over most NIR fluorochromes when considering intraoperative imaging and
detection of surface tumors where limited tissue penetration is not impeding the diagnostic
value.
2.3:

Radiolabeled Compounds

2.3.1: The First Radiolabeled PARP Inhibitors
The first radiolabeled PARPi was developed for imaging the PARP1 hyperactivation in diabetes
type I related necrosis. [11C]PJ3418 was based on PJ34 (IC50=170.2 nM19), which showed
promise as a therapeutic agent for diabetes related endothelial dysfunction20. A rat model of
type I diabetes showed higher uptake of [11C]PJ34 relative to untreated controls in the liver and
the pancreas, indicating that [11C]PJ34 was capable of detecting disease related increased
PARP1 activity.
The first

18

F labeled PARPi, [18F]FE-LS-75 (Ki=200nM)21, was designed to investigate the

potential of LS-75 (Ki=18nM) to act as a neuroprotective agent by regulating PARP1 activity.
[18F]FE-LS-75 was stable in plasma over 120 min, but no further biological studies have been
published.
2.3.2: Olaparib Based Tracers
The first radiolabeled PARPi with structural similarity to olaparib used for PET imaging was
18

F-BO (IC50=17.9nM). Analogous to the fluorescent compounds, the cyclopropyl group of

olaparib was replaced with an

18

F labeled moiety. The probe was synthesized by TCO/Tz

bioorthogonal click chemistry and purified either by conventional semipreparative HPLC22, or
with the aid of magnetic TCO functionalized scavenging beads23. In vitro experiments in breast
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Figure 2.3.1. Radiolabeled PARP imaging agents. Nicotinamide mimicking benzamide moiety
is highlighted in blue, fluorescent moieties are highlighted in green, and radioactive nuclides are
highlighted in red.

Table 2.3.1. Properties of fluorescent PARP imaging agents.
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cancer cells showed higher uptake of

18

F-BO in MDA-MB-436 compared to MDA-MB-231 cells,

which coincided with PARP1 expression. MDA-MB-436 xenografts showed an SUV of 0.9, and
specificity was shown by blocking with 100mg/kg olaparib 12 hours prior to
which reduced the SUV to 0.4.

18

18

F-BO imaging,

F-BO uptake also correlated to PARP1 expression in ovarian

(SCOV3, A2780) and pancreatic (MIAPaCa-2, PANC-1) tumor models9. To evaluate the
potential of

18

F-BO to monitor treatment response, A2780 xenograft bearing mice were treated

with therapeutic doses of olaparib and imaged with
18

18

F-BO and FDG before and after treatment.

F-BO showed a drop in tumor/muscle ratio from 3.8 to 1.3 after treatment with olaparib, while

no changes were observed for FDG. This shows PARP targeted specificity for

18

F-BO but no

specificity for FDG.
The other olaparib based radiotracers,

18

F-PARPi-FL and [18F]PARPi are the main subjects of

this work in general and will be greatly elaborated upon in the following chapters. However, a
brief summery will be given here.
18

F-PARPi-FL24,25 is a radiolabeled analog of PARPi-FL and currently the only dual modal

PET/fluorescent PARP probe available. The radiosynthesis was achieved via Lewis acid
assisted fluoride exchange with either triflic anhydride24 or tin tetrachloride25. With this kind of
reaction, it was only possible to produce

18

F-PARPi-FL with a maximum specific activity of just

333 MBq/µmol. Irrespective of this, PET images showed tumor uptake, and quantification of
18

F-PARPi-FL in U87 glioblastoma xenografts at 2 hours p.i. showed a tumor standard uptake

value (SUV) of 1.1. Blocking with 50 mg/kg olaparib reduced the SUV by 91% to 0.1, which was
a strong improvement compared to

18

F-BO, where blocking reduced the SUV by only 56%. Dual

modal functionality was confirmed using epifluorescence imaging and autoradiography, where
similar tumor/brain ratios between the radioactive (9:1) and fluorescent (7:1) signals were found.
PET and biodistribution data, however, also revealed a relatively high signal in the bone (>10
%ID/g), indicating that 18F-PARPi-FL suffered from defluorination in vivo.
[18F]PARPi2,8 sacrificed BODIPY FL for a highly stable fluorobenzene ring without negatively
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affecting uptake and specificity. [18F]PARPi uptake in orthotopic U251 glioblastoma xenografts2
was increased to 2.2 %ID/g (18F-PARPi-FL: 0.8 %ID/g), with the similarly high specificity (87%
blocking;

18

F-PARPi-FL:

81%).

Autoradiography

revealed

very

high

tumor/brain

and

tumor/muscle ratios (700:1 and 30:1). Biodistribution studies with subcutaneous xenografts
confirmed the uptake and specificity findings. Bone uptake was much lower compared to 18F
PARPi FL and could also be blocked by olaparib (83% reduction in uptake), indicating specific
uptake rather than defluorination. [18F]PARPi was also evaluated for imaging of diffuse intrinsic
pontine glioma in a genetically engineered mouse model8. This malignancy is difficult to monitor
with established methods, and has seen very limited progress in terms of treatment options over
the past decades26. Autoradiography and PET imaging showed localized, specific uptake.
[18F]PARPi could also be used to monitor tumor progression non-invasively over several weeks,
suggesting potential therapy monitoring applications.
In addition to fluorinated PARPi, the iodinated compound

124 131

/

developed. It is chemically identical to [18F]PARPi except that
computed tomography) or
Like [18F]PARPi,

124 131

/

124

I (PET), takes the place of

18

I-PARPi10,27 (IC50=9nM) was

131

I

(single-photon emission

F in the halogenated benzene ring.

I-PARPi studies were first performed in orthotopic U251 tumors10.

Autoradiography showed high tumor/brain (16:1) and tumor/muscle (6:1) ratios and high
specificity (65% blocking). Single-photon emission computed tomography imaging with
131

I-PARPi was possible, and PET quantification with

124

I-PARPi showed 0.43 %ID/g tumor

uptake and a tumor/brain ratio of 40:1. A later study27 showed an alternative synthetic route to
this radioiodinated PARPi with

123

I and

125

I. The study presented a single step iodination using a

solid-state halogen exchange with a Br leaving group – producing higher overall yields and
specific activities.
2.3.3: Rucaparib Based Tracers
Rucaparib (Ki=1.4nM28), the second Food and Drug Administration approved PARPi, has also
inspired radiolabeled analogs, which are based on the former lead compound AG14361
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(Ki=5.8nM). AG14361, which has been shown to be specific to PARP1
radiotracers

feature

a

[18F]FluorThanatrace19,29–31

benzimidazole
([18F]FTT,

methanamine on AG14361 with

18

instead

IC50=6.3nM),

of

rucaparib’s

which

replaces

28

, and its derived

fluorinated

indole.

dimethyl

phenyl

F fluoroethoxy benzene, was first tested in MDA-MB-436 and

MDA-MB-231 xenografts. PET imaging showed 3-5 %ID/g tumor uptake after 60 min, which
was reduced to 2 %ID/g after olaparib blocking. [18F]FTT uptake was imaged in BRCA mutant
(HCC1937) and compared to BRCA wild type (MDA-MB-231 and MCF7) tumor models. In vitro
[18F]FTT uptake, reported as specific binding ratios in which nonspecific binding was subtracted,
correlated with PARP1 and PAR levels, which were higher in BRCA mutant cells. PET imaging
showed higher tumor/muscle ratios for HCC1937 (1.9:1) compared to MDA-MB-231 (1.5:1) and
MCF7 (1.2:1). A different study29 compared in vitro [18F]FTT uptake in BRCA mutant (SNU-251)
and wild type (SCOV-3) ovarian cancer cells. Again, it was shown that specific binding ratios
correlated with PARP1 and PAR, which showed higher levels in SNU-251. It was further shown
that BRCA mutant SNU-251 were more sensitive to PARP inhibition and radiation therapy than
SCOV-3 cells. These findings suggest that [18F]FTT might be used to predict treatment efficacy
using PARP inhibitor therapy, radiation or a combination of the two.
In addition to [18F]FTT, there are two iodinated32,33 compounds based on the benzimidazole
scaffold of AG14361. [125I]KX1 (Ki<8nM) is structurally identical to [18F]FTT except that

125

I

replaces the fluorethoxy moiety32,33. It was shown in vitro that [125I]KX1 correlated with PARP1
expression in a panel of breast and ovarian cancer cell lines, but not with PAR, as observed
with [18F]FTT. Biodistribution showed that HCC1937 tumors had significantly higher uptake than
MDA-MB-231, corresponding to PARP1 expression levels. Blocking with olaparib reduced
[125I]KX1 uptake in HCC1937 tumors, but this was not statistically significant. No blocking was
seen for MDA-MB-231. Autoradiographically, unblocked/blocked ratios of 2.7:1 for HCC1937
and 0.92:1 for MDA-MB-231 tumors were found.
Another study33 presented [125I]KX-02-019 (Ki=13.9 nM), a modified version of [125I]KX1, which
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features a bicyclic instead of a tricyclic benzimidazole. [125I]KX-02-019 is a close analog of
AG1403234 (Ki=6.7 nM), another rucaparib predecessor, with its chloride replaced by 125I. In vitro
studies showed that [125I]KX-02-019 had higher specific binding ratios to PARP1 knockout
mouse embryonic fibroblasts compared to either [18F]FTT or [125I]KX1. Biodistribution with
EMT-6 murine mammary carcinoma bearing mice showed uptake close to 1 %ID/g at 2 hours
with a tumor/muscle ratio of about 5.
2.4:

Clinical Translation of PARP Imaging Agents

[18F]FTT is the first PARP targeted radiotracer that has been tested in humans
(NCT02469129)31. [18F]FTT was tested in 8 healthy volunteers and in 8 patients with a variety of
malignancies. It was found that, with a 370 MBq dose, the total effective dose was 5.1 mSv for
males and 6.9 mSv for females, with the highest uptake in the spleen, pancreas and liver. PET

Figure 2.4.1. First-in-human [18F]FTT study31. (a) Representative maximum-intensity projection
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from healthy volunteer. (b) [18F]FTT uptake in liver metastasis (arrows) from patient with
biphenotypic hepatocellular carcinoma and cholangiocarcinoma.
images showed increased uptake in tumor regions for two patients, one with recurrent
pancreatic

ductal

adenocarcinoma,

and

the

other

with

biphenotypic

hepatocellular

carcinoma/cholangiocarcinoma (Figure 2.4.1). In addition to this, one phase I/II study recently
opened to evaluate PARPi-FL for early detection of oral cancer after topical application
(NCT03085147). The addition of molecularly targeted fluorescence contrast for visual tumor
detection and navigation during surgery could represent an asset for physicians to discriminate
healthy tissue and malignant growth.
2.5:

Conclusion

PARP has been shown to be an interesting and valuable target for imaging. A wide variety of
cancer types have been imaged with diverse clinical applications in mind. These include
fluorescence assisted screening and diagnosis, intraoperative fluorescence guided surgery and
PET guided patient stratification and treatment monitoring. Although the first PARP imaging
agent was reported a mere 12 years ago, there are already two compounds in clinical trials.
While, preclinically, PARP imaging agents are powerful tools for understanding the biology
behind the DNA damage response system, the ultimate translational and clinical aims of these
agents are to provide a real and tangible improvement in overall patient care.
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CHAPTER 3: 18F-PARPI-FL
This chapter is an adaptation of published work, and is reproduced in part, from Carlucci, G.,
Carney, B., Brand, C., Kossatz, S., Irwin, C. P., Carlin, S. D., Keliher, E. J., Weber, W. & Reiner,
T. Dual-Modality Optical/PET Imaging of PARP1 in Glioblastoma. Mol Imaging Biol (2015).
Copyright

3.1:

Introduction

Among molecular imaging techniques, PET In particular has become one of the most prevalent
in the clinical setting, emerging as one of the key diagnostic tools for whole-body imaging of
cancer in the clinic. PET imaging is highly sensitive as well as quantitative and provides a
resolution of tumors on a lesion-by-lesion basis. However, the technology does not outperform
other imaging technologies in every aspect. PET is expensive, it exposes the patient to ionizing
radiation, and it has poor temporal and spatial resolution1,2.
Several features of intraoperative fluorescence imaging are orthogonal to PET: the fluorescently
emitted light—typically in the visible and near-infrared (NIR) range—is heavily attenuated, which
prevents deep-tissue imaging. However, intraoperative fluorescence imaging provides much
higher (up to sub-cellular) resolution and has recently been used to add artificial optical contrast
during surgical interventions3,4. This technique could become an important tool in the operating
room and help to achieve more complete tumor resections, but it still lacks the deep tissue
penetration to discover growths buried deep in the patient tissue as PET imaging is able to do.
The creation of targeted bimodal probes, which fuse the benefits of different types of imaging
agents, could lead to better and more accurate location of diseased tissue5,6. Bimodal
intraoperative and deep tissue contrast could ultimately become particularly important for the
surgical resection of glioblastoma, a highly infiltrative disease, where resection often remains
incomplete7–9. Recently, it was demonstrated that enhanced fluorescent contrast agents
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facilitate

more

complete

resection

of

glioblastoma.

The

use

of

contrast-enhancing

5-aminolevulinic acid during neurosurgical resections of glioblastoma resulted in a 6-month
improved progression free survival4.
Different reports have shown that the nuclear DNA repair enzyme PARP1 is overexpressed in a
variety of diseases and that the expression levels of PARP1 have prognostic value10–13. This is
evidenced in brain malignancies with elevated rates of PARP1 that contrast significantly with the
low PARP1 protein content in healthy brain tissue14,15. Following these findings, we have shown
that the elevated PARP1 expression can be exploited to image glioblastoma in mouse models
of cancer with PARPi-FL, a fluorescently labeled PARP1-targeted imaging agent16–18. Similar to
other fluorescent imaging agents, however, the tissue penetration depth of PARPi-FL is limited.
Therefore, we hypothesized that a bimodal version of this small molecule would allow the
detection of glioblastoma—both noninvasively using PET and at high resolution using
fluorescence imaging. The goal of the current study was to use a

18

F/19F exchange reaction19–22

to transform the fluorescent PARPi-FL molecule into a structurally identical but PET-active
imaging agent,

18

F-PARPi-FL22. In the current study, we show that the PARPi-FL can be

radiolabeled and used to augment the limitations of the “fluorescence only” intraoperative
imaging molecule.
3.2:

Radiosynthesis of 18F-PARPi-FL

The molecular structure of PARPi-FL is based on the PARP1 inhibitor olaparib18,23. Figure
3.2.1a

(top) shows both the PARP1 targeting 2H-phthalazin-1-one scaffold of the small

molecule (blue) as well as its fluorescent BODIPY-FL component (orange). In
fluorination, one of the BODIPY-FL fluorine atoms is exchanged with

18

F/19F trans-

18 −

F , generating a bimodal,

but otherwise structurally identical version of the fluorescent imaging agent (Figure 3.2.1a
bottom). Based on previous reports19–22, we devised an automated strategy to generate the
radiolabeled bimodal

18

F-PARPi-FL (Figure 3.2.1b). The

18

F/19F exchange was facilitated by the

Lewis acid SnCl4 (Figure 3.2.2), yielding the targeted dual-modality imaging agent, as
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Figure 3.2.1. 18F-PARPi-FL synthesis. (a) Structure of PARPi-FL (top) and
(bottom). (b) Flow diagram for automated synthesis.

18

F-PARPi-FL

Figure 3.2.2. 18F-PARPi-FL radiosynthesis scheme. The radiotracer was produced in a single
step through a Lewis acid assisted isotope exchange.
determined by reversed-phase HPLC and confirmed by mass spectrometry (MS) analysis
[C34H32BF3N6O3: expected ESI-MS=640.2; observed ESIMS 639.2 (M-H+); Figures A.3.1 and
A.3.2]. The manual execution of the

19

F/18F trans-fluorination yielded specific activities of 2.9 ±

0.7 mCi/µmol, with isolated radiochemical yields of 23 ± 8.2 % and radiochemical purities of 85
± 9.8 %. The manual synthesis required 90 min, including HPLC purification, evaporation of
solvents, and formulation of an injectable solution. For the optimization procedure, one condition
at a time (time, temperature, concentration of starting material, starting activity, reaction volume,
and concentration of SnCl4) was varied in order to find optimal reaction parameters (Figure
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3.2.3a). Radiochemical yields correlated to the amount of 18F− starting activity (34.8 ± 1.1 % with
45 mCi of

18 −

F ). Yields were also seen to increase with decreasing amounts of SnCl4 [40.6 ± 3.3

% with 10 eq. SnCl4 (µmol)/PARPi-FL (µmol)]. The specific activity was proportional to the
activity of added

18

F. With increasing temperature and SnCl4, the yields decreased, presumably

due to larger fractions of PARPi-FL being subjected to degradation. Longer reaction times did
not markedly increase the labeling yield. The automated

18

F-PARPi-FL synthesis was beneficial

compared to the manual process (Figure 3.2.3b). Based on our screening, we were able to
increase the specific activity by 266 % (from 3 to 9 mCi/µmol). The isolated radiochemical yields
were increased by 187 % (from 23 to 43 %). Finally, the automated synthetic process was
faster, allowing the

18

F-PARPi-FL synthesis to be performed in only 70 min (90 min for manual).

Figure 3.2.3. Optimization of 18F-PARPi-FL radiosynthesis.
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3.3:

Immunohistochemistry and Autoradiography

Using histological sections of healthy mouse brain and U87 MG glioblastoma xenografts, we
showed that the PARP1 expression in the U87 MG tissues is increased by a factor of 11.4 (17.1
± 1.6 and 1.5 ± 0.9% PARP1-positive area for U87 MG and healthy mouse brains, respectively,
Figure 3.3.1). To probe the selective uptake of

18

F-PARPi-FL, we performed autoradiographic

staining on resected tissues (U87 MG tumor, brain, muscle) obtained from mice, which were

Figure 3.3.1. H&E and PARP1 staining of U87 MG xenografts and brain tissues. PARP1
expression in normal mouse brain (top) and U87 MG xenograft tissue (bottom). Morphological
aspects are shown in H&E staining (left). PARP1 staining in adjacent sections is shown in low
(middle panel) and high magnification (right).

Figure 3.3.2. 18F-PARPi-FL autoradiography. H&E staining (left panels) and autoradiography
(right panels) of (a) unblocked and (b) blocked U87 MG tumor slices; (c) tissue/muscle ratio
calculated for tumors (unblocked and blocked) and brains (unblocked and blocked).
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injected with only the

18

F-PARPi-FL (non-blocked) or

18

F-PARPi-FL 30 min after injection of

olaparib as blocking agent (blocked). Autoradiography showed a homogeneous distribution of
radioactivity in the tumors of non-blocked mice (Figure 3.3.2a). The uptake in tumors of blocked
mice was markedly lower, with an overall reduction of 80 ± 12 % (Figure 3.3.2b). Hematoxylin
and eosin (H&E) staining demonstrated that the retention of radioactive material colocalized
with viable tumor tissue. Blocking lowered the

18

F-PARPi-FL tumor to muscle ratio by

approximately 66% (7.5 ± 0.9 and 2.6 ± 1.6, PG0.001 for non-blocked and blocked mice,
respectively). In contrast, the brain to muscle ratio did not undergo statistically significant
changes (0.87 ± 0.48 and 1.02 ± 0.22 for non-blocked and blocked mice, P=0.646, respectively,
Figure 3.3.2c).
3.4:

Surface Fluorescence Imaging

Figure 3.4.1. Full organ fluorescence and autoradiography; (a) representative images of tumor
and brain tissue obtained by IVIS optical imaging, including the corresponding (b)
autoradiography and (c) white light images; (d) fluorescence intensity profiles across tumor and
brain and (e) autoradiographic profile plot of the same organs. Radiant efficiency=emission light
(photons/s/cm2/str)/excitation light (mW/cm2). White lines in panels (a) and (b) indicate the data
used for the profiles in (d) and (e).
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The

bimodal

imaging

capabilities

of

18

F-PARPi-FL

optical/autoradiographic ex vivo analysis. The uptake of

18

were

determined

by

combined

F-PARPi-FL in the tumor was higher

than the observed accumulation in brain and muscle in both surface fluorescence imaging
(tumor to brain ratio was sevenfold increased) and autoradiography (tumor to brain ratio was
ninefold higher) (Figure 3.4.1a–c). The differences in imaging ratios (sevenfold versus ninefold)
are likely due to the differences in penetration depths and readout techniques for the two
imaging modalities.
Olaparib-blocked organs showed greatly reduced uptake in the tumor (74 ± 12 and 66 ± 9%
reduction for surface fluorescence imaging and autoradiography, respectively). Line profiles of
tumors and brains were obtained with both imaging techniques. Autoradiographic staining and
epifluorescence imaging provided corresponding organ uptake profiles (Figure 3.4.1d, e). These
results indicate that

18

F-PARPi-FL should be capable of generating high-contrast bimodal

images of tumor tissue and that the tumor to brain ratio is sufficiently high to allow effective
imaging of the tracer in the brain during intraoperative imaging procedures.
3.5:

Small Animal PET Imaging

Small animal PET imaging studies were conducted to investigate

18

F-PARPi-FL as a whole-

body imaging agent. After administration of 100 – 200 µl (80 – 160 mCi/µmol) of the tracer, U87

Figure 3.5.1. PET/CT images. (a) PET coronal and axial images (left) and corresponding CT
images (right) of a mouse injected with 18F-PARPi-FL (b) PET coronal and axial images (left)
and corresponding CT images (right) after pre-injection of blocking agent.
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MG glioblastoma xenografts could be identified in the right shoulder of tumor-bearing mice in
both coronal and axial PET/CT reconstructions (Figure 3.5.1a). The uptake of

18

F-PARPi-FL in

U87 MG tumors was 0.78 ± 0.1 %ID/g, which we were able to reduce to 0.15 ± 0.06 %ID/g by
blocking with an excess of olaparib (500 mM, 3.7 µmol, in 100 µl 15% PEG300 85% 0.9%
saline), similar to what has been done before17. The standardized uptake value (SUV) in U87
MG tumors was 1.10 ± 0.53, which also could be reduced to 0.10 ± 0.06 by blocking preinjection of an excess of olaparib (50-fold).
PET imaging revealed a high uptake in the liver and in the intestinal tract, which is consistent
with hepatobiliary excretion and analogous to what we and others have seen for monomodal
radiolabeled PARP1 imaging agents24,25 (Figure 3.5.1a, b). Activity was also observed in the
bone and junctures, typically a result of defluorination of radiolabeled imaging agents during
metabolic degradation.
3.6:

Blood Half-life and Biodistribution

In order to explore the potential in vivo applications of

18

F-PARPi-FL as a multimodality imaging

probe, we evaluated its blood half-life (Figure A.3.6a). After tail vein injection of

18

F-PARPi-FL

(27 µCi, 100 µl), the observed weighted t1/2 was 15.6 min. The calculated tumor uptake in the
positive control group, at 90 min p.i., was 0.78 ± 0.1% injected dose/gram (%ID/g). Tumor
uptake dropped to 0.1 ± 0.02 %ID/g at 90 min p.i. for mice that received a pre-injection of
olaparib. For each group, liver and kidney uptake of the radiotracer was lower in mice receiving
a pre-injection of olaparib, indicating specific binding of the tracer to a certain extent additionally
to the uptake due to excretion. (Liver 3.8±0.4 and 2.02±0.2 %ID/g, PG0.001 and kidneys
0.7±0.1 and 0.4±0.1 %ID/g, PG0.05, for non-blocked and blocked, respectively) (Figure 3.5.1).
The tumor to muscle ratio of

18

F-PARPi-FL was 4 ± 0.6 at 90 min post injection. The tumor to

brain tissue ratio of 12±2.1 (Figure A.3.6b) indicates a significant potential clinical value for the
probe.
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Figure 3.5.1. Biodistribution study in selected tissues. After injection of 18F-PARPi-FL into tumor
xenograft mice, mice were euthanized and the radioactivity in the organs was counted (n=4). (a)
shows data scaled to the high bone uptake while (b) shows highlights the specificity of
18
F-PARPi-FL at the tumor sight and the relatively low signals of muscle and brain background
tissues.

!

36!

3.7:

Conclusion

The primary objective of this study was to explore the synthesis and in vivo pharmacokinetics of
18

F-PARPi-FL as a potential bimodal PET/optical imaging agent for PARP1-targeted imaging of

glioblastoma. We were able to develop a 70 minute automated protocol to produce the tracer
with optimal yield and specific activity, which is inherently limited by the transfluorination
reaction. This limitation, however, is mitigated by the need for such bimodal agents to adopt
specific activities suitable to the fluorescent moiety as well as the PET26. We observed high
tumor to noise ratios in both whole organ autoradiography and ex vivo fluorescent imaging. Both
of these signals were highly specific, as demonstrated by the near complete blocking afforded
by pre-injection of olaparib. This was confirmed in PET/CT images, which showed 0.78 %ID/g
uptake with near complete blocking by pre-injection of olaparib. The PET/CT images also
revealed hepatobiliary excretion, in accord with what has been reported before. The PET/CT
images also showed high bone uptake, and all of these observations were corroborated by
biodistribution studies. The high bone uptake was ascribed to metabolic defluorination, an
explanation in agreement with known BODIPY chemistry27,28. Defluorination might limit the
broad applicability of the imaging agent. However, the rate of defluorination and the resulting
bone uptake might be reduced in vivo by addition of cytochrome P450 isozyme 2E1 (CYP2E1)
inhibitors29,30. Nevertheless, we were able to show that

18

F-PARPi-FL is a potentially valuable

bimodal imaging agent that fuses optical and PET imaging, combining the advantages of wholebody and high-resolution imaging.
3.8:

Experimental

Materials. Commercially available compounds were used without further purification unless
otherwise stated. Tetrabutylammonium bicarbonate (TBAB, 0.075 M in water) was purchased
from ABX advanced biochemical compounds GmbH (Radeberg, Germany). Extra dry
acetonitrile (MeCN) over molecular sieves was purchased from Acros Organics (Geel, Belgium).
Water (>18.2 MΩcm-1 at 25 °C) was obtained from an Alpha-Q Ultrapure water system from
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Millipore (Bedford, MA). Tin(IV) chloride (SnCl4, 1 M in methylene chloride) was purchased from
Sigma Aldrich (St. Louis, MO). BODIPY-FL succinimidyl ester was purchased from Life
Technologies (Carlsbad, CA). (AZD2281) was purchased from LC Laboratories (Woburn, MA).
PARPi-FL was synthesized as described earlier18. No-carrier-added (n.c.a.) [18F]fluoride was
obtained via the

18

O(p,n)18F nuclear reaction of 11-MeV protons in an EBCO TR-19/9 cyclotron

using enriched

18

O-water. QMA light ion-exchange cartridges and C-18 light Sep-Pak®

cartridges were obtained from Waters (Milford, MA). High performance liquid chromatography
(HPLC) purification and analysis was performed on a Shimadzu UFLC HPLC system equipped
with a DGU-20A degasser, a SPD- M20A UV detector, a RF-20Axs fluorescence detector, a LC20AB pump system, and a CBM-20A communication BUS module. A LabLogic Scan-RAM
radio-TLC/HPLC-detector was used for purifications while a PosiRAM Model 4 was used for
analysis. HPLC solvents (Buffer A: 0.1% TFA in water, Buffer B: 0.1% TFA in MeCN) were
filtered before use. HPLC purification and analysis was performed on a reversed phase Atlantis
T3 column (C18, 5 µm, 4.6 mm × 250 mm; flowrate: 0.8 ml/min; gradient: 0-17 min 30-90% B;
17-24 min 90% B; 24-28.5 min 90%-30% B; 28.5-30 min 30% B).
Electrospray ionization mass spectrometry (ESI-MS) spectra were recorded with a Shimadzu
LC-2020 with electrospray ionization SQ detector. All PET imaging experiments were conducted
on a microPET INVEON camera equipped with a CT scanner (Siemens, Knoxville, TN). Digital
phosphor autoradiography of histological U87 MG tumors, muscle and brain were obtained
using a Typhoon FLA 7000 laser scanner from GE Healthcare (Port Washington, NY).
Cell culture. The human glioblastoma cell lines U87 MG were kindly provided by Dr. Ronald
Blasberg (MSKCC, New York, NY). Cell lines were grown in Eagle’s Minimal Essential Medium
(MEM), 10% (vol/vol) heat inactivated fetal bovine serum, 100 IU penicillin, and 100 µg/mL
streptomycin, purchased from the culture media preparation facility at MSKCC (New York, NY).
Mouse models. All animal experiments were done in accordance with protocols approved by
the Institutional Animal Care and Use Committee of MSKCC and followed National Institutes of
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Health guidelines for animal welfare. Female athymic nude CrTac:NCrFoxn1nu mice at age 6 8 weeks were purchased from Taconic Laboratories (Hudson, NY). Non tumor-bearing mice
used to determine the blood half-life of PARPi-FL (n = 4). Xenograft mouse models were used
to determine the pharmacokinetics (n = 20). For subcutaneous injections, mice were
anesthetized with 2% isoflurane (Baxter Healthcare) (2 l/min medical air). U87 MG cells were
implanted subcutaneously (5 × 106 cells in 200 µl 1:1 PBS/matrigel® (BD Biosciences, San
Jose, CA) in the right shoulder and allowed to grow for approximately two weeks until the
tumors reached 5–10 mm in size. For all intravenous injections, mice were gently warmed with a
heat lamp and placed on a restrainer. The tails were sterilized with alcohol pads, and injection
took place via the lateral tail vein.
Immunohistochemistry. Immunohistochemical staining of PARP1 was performed with
formalin-fixed, paraffin-embedded U87 MG xenografts and mouse brain using the Discovery XT
processor (Ventana Medical Systems, Tucson, AZ) at the Molecular Cytology Core Facility of
MSKCC. Following deparaffinization with EZPrep buffer and antigen retrieval with CC1 buffer
(both Ventana Medical Systems), sections were blocked for 30 min with Background Buster
solution (Innovex, Lincoln, RI). Primary rabbit anti-PARP1 antibody (sc-7150, 0.4 µg/ml, Santa
Cruz, Dallas, TX) was incubated for 5 h followed by a biotinylated goat anti-rabbit IgG for 1 h
(PK6101, 1:200 Vector labs, Burlingame, CA). Signal detection was performed with a DAB
detection kit (Ventana Medical Systems, Tucson, AZ) according to the manufacturers
instructions. Sections were counterstained with hematoxylin and coverslipped with Permount
(Fisher Scientific, Waltham, MA). Adjacent sections were stained with Hematoxylin and Eosin
for morphological evaluation of the tissue.
Radiosynthesis. In a typical experiment, the [18F]fluoride (~50mCi) in water was transferred
into a sealed conical drying vessel containing TBAB (75 mM in water, 80 µl, 1.8 mg, 6.0 µmol).
Water was removed from the [18F]F-/TBAB solution by azeotropic distillation with dry acetonitrile
(3 × 1 ml) under a gentle stream of nitrogen at 110 °C. The dry residue was reconstituted with
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100 µl of MeCN and cooled to room temperature. To this, PARPi-FL (50 µg, 0.78 µmol) in
MeCN (50 µl) was added, followed by 10 equivalents of SnCl4 (100 mM in acetonitrile, 7.8
µmol). The mixture was then heated at 35 °C for 30 min. After incubation, the reaction mixture
was cooled to room temperature and diluted with ultrapure water to reach a final 20% MeCN
concentration. The crude mixture was filtered with PES 0.22 µm 30 mm diameter (Shirley, MA)
and automatically injected into the HPLC system (gradient A) for purification. The

18

F-PARPi-FL

peak was collected (rt: 17.5 min) and the solution passed through a C18 light-SepPak®
cartridge (preconditioned with EtOH (5 ml) and water (5 ml). The cartridge was washed with
water (3 ml) and

18

F-PARPi-FL was eluted using EtOH (1 ml). The organic solvent was removed

by rotary evaporation at 40 °C and the residual product formulated in 15% PEG300 in 0.9%
saline for in vivo animal imaging and biodistribution. The labeling procedure was fully automated
using a ScanSys radiochemistry module from ScanSys (Vaerloeser, Denmark).
Small-animal PET imaging. Mice bearing subcutaneous U87 MG (n = 12) were divided in two
groups (non blocked and blocked) and administered with

18

F-PARPi-FL [200 µCi, 160

mCi/µmol) in 200 µl 15% PEG300 in 0.9% sterile saline] via tail vein injection. Approximately 5
min prior to PET acquisition, mice were anesthetized by inhalation of a mixture of isoflurane
(Baxter Healthcare, Deerfield, IL, USA; 2% isoflurane, 2 l/min medical air) and positioned on the
scanner bed. Anesthesia was maintained using a 1% isoflurane/O2 mixture. PET data for each
mouse was recorded using static scans of 30 minutes and acquired at 1 h postinjection. The
blocked cohort (n = 6) was pre-injected with the PARP1 inhibitor olaparib (500 mM, 3.7 µmol, in
100 µl 15% PEG300 / 85% 0.9% saline). Images were analyzed using INVEON software
(Siemens, Knoxville, TN). Quantification and %ID/g values were calculated by manually drawing
regions of interests in four different frames and calculating the average values. Standard Uptake
Values (SUV) were calculated for 3D regions of interest (ROI), using Inveon Research
Workplace software (Siemens Medical Solutions, Knoxville, TX). Tumor ROIs drawn on the
images, normalized to the injected dose and body weight and converted to SUV.
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Ex vivo biodistribution. Biodistribution studies were performed in U87 MG xenografted
athymic nude mice (n = 4). Mice were divided in two groups (positive controls and blocked) and
administered with

18

F-PARPi-FL [approximately 27 µCi, 160 mCi/µmol) in 200 µl, 15% PEG300

in 0.9% sterile saline] via tail vein injection. The blocked group was pre-injected with an excess
of olaparib (500 mM, 3.7 µmol, in 100 µl 15% PEG300 / 85% 0.9% saline). Mice were sacrificed
by CO2 asphyxiation at 90 min p.i. and major organs were collected, weighed, and counted in a
WIZARD2 automatic γ-counter (PerkinElmer, Boston, MA). The radiopharmaceutical uptake was
expressed as a percentage of injected dose per gram (%ID/g) using the following formula:
[(activity in the target organ/grams of tissue)/injected dose]×100%.
Blood half-life. The blood half-life of

18

F-PARPi-FL was calculated by measuring the activity of

blood samples collected at different time points p.i. (5, 15, 30, 60, and 120 min). Female nude
mice (n = 4) were injected via lateral tail vein with

18

F-PARPi-FL (50 µCi in 200 µl 15% PEG300

in 0.9% sterile saline) and blood samples were collected from the great saphenous vein of each
animal at the predetermined time point. The collected blood was weighed and counted in a
WIZARD2 automatic γ-counter (PerkinElmer, Boston, MA). The blood half-life was calculated
using Prism 6.0c (GraphPad Software, La Jolla, CA) using a two-phase decay least squares
fitting method and expressed as %ID/g.
Autoradiography and Hematoxylin–Eosin staining. The collected organs were flash-frozen
in liquid Nitrogen and fixed in Tissue-Tek O.C.T. compound (Sakura Finetek, Torrance, CA) and
cut into 10 µm sections using a Vibratome UltraPro 5000 Cryostat (Vibratome, St. Louis, MO). A
storage phosphor autoradiography plate (Fujifilm, BAS-MS2325, Fiji Photo Film, Japan) was
exposed to the tissue slices overnight at -20 °C and read the following day. Relative count
intensity of the sections in each image was quantified using ImageJ 1.47u processing software
(source: http://rsbweb.nih.gov/ij/)31. Tumor/muscle and brain/muscle ratios were calculated
using Prism 6.0c (GraphPad Software, La Jolla, CA). The same sections were subsequently
subjected to H&E staining (hematoxylin–eosin) for white light microscopy. Surface fluorescence
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imaging While the cellular pharmacokinetics16,18,32 and macroscopic/organ-specific distribution17
of PARPi-FL have been reported in the past, the possibility of bimodal optical/PET imaging with
18

F-PARPi-FL has not been described. For this, U87 MG tumor bearing mice (n = 12) were

injected with

18

F-PARPi-FL [approximately 27 µCi, 160 mCi/µmol in 200 µL 15% PEG300 in

0.9% sterile saline] via tail vein injection. After PET imaging, the mice were sacrificed and
tumor, brain, and muscle harvested, placed on a petri dish and imaged with an IVIS Spectrum
fluorescence imaging system (PerkinElmer, Boston, MA) and Living Image 4.4 software. As a
negative control group, U87 MG tumor bearing mice (n = 4) were injected with vehicle only (200
µl 15% PEG300 in 0.9% sterile saline). For blocking studies, U87 MG cells were implanted and
grown in mice as stated above. The mice were injected with 18F-PARPi-FL as stated above, with
the exception that they were injected with an excess Olaparib in 100 µl of 15% PEG300 in 0.9%
sterile saline prior to injection of 18F-PARPi-FL. Image analysis for the

18

F-PARPi-FL uptake and

blocking study was performed by drawing regions of interest through each organ to calculate the
cross-section fluorescence with ImageJ 1.47u image processing software.
Statistical analysis. All data are expressed as mean ± SD. Differences between mouse
cohorts were analyzed with the 2-sided unpaired Student test and were considered statistically
significant when P < 0.05.
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CHAPTER 4: [18F]PARPI-GLIOBLASTOMA MULTIFORME
This chapter is an adaptation of published work, and is reproduced in part, from Carney, B.,
Carlucci, G., Salinas, B., Di Gialleonardo, V., Kossatz, S., Vansteene, A., Longo, V. A.,
Bolaender, A., Chiosis, G., Keshari, K. R., Weber, W. A. & Reiner, T. Non-invasive PET Imaging
of PARP1 Expression in Glioblastoma Models. Mol Imaging Biol 18, 386-392 (2016). Copyright

4.1:

Introduction

Although

18

F-PARPi-FL1 represented a step forward in the design of PARP targeted PET

agents, and the probe was especially valuable insofar as it offered a fluorescent moiety in
addition to the PET, it’s clinical utility was limited by the high bone uptake attributed to metabolic
defluorination. Our goal here was to design and synthesize a new molecule that exhibited
similar tumor targeting properties as well as the high specificity of

18

F-PARPi-FL, but also

possessed greater in-vivo stability. To this end, we aimed to sacrifice the fluorescent BODIPY
moiety that also served as a foundation for the boron-18F-fluorine bond that showed itself to be
metabolically instable in order to install a more stable PET active moiety. With this motivation in
mind, and inspired by our earlier designs1–7 and the work of others8, we synthesized [18F]PARPi,
a single model

18

F-labeled derivative of PARPi-FL. We determined the performance and basic

binding parameters of [18F]PARPi in biochemical assays then showed that in optical imaging
experiments, the radiolabeled tracer reaches its target on a cellular level, saturating PARP1 in
the nuclei of glioblastoma cells. We determined the biodistribution of [18F]PARPi and showed in
subcutaneous and orthotopic mouse models of glioblastoma that PARP1 expression can be
visualized by PET with high signal/noise ratios. Even though the monomodel [18F]PARPi lacks
the advantage of the dual model fluorescent signal of

18

F-PARPi-FL, we believe that the two

probes taken together, with the addition of olaparib and perhaps other PARP targeted
therapeutics, could represent a targeted, highly specific and actionable imaging toolbox with
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many possible clinical applications.
4.2:

PARP1 Expression in Glioblastoma Models and Healthy Tissues

Figure 4.2.1. PARP1 staining of an orthotopic mouse model. PARP1 immunohistochemical
staining was conducted on formalin-fixed, paraffin-embedded mouse brains of nude mice using
an anti-PARP antibody and IHC detection. Brown=PARP1 positive tissue. Blue=Hematoxylin
counterstain. Red: Eosin stain.
Even though our previous work with

18

F-PARPi-FL utilized subcutaneous U87 MG xenografts,

we wished to follow-up on the work done by Salinas et al.9 which made use of orthotopic U251
MG xenografts. To that end, we wanted first to verify PARP expression in this model, which was
only performed on subcutaneous U251 MG xenografts in the previous work. We found that
PARP1 expression was strongly elevated in the area of the tumor growth with clear margins to
surrounding normal brain tissue (Figure 4.2.1), corroborating the earlier findings. In addition to
this, we measured PARP1 expression in several healthy tissues. A high PARP1 expression was
also observed in the lymph node, concentrated to the follicle regions, and the spleen,
particularly around the germinal centers (Figure 4.2.2). These areas correspond to areas of high
B cell concentration. These B cell areas exhibit high PARP1 expression compared to areas like
the paracortical area and the medullary chords in the lymph nodes, which respectively contain
mostly T cells and macrophages, suggesting that B cells in particular among the lymphocytes
exhibit high PARP1 expression.
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Figure 4.2.2. PARP1 staining of healthy organs. Left to right, mouse lymph node (popliteal)
spleen, liver, kidney, brain, and lung were immunostained to assess inherent PARP1
expression. Tissue was formalin-fixed, paraffin-embedded and derived from B6 mice.
Brown=PARP1 positive tissue.
4.3:

Chemistry and Radiochemistry

The molecular structure of [18F]PARPi is based on the previously tested and validated
2H-phthalazin-1-one scaffold of the small molecule therapeutic olaparib10. Our tracer was
obtained by conjugating a 4-[18F]fluorobenzoic acid group to the PARP1 targeting small
molecule. Its cold reference compound,

19

F-PARPi, was synthesized in a single synthetic step

from 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one10 and 4-fluorobenzoic
acid, similar to coupling procedures applied earlier2 (Figure 4.3.1).

19

F-PARPi was obtained with

an isolated yield of 43%, and its identity confirmed by ESI-MS, ESI-HRMS, and NMR
spectroscopy (Figure A.4.2-A.4.4).
The radiolabeled version of the PARP1-targeted tracer, [18F]PARPi, was synthesized in three
consecutive synthetic transformations. Similar to the cold material, it was produced from the
PARP1-targeted

2H-phthalazin-1-one

fragment.

Its

radiolabeled

reaction

partner

4-[18F]fluorobenzoic acid was obtained from ethyl 4-nitrobenzoate, which was added to dry
K[18F]-K222 and heated to 150 °C for 15 min to give ethyl 4-[18F]fluorobenzoate. The
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Figure 4.3.1. [18F]PARPi radiosynthesis scheme. The radiotracer was produced in three steps
starting from the labeling of ethyl nitro benzoate. The ester is then hydrolysed and coupled to
the precursor with standard HBTU chemistry.
decay corrected radiochemical yield (dcRCY) for this transformation was determined by HPLC
and found to be 70 %. Then, the ethyl protective group was removed in the presence of sodium
hydroxide to yield 4-[18F]fluorobenzoic acid (dcRCY = 99%). Analogous to the non-radioactive
material, the radiolabeled 4-[18F]fluorobenzoic acid was coupled to the phthalazinone precursor
(dcRCY=35 %). The total synthesis time from the start of synthesis to obtaining an injectable
formulation was 90 min, and the overall uncorrected radiochemical yield was 10%, with a
specific activity of 48 mCi/µmol (1.8 GBq/umol, Figures 4.3.1 & Figure A.4.1).
4.4:

PARP1 Affinity, logP, and Plasma Protein Binding

First, we determined the ability of our tracer to bind to PARP1 in a biochemical assay,
analogous to methods we have previously described11. We found that the IC50 of 19F-PARPi was
2.8±1.1 nM (Figure 4.4.1a), which is on par with the small molecule parent compound olaparib
(5 nM10). We calculated the logPCHI of 19F-PARPi from its chemical hydrophobicity index (CHI), a
measure of HPLC retention time12. The CHI for

19

F-PARPi was 57.5, which translates to a

logPCHI of 2.15±0.41. This is concordant with measuring the octanol/water partition
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Figure 4.4.1. Biophysical properties. (a) The tracer exhibits binding properties similar to
olapabarib and PARPi-FL. (b) The tracer also exhibits ideal biophysical properties for delivery to
the nuclear target.
coefficient of [18F]PARPi, where we determined the logPO/W to be 1.76 ±0.18 (Figure 4.4.1b).
The logP of

19

F-PARPi was higher than for olaparib (CHI=34.1, logPCHI=0.8), but both small

molecules had comparable plasma protein binding (64 and 65 % for

19

F-PARPi and olaparib,

respectively).
4.5:

In Vitro Characterization

We determined on a subcellular level whether [18F]PARPi binds to the same target as its parent
compound olaparib. To show this, we performed in vitro assays with the nonradioactive
19

F-PARPi, olaparib, and the fluorescent imaging agent PARPi-FL, which we have shown to be

Figure 4.5.1. PARPi-FL blocking. (a) In-vitro PARPi-FL blocking studies show target
engagement from non fluorescent molecules. (b) Quantification shows that both 19F-PARPi and
olaparib are capable of blocking the fluorescent signal from PARPi-FL, suggesting that all three
molecules hit the same target.

!

47!

highly selective for PARP1 and suitable as a surrogate marker to infer the subcellular
distribution of olaparib6. Labeling cells with PARPi-FL leads to strong nuclear fluorescence due
to retention of the imaging agent by PARP1. In the presence of olaparib, the binding sites for
PARPi-FL were occupied, and the observed fluorescence is reduced by 69.6 ±22.3 % and
71.2±20.0 % for U251 MG and U373 MG cells, respectively. Similarly,

19

F-PARPi was able to

compete for the same binding sites as PARPi-FL, resulting in a reduction of fluorescence
intensity in the nucleus by 80.0±10.8 % and 78.8±10.4 % for U251 MG and U373 MG cells,
respectively (Figure 4.5.1).
4.6:

Blood Stability and Blood Half life

We estimated the in vivo stability of [18F]PARPi by incubating the radiotracer in whole blood for
up to 4 h. Over the given time period, no radioactive metabolites were observed, indicating
excellent stability and potentially low bone uptake of the tracer for in vivo applications (Figure
4.6.1a). The blood half-life of [18F]PARPi was determined in athymic nude mice, which received
the tracer via tail vein injection. Analogous to other small molecules of this type1,2,6, the agent
was cleared rather quickly, with an alpha blood half-life of 1.27 min (85.51 %) and beta blood
half-life of 31.14 min (14.49 %), resulting in a weighted blood half-life of t1/2(weighted)=5.6 min
(Figure 4.6.1).

Figure 4.6.1. Blood studies. (a) Stability studies show no radioactive metabolites for four hours.
(b) The blood half life measurement shows a quick two phase decay with a relatively short
weighted blood half life of 5.6 minutes.
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4.7:

Biodistribution

Figure 4.7.1. Biodistribution studies. Biodistribution measurements show highly specific tumor
uptake in the tumor as well as several other organs such as the spleen and lymph nodes.
Hepatobiliary excretion is also exhibited.
The tumor-to-muscle ratio was 5.1±0.9, and the tumor-to-brain ratio was 54.9±14.1 (Figure
A.3.6.b). A high uptake was also observed in the hepatobiliary system with liver uptake values
of 3.98±0.56 and 3.61±2.04 %ID/g, small intestine uptake of 2.94±0.91 and 2.35±0.70 %ID/g,
and large intestine uptake of 2.24±0.59 and 1.73±0.80 %ID/g for unblocked and blocked
cohorts, respectively. We also found that lymph node and spleen uptake were high, with
2.80±0.51 and 4.04 ±1.23 %ID/g, respectively, and that their uptake was reduced after preinjection of olaparib by 95 and 94%, respectively (Figure 4.7.1). Highly selective uptake in these
organs is based on their rather high PARP1 expression, shown in immunohistochemical
stainings, which were obtained in non-tumor-bearing mice (Figure 4.2.2). Our biodistribution
data was corroborated by PET/X-ray computed tomography (CT) imaging, with whole axial and
coronal slices of subcutaneous tumor-bearing mice receiving only [18F]PARPi and both
olaparib/[18F]PARPi (Figure 4.9.1).
4.8:

Autoradiography

We used an orthotopic mouse model of U251 MG to determine the potential clinical impact of
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Figure 4.8.1. Autoradiography in orthotopic U251 MG tumor-bearing mice. (a) Autoradiography
and H&E staining of brain sections either unblocked (left) or blocked (right) with olaparib. Yellow
arrows indicate location of tumor tissue. (b) Quantification of activity on autoradiographic
sections in orthotopic U251 MG tumors and mouse brain and (c) muscle (n=6). Error bars are
mean±SD. P values were calculated with Student’s t-tests, unpaired; *P<0.05; **P<0.01;
***P<0.001; ****P<0.0001.
[18F]PARPi as a non-invasive PARP1 imaging tracer. U251 MG cells expressed PARP1 at much
higher levels than healthy brain, and orthotopic brain tumors had a high gradient in PARP1
expression (Figure 4.2.1). In order to assess the alignment of [18F]PARPi retention and PARP1
expression on a microscopic level in vivo, tumor-bearing mice were injected with [18F]PARPi and
autoradiography was performed (Figure 4.8.1a). Using histology to localize the tumor regions of
the brain, the autoradiographic analysis revealed significantly higher retention of [18F]PARPi
inside orthotopic tumor tissue than in healthy surrounding brain (Figure 4.8.1a, 46.66±14.94 AU
and 0.06±0.02 AU for orthotopic tumor and surrounding brain, respectively). Similarly—and
consistent with in vitro imaging— we found that pre-injection of olaparib and hence saturation of
PARP1 binding sites lead to almost quantitative reduction of [18F]PARPi (99 %, 0.44±0.41 AU
and 0.03 ±0.01 AU for orthotopic tumor and surrounding brain, respectively). The uptake of
[18F]PARPi in orthotopic tumor tissue was distinctly higher than in muscle (Figure 4.8.1b, c
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1.36±0.21 AU and 1.50±0.31 AU for muscle tissue in tumor bearing and healthy mice,
respectively).
4.9:

PET/CT and PET/MR Imaging

We used both small-animal PET/CT and PET/magnetic resonance imaging (MRI) scanners to
determine the accuracy and selectivity of non-invasive glioblastoma delineation with [18F]PARPi.
Beginning with subcutaneous xenografts (Figure 4.9.1), PET images showed clear tumor
delineation in addition to lymph node localization, an observation that has not been made before
in PARP PET imaging. The images also showed the usual hepatobiliary excretion pattern

Figure 4.9.1. PET images from subcutaneous U251 MG xenograft models. (a) Full body slices
of unblocked mice centered at tumor site collected at 30 min (top) and 2 h (bottom) p.i. (b) Full
body maximum intensity projections (MIPs) of unblocked mice collected at 30 min (left) and 2 h
(right) p.i. (c) Full body slices of mice blocked by preinjection of olaparib, centered at tumor site.
Images collected at 30 min (top) and 2 h (bottom) p.i. (d) Full body MIPs of mice blocked by
preinjection of olaparib. Images collected at 30 min (left) and 2 h (right) p.i.
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exhibited by PARP imaging agents, and all of these observations corroborate the
measurements acquired in the biodistribution studies. As with the biodistribution studies, the
PET images demonstrate the high specificity of the molecule at the tumor site as well as the
stability of the compound with respect to defluorination, in sharp contrast to 18F-PARPi-FL.
Imaging studies using othotopic xenografts showed similar results to the PET images of
subcutaneous tumor bearing mice. Figure 4.9.2a shows axial brain slices, obtained 120 min
after radiotracer injection, of tumor-bearing animals that received either only [18F]PARPi or
olaparib/[18F]PARPi. For animals receiving only [18F]PARPi, the retained activity (2.15±0.79
%ID/g) was eightfold higher than for animals that received both olaparib and [18F]PARPi

Figure 4.9.2. PET/CT imaging of [18F]PARPi in orthotopic brain tumor-bearing mice. (a) Fused
PET/CT axial images of an orthotopic U251 MG tumor bearing mouse acquired at 2 h postinjection of [18F]PARPi either unblocked (left) or blocked (right) with olaparib. (b) PET
quantification of U251 MG tumors from images acquired at 30 min and 2 h post injection (n=10).
(c) Representative 3D PET/CT images of an unblocked (left) or blocked (right) orthotopic U251
MG tumor bearing mouse. Error bars are mean±SD. P values were calculated with Student’s
t-tests, unpaired; *P<0.05.
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(0.28±0.01

%ID/g,

reconstructions

of

Figure

4.9.2b).

orthotopic

Figure

4.9.2c

tumor-bearing

shows

mice

that

representative
received

3D

PET/CT

[18F]PARPi

or

olaparib/[18F]PARPi.
PET/MRI was used to confirm uptake of [18F]PARPi in the tumor tissue which is not well
differentiated brain tissue with CT. MRI identified the tumor area based on on T1-weighted postcontrast images, and the PET signal was confirmed to coalign with this MRI identified tumor
area (Figure 4.9.3).

Figure 4.9.3. PET/MRI images of [18F]PARPi in orthotopic brain tumor-bearing mice. Coronal
view of [18F]PARPi PET images, contrast-enhanced MRI, and fused PET/MRI of orthotopic
U251 MG tumor-bearing mice, either unblocked (top) or blocked (bottom) with excess olaparib.
4.10:

Conclusion

The primary objective of this study develop a PARP1 targeted PET imaging agent with tumor
targeting properties similar to that of

18

F-PARPi-FL, but without the in-vivo defluorination

presented by that molecule. Sacrificing the fluorescent moiety not only yielded a compound with
high in vivo stability, but it also afforded higher specific activity than could be attained with the
transfluorination reaction that yielded

18

F-PARPi-FL. This could be one reason that [18F]PARPi

showed higher uptake in tumor models than

18

F-PARPi-FL, but it should also be pointed out that

the two studies made use of two different tumor models, and that the U251 MG used in this
study has slightly higher PARP1 expression than the U87 MG cell line used in the previous
study as measured by the mRNA expression patterns reported by the cancer line encyclopedia
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(CCLE)13.
The novel PET imaging agent [18F]PARPi demonstrates an outstanding ability to non-invasively
image PARP1 expression of gliomas and could have various applications in brain tumor
research. Besides serving as a companion imaging agent for PARP1-targeting therapeutics, the
agent could serve as a diagnostic for monitoring PARP1 expression before, during, and after
treatment with cytotoxic agents. This could lead to new insights into the function of PARP1
during cellular DNA damage response. Furthermore, the biodistribution data indicates that the
imaging of PARP1 expression is not only feasible for brain tumors but potentially also for lung
and soft tissue tumors. This is of high clinical relevance, because PARP1 inhibitors are under
clinical investigation in lung cancer, breast cancer, and sarcomas. These properties make
[18F]PARPi an excellent candidate for clinical translation.
4.11:

Experimental

Materials. Commercially available compounds were used without further purification unless
otherwise stated. 4,7,13,16,21,24-Hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane (K222) was
purchased from Sigma Aldrich (St. Louis, MO). Extra dry dimethyl sulfoxide (DMSO) over
molecular sieves was purchased from Acros Organics (Geel, Belgium). Water (>18.2 MΩcm-1
at 25 °C) was obtained from an Alpha-Q Ultrapure water system from Millipore (Bedford, MA).
Olaparib (AZD2281) was purchased from LC Laboratories (Woburn, MA). PARPi-FL was
synthesized as described earlier2. No-carrier-added (n.c.a.) [18F]fluoride was obtained via the
18

O(p,n)18F nuclear reaction of 16.5-MeV protons in an GE Healthcare PETTrace 800 using

enriched

18

O water. QMA light ion-exchange cartridges and C-18 light Sep-Pak® cartridges

were obtained from Waters (Milford, MA). High performance liquid chromatography (HPLC)
purification and analysis was performed on a Shimadzu UFLC HPLC system equipped with a
DGU-20A degasser, a SPD-M20A UV detector, a LC-20AB pump system, and a CBM-20A
communication BUS module. A LabLogic Scan-RAM radio-TLC/HPLC-detector was used for the
radioactive signal. HPLC solvents (Buffer A: 0.1% TFA in water, Buffer B: 0.1% TFA in MeCN)
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were filtered before use. HPLC analysis and purification was performed on a reversed phase
Phenomenex Gemini column (C6-Phenyl, 5 µm, 4.6 mm, 250 mm). Analysis was performed with
Method A (flowrate: 1.5 mL/min; gradient: 0-14 min 5-100% B; 14-17.5 min 100% B; 17.5-18
min 100%-5% B); purification was performed with Method B (flowrate: 1.5 mL/min; isocratic:
0-14 min 5-100% B; 14-17.5 min 100% B; 17.5-18 min 100%-5% B). Electrospray ionization
mass spectrometry (ESI-MS) spectra were recorded with a Shimadzu LC-2020 with
electrospray ionization SQ detector. All PET imaging experiments were conducted on a
microPET INVEON camera equipped with a CT scanner (Siemens, Knoxville, TN). Digital
phosphor autoradiography of orthotopic U251 MG tumors with surrounding brain tissue as well
as muscle were obtained using a Typhoon FLA 7000 laser scanner from GE Healthcare (Port
Washington, NY).
Cell culture. The human glioblastoma cell lines U251 MG and U373 MG were kindly provided
by the Laboratory of Dr. Ronald Blasberg (MSKCC, New York, NY). Cell lines were grown in
Eagle’s Minimal Essential Medium (MEM), 10% (vol/vol) heat inactivated fetal bovine serum,
100 IU penicillin, and 100 µg/mL streptomycin, purchased from the culture media preparation
facility at MSKCC (New York, NY).
Mouse models. All animal experiments were done in accordance with protocols approved by
the Institutional Animal Care and Use Committee of MSKCC and followed National Institutes of
Health guidelines for animal welfare. Female athymic nude CrTac:NCr-Foxn1nu mice at age 6-8
weeks were purchased from Taconic Laboratories (Hudson, NY). Non tumor-bearing mice were
used to determine the blood half-life of [18F]PARPi (n = 3). Xenograft mouse models were used
to determine the pharmacokinetics (n = 12). For subcutaneous injections, mice were
anesthetized with 2% isoflurane (Baxter Healthcare) (2 l/min medical air). U251 MG cells were
implanted subcutaneously (5⨉106 cells in 150 µL 1:1 PBS/matrigel® (BD Biosciences, San
Jose, CA) in the right shoulder and allowed to grow for approximately two weeks until the
tumors reached 5–10 mm in diameter. For orthotopic injections, mice were anesthetized with
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2% isoflurane (Baxter Healthcare) (2 L/min medical air). U251 MG cells (5⨉105 cells in 2 µL
PBS) were injected 2 mm lateral and 1 mm anterior to the bregma using a Stoelting Digital New
Standard Stereotaxic Device and a 5 µL Hamilton syringe. Cells were allowed to grow for
approximately three weeks. For all intravenous injections, mice were gently warmed with a heat
lamp and placed on a restrainer. The tails were sterilized with alcohol pads, and injection took
place via the lateral tail vein.
PARP1 Immunohistochemistry. Immunohistochemical staining of PARP1 was performed on 3
µm section, obtained from with formalin-fixed, paraffin-embedded tumor-bearing and normal
mouse brain using the Discovery XT processor (Ventana Medical Systems, Tucson, AZ) at the
Molecular Cytology Core Facility of MSKCC. Following deparaffinization with EZPrep buffer and
antigen retrieval with CC1 buffer (both Ventana Medical Systems), sections were blocked for 30
minutes with Background Buster solution (Innovex, Lincoln, RI). Primary rabbit anti-PARP-1
antibody (sc-7150, 0.4 µg/mL, Santa Cruz, Dallas, TX) was incubated for 5 hours followed by a
biotinylated goat anti-rabbit IgG for 1 h (PK6101, 1:200 Vector labs, Burlingame, CA). Signal
detection was performed with a DABdetection kit (Ventana Medical Systems, Tucson, AZ)
according to the manufacturer’s instructions. Sections were counterstained with hematoxylin
and coverslipped with Permount (Fisher Scientific, Waltham, MA). Adjacent sections were
stained with Hematoxylin and Eosin for morphological evaluation of the tissue.
Synthesis of

19

F-PARPi. 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one was

synthesized as previously described10. To 20 mg (54.5 µmol) of 4-(4-fluoro-3-(piperazine-1carbonyl)benzyl)phthalazin-1(2H)-one dissolved in 1 mL of MeCN, 9.2 mg (65.5 µmol) 4fluorobenzoic acid was added followed by 24.8 mg (65.5 µmol) of N,N,N’,N’-Tetramethyl-O-(1Hbenzotriazol-1-yl)uranium hexafluorophosphate (HBTU) and 18 µL (131 µmol) of Et3N. The
reaction mixture was stirred for 5 minutes and purified by HPLC to yield the compound as an
orange solid (11.5 mg, 23.5 µmol, 43%).1H-NMR (500 MHz, CDCl3) δ = 10.74 (s, 1H), 8.518.49 (d, 1H), 7.83-7.76 (m, 2H), 7.82 (s, 1H), 7.45-7.44 (m, 2H), 7.38-7.36 (m, 2H), 7.14-7.08
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(m, 3H), 4.33 (s, 2H), 3.75-3.39 (m, 8H). MS-ESI m/z [M + Na]+ = 511.2. HRMS-ESI m/z
calculated for [C27 H22 N4 O3 F2 Na]+ 511.1558, found 511.1569 [M + Na]+.
Radiosynthesis of [18F]PARPi. A QMA cartridge containing cyclotron-produced [18F] fluoride
ion was eluted with a solution containing 9mg Kryptofix [2.2.2] (4,7,13,16,21,24-hexaoxa-1,10diazabicyclo[8.8.8]hexacosane), 0.08 mL 0.15 M K2CO3 and 1.92 mL MeCN into a 5 mL
reaction vial. Water was removed azeotropically at 120 °C. 500 µg of ethyl 4-nitrobenzoate
dissolved in 100 µL of DMSO was then added to the reaction vial and heated to 150 °C for 15
minutes. The reaction vial was then allowed to cool as 50 µL of 1M NaOH was added. The
reaction mixture was stirred for 1 min and 50 µL of 1M HCl was added to quench. Then, 2 mg of
4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one dissolved in 100 µL of DMSO
was added followed by 10 mg of HBTU dissolved in 100 µL of DMSO and 20 µL of Et3N. The
reaction mixture was stirred for 1 minute. 400 µL MeCN followed by 700 µL H2O was then
added and the solution was injected onto a C6-Phenyl analytical HPLC column and eluted
under isocratic conditions (Method B). [18F]PARPi eluted at (tR = 25.5 min), which was well
resolved from the nitro analogue (4-(4-fluoro-3-(4-(4-nitrobenzoyl)piperazine-1-carbonyl)benzyl)
phthalazin-1(2H)-one; tR = 30.1 min). For intravenous administration, the product-containing
fraction was passed through a C18 light-SepPak® cartridge preconditioned with EtOH (10 mL)
and water (10 mL). The cartridge was washed with water (3 mL) and [18F]PARPi was eluted
using EtOH (400 µL). The solution was then diluted with 0.9% saline to 10% EtOH. The
radiochemical purity of the final formulation was confirmed using analytical HPLC. Coelution
with nonradioactive

19

F reference compound confirmed the identity of the radiotracer. To

measure radiochemical and chemical purity (>99%), [18F]PARPi was reinjected onto an
analytical C6-Phenyl column (gradient A; tR = 11.4 min).
IC50 Determination. A commercially available colorimetric assay (Trevigen, Gaithersburg, MD)
was used to measure PARP-1 activity in vitro in the presence of varying concentrations of
19
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F-PARPi. Three-fold dilutions of
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F-PARPi (final concentrations ranging from 1 µM to 33 pM)
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were incubated with 0.5 U of PARP high specific activity (HSA) enzyme for 10 minutes in
histone-coated 96-well plates. All experiments were carried out in triplicate. Positive control
samples did not contain inhibitor, and background measurement samples did not contain
PARP1. All reaction mixtures were adjusted to a final volume of 50 µL and a final concentration
of 2% dimethyl sulfoxide (DMSO) in assay buffer. The remainder of the assay was performed
according to the manufacturer’s instructions. PARP1 activity was measured by absorbance at
450 nm in each well using a Molecular Devices SpectraMax M5 microplate reader (Molecular
Devices, Sunnyvale, CA).
Chromatographic Hydrophobicity Index (logPCHI). The Chemical Hydrophobicity Indices
(CHI) were measured using a previously developed procedure12. Briefly, reverse phase HPLC
was used to measure the retention times of a set of standards with known CHI. A standard
curve was then created to calculate the CHI of

19

F-PARPi based on the HPLC retention time.

Octanol−Water Partition Coefficient (logPO/W) The lipophilicity of the [18F]PARPi was acquired by
adding 2.5 µCi to a mixture of 0.5 mL of 1-octanol and 0.5 mL of 25 mM phosphate buffered
saline (pH 7.4) and mixed for 5 minutes. Then, the mixture was centrifuged at 15000 rpm for 5
minutes. 100 µL samples were obtained from organic and aqueous layers, and the radioactivity
of the samples were measured in a γ-counter WIZARD2 automatic γ-counter (PerkinElmer,
Boston, MA). The experiment was performed in triplicate, and the resulting logPO/W was
calculated as the mean ± SD.
Plasma Protein Binding. The plasma protein fraction was determined using the Rapid
Equilibrium Dialysis Device System (Life Technologies, Grand Island, NY) according to the
manufacturer’s protocol. Membrane dialysis was performed with 500 µM
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F-PARPi in serum

(500 µL) on one side of the membrane and PBS (700 µL) on the other side. The system was
sealed with parafilm and incubated for 4 h at 37 °C on an orbital shaker set to 100 rpm.
Thereafter, 50 µL of solution was taken from both sides, and samples were treated with 300 µL
of precipitation buffer (90/10 acetonitrile/water with 0.1% formic acid) and vortexed to remove
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protein before HPLC analysis. After injection, the [18F]PARPi peaks from each sample were
integrated, and the protein bound fraction determined as %bound= [1 – (Concentration buffer
chamber/Concentration plasma chamber)]⨉100. The final Albumin binding was calculated as
the mean ± SD.
PARPi-FL Blocking Studies. U251 MG or U373 MG (1 ⨉ 104 cells per well) cells were seeded
into 12 wells each on a 96-well plate and cultured for 24 hours. The cells were then incubated
either alone, with PARPi-FL (500 nM), or with PARPi-FL (500 nM) and Olaparib or

19

F-PARPi in

10-fold excess (5 µM) at 37 °C for 30 minutes. Experiments were performed in triplicate.
Following incubation, cells were washed twice with media and twice with PBS and imaged with
a Zeiss LSM 5Live confocal microscope. Images were then quantified using ImageJ 1.47u
processing software.
Blood Half-Life. The blood half-life of [18F]PARPi was calculated by measuring the activity of
blood samples collected at different time points p.i. (5, 15, 30, 45, 60, 90 and 120 minutes).
Female nude mice (n = 3) were injected via lateral tail vein with [18F]PARPi (50 µCi in 200 µL
10% EtOH in 0.9% sterile saline) and blood samples were collected from the great saphenous
vein of each animal at the predetermined time point. The collected blood was weighed and
counted in a WIZARD2 automatic γ-counter (PerkinElmer, Boston, MA). The blood half-life was
calculated using Prism 6.0c (GraphPad Software, La Jolla, CA) using a two-phase decay least
squares fitting method and expressed as %ID/g.
Blood Stability. [18F]PARPi (approximately 200 µCi, 45 mCi/µmol in 200 µL, 10% EtOH in 0.9%
sterile saline) was added to 250 µL of whole human blood and incubated at 37 °C for increasing
lengths of time (15, 30, 60, 120 and 240 minutes). [18F]PARPi was then extracted with 750 µL of
MeCN, then centrifuged (5 minutes at 5000 rpm) to pellet blood cells and proteins. The
supernatant was collected and prepared for HPLC injection by adding 750 µL mQ H2O and
filtering. The blood stability was measured by HPLC analysis (Method A).
Autoradiography and Hematoxylin–Eosin staining. One day after PET/CT imaging, the
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same orthotopic U251 MG tumor bearing mice were administered with [18F]PARPi (80 µCi, 45
mCi/µmol in 300 µL 10% EtOH in 0.9% sterile saline) via tail vein injection. Blocked mice from
the previous day received another dose of Olaparib (37 mM, 3.7 µmol, about 80 mg/kg, in 100
µL 15% PEG300 / 85% 0.9% saline). The mice were sacrificed after 2 hours and brain and
muscle tissues harvested. The collected organs were fixed in Tissue-Tek O.C.T. compound
(Sakura Finetek, Torrance, CA) and flash-frozen in liquid nitrogen and cut into 20 µm sections
using a Vibratome UltraPro 5000 Cryostat (Vibratome, St. Louis, MO). A storage phosphor
autoradiography plate (Fujifilm, BAS-MS2325, Fiji Photo Film, Japan) was exposed to the tissue
slices overnight at -20 °C and read the following day. Relative count intensity of the sections in
each image was quantified using ImageJ 1.47u processing software. Tumor/muscle and
brain/muscle ratios were calculated using Prism 6.0c (GraphPad Software, La Jolla, CA). The
same sections were subsequently subjected to H&E staining (hematoxylin–eosin) for
morphological evaluation of tissue pathology and to compare the localization of the radiotracer
with the location of tumor tissue.
Ex vivo biodistribution. Biodistribution studies were performed in subcutaneous U251 MG
xenograft bearing athymic nude mice (n = 12). Mice were divided in two groups (blocked and
unblocked) and administered with [18F]PARPi (approximately 50 µCi, 45 mCi/µmol in 200 µL,
10% EtOH in 0.9% sterile saline) via tail vein injection. The blocked group was pre-injected 30
min prior with a 500-fold excess of olaparib (18 mM, 2 µmol, about 40 mg/kg, in 100 µL 15%
PEG300 / 85% 0.9% saline). Mice were sacrificed by CO2 asphyxiation at 120 min p.i. and
major organs were collected, weighed, and counted in a WIZARD2 automatic γ-counter
(PerkinElmer, Boston, MA). The radiopharmaceutical uptake was expressed as a percentage of
injected dose per gram (%ID/g) using the following formula: [(activity in the target organ/grams
of tissue)/injected dose]⨉100%.
PET/CT imaging. Mice bearing orthotopic U251 MG (n = 8) were divided in two groups
(unblocked and blocked) and administered with [18F]PARPi (150 µCi, 45 mCi/µmol in 300 µL
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10% EtOH in 0.9% sterile saline) via tail vein injection. The blocked cohort (n = 4) was preinjected with olaparib (37 mM, 3.7 µmol, about 80 mg/kg, in 100 µL 15% PEG300 / 85% 0.9%
saline) 30 min prior to injection of [18F]PARPi. Approximately 5 min prior to PET acquisition,
mice were anesthetized by inhalation of a mixture of isoflurane (Baxter Healthcare, Deerfield, IL,
USA; 2% isoflurane, 2 L/min medical air) and positioned on the scanner bed. Anesthesia was
maintained using a 1% isoflurane/O2 mixture. PET data for each mouse was recorded using
static scans of 10 minutes and acquired at 30 and 120 minutes post injection. Quantification and
%ID/g values were calculated by manually drawing regions of interests in three different frames
and determining the average values using ASI Pro VM™ MicroPET Analysis software (Siemens
Medical Solutions, Knoxville, TX).
PET/MRI imaging. [18F]PARPi PET images were acquired on integrated in-line preclinical
whole-body 1T PET/MRI system (Mediso, Budapest, Hungary). The animals were injected with
200 µCi of [18F]PARPi and a 20 minutes static PET scan was acquired 2 hours post injection.
200 µL of diluted gadopentate dimegumine in saline solution (1:5) (Magnevist®; Bayer Pharma,
Wayne, NJ) was administered intravenously one minute prior to MRI acquisition. Tumor regions
were identified on anatomic images acquired using a post-contrast T1-weigthed spin-echo (SE)
acquisition (TE/TR = 12.4/671 ms, 0.3125 x 0.3125 mm in plane resolution and 1 mm slice
thickness). 30 slices were acquired in order to cover the mouse. Data analysis and PET/MRI coregistration was performed using VivoQuant™ software (inviCro LLC, Boston, USA).
Statistical analysis. All data are expressed as mean ± SD. Differences between mouse
cohorts were analyzed with the 2-sided unpaired Student test and were considered statistically
significant when P < 0.05.
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CHAPTER 5: [18F]PARPI-DIFFUSE INTRINSIC PONTINE GLIOMA
This chapter is an adaptation of published work, and is reproduced in part, from Kossatz, S.,
Carney, B., Schweitzer, M. E., Carlucci, G., Miloushev, V., Maachani, U. B., Rajappa, P.,
Keshari, K., Pisapia, D. J., Weber, W. A., Souweidane, M. M. & Reiner, T. Biomarker based
PET Imaging of Diffuse Intrinsic Pontine Glioma in Mouse Models. Cancer Res (2017).
Copyright

5.1:

Introduction

Brain and central nervous system (CNS) tumors are the most common solid tumor and the
second leading cause of cancer related death in individuals 0 to 19 years of age in the United
States and Canada1,2. Although the treatment and survival rates for more common forms of
pediatric CNS tumors have improved3, survival significantly depends on the location and
histologic subtype of the individual CNS lesions4,5. Certain types of brainstem tumors,
particularly the diffuse intrinsic pontine glioma (DIPG), face a grim prognosis. Dozens of clinical
trials have been conducted over several decades, evaluating a wide range of therapeutic
strategies, but none of them could demonstrate a survival benefit beyond traditional external
beam radiotherapy6–12. DIPG remains an incurable disease, with the mean survival being less
than a year from diagnosis13. One unique feature of this tumor is the infiltrative and nonfocal
growth pattern and the sparse uptake of MR contrast agents. Critically, although MRI can be
used for initially diagnosing DIPG, this approach has proven imperfect for defining the true
tumor burden and monitoring of treatment response14,15.
As a result, established methods used for response monitoring in other CNS tumors are of
limited value in DIPG16. Length of survival thus serves as the conventional measure of
therapeutic efficacy. Intuitively, this falls short of being able to accurately monitor response to
experimental therapeutics in early stages of clinical development, which therefore hinders the
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effective and hypothesis-driven discovery of therapeutic strategies. Accordingly, CNS tumors
that share an infiltrative and non-enhancing morphology would benefit enormously from new
imaging technologies that can accurately diagnose and delineate tumor tissue.
Particularly for brainstem diseases such as DIPG, where obtaining ex vivo materials for aiding
diagnostic decision-making is not only challenging, but also not feasible on a longitudinal basis,
we recognized that a noninvasive imaging biomarker has enormous value. We have used
optically (PARPi-FL) and isotopically ([18F]PARPi) labeled versions of PARP1-targeted
molecules previously for imaging of solid tumors and have shown their capability to image
PARP1 expression in tumors with high specificity and sensitivity17–22. Using the

18

F-labeled

PARP1-targeted small molecule, [18F]PARPi, and its fluorescent sister agent PARPi-FL, we aim
to explore three clinically relevant questions: (i)How does PARP1 expression in DIPG compared
with healthy tissue, and do genetically engineered mouse models (GEMM) accurately reflect
this? (ii) Do

18

F-labeled PARP1 agents allow noninvasive delineation of DIPG in a pediatric

DIPG mouse model? (iii) How accurately does [18F]PARPi reflect the tumor burden and tumor
growth?
We believe that a quickly and selectively distributing PARP1-targeted marker that can be
injected intravenously can overcome many hurdles currently hampering the development of
efficient DIPG therapeutics. Here, we test one such PET tracer, validate its high sensitivity and
accuracy in pediatric GEMMs, and demonstrate its ability to delineate and monitor DIPG in vivo.
5.2:

PARP1 Expression in DIPG

To probe the clinical relevance of PARP1 in DIPG, we obtained both biopsy tissue specimens
as well as autopsy tissue from patients with histopathologically confirmed DIPG. In the
examined infiltrative malignant brainstem glioma biopsies (n = 4), more than 90% of observed
cell nuclei were positive for PARP1. PARP1 expression was present throughout the tumors, with
the exception of necrotic tissue and areas with proliferative vasculature (Figure 5.2.1). Similarly,
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Figure 5.2.1. PARP1 expression in human biospecimens of DIPG. (a) Immunohistochemical
staining of DIPG biopsy tissue for PARP1 (top) and H&E (bottom). From left to right: low
magnification overview, viable tumor tissue, tumor area with microvascular proliferation (MVP),
and necrosis (N). (b) PARP1 staining of a DIPG autopsy specimen showing infiltrative PARP1positive tumor cells in the dentate nucleus (top), but low PARP1 expression and cellular density
in the frontal cortex of the same brain (bottom) (H&E in Supplementary Fig. S1A). (c) and (d),
Quantification of PARP1 in biopsy (c) and autopsy (d). n = 4 histopathologically confirmed cases
of DIPG; n = 1 DIPG autopsy brain.
high PARP1 expression was observed in the autopsy specimen, where we were able to
compare the tumor region with non-neoplastic neocortex in the same patient, which showed no
tumor involvement. As opposed to the tumor, in the frontal cortex only, a subset of cells
expressed PARP1, such as nuclei of oligodendritic cells and astrocytes, as well as nucleolei of a
subset of neurons (Figure 5.2.1b and Figure A.5.1a). PARP1 abundance in DIPG was further
amplified by the much higher cellularity of high-grade DIPG tissue compared with healthy tissue
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(Figure 5.2.1b). In grade IV biopsy and autopsy tissue, the total area covered by PARP1positive nuclei was high (28.5% ± 8.7% PARP1-positive area in biopsy and 17.5% ± 2.9% in
autopsy tissue vs. 3.5% ± 0.9% in the frontal cortex of the same brain Figure 5.2.1c and Figure
5.2.1d). The PARP1-positive area, together with the associated high target abundance, is
fundamental for sufficient uptake of a molecularly targeted tracer, and to achieve a high tumortobackground contrast.
5.3:

PARP1 Expression in Mouse Models

Encouraged by the robustness of PARP1 expression in human DIPG, we turned to a mouse
model with the aim of determining whether the high levels of PARP1 expression found in human
tissue of DIPG is reflected in GEMMs of this malignancy. Specifically, we quantified and
correlated PARP1 overexpression in a previously established DIPG mouse model of
ntv-a/p53fl/fl, where tumors are formed after somatic gene transfer of oncogenes via retroviral
delivery

23

. For this study, we used two variants of the model, where cells are either injected into

the pons of 2- to 4-day old mice (juvenile model) or into the right hemisphere of 4- to 6- weekold mice (adult model). Upon occurrence of symptoms, which appear in both models within 4–6
weeks after inoculation, brains were processed for histology and stained for PARP1 expression,
proliferation index (Ki67), and morphological features (H&E).
In the juvenile model, tumors were located primarily in the pons, but also showed spread to the
third ventricle and parts of the hippocampus (Figure 5.3.1a). All tumor areas showed a strong
proliferative activity, particularly toward the infiltrative edges, whereas the central regions of
tumors contained a mix of Ki67-positive and Ki67-negative cells. All other regions of the brain
showed almost no Ki67 expression at all (Figure 5.3.1a). Analogous to what was found for Ki67,
PARP1 expression was also significantly higher within areas of infiltration as compared with
healthy, nontumorous tissues (Figure 5.3.1a). Interestingly, PARP1 expression was rather
homogeneous throughout the tumor, with the exception of necrotic areas. Regarding
nontumorous brain areas, we detected slightly higher PARP1 expression in the cortex and the
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Figure 5.3.1. PARP1 expression in mouse model. (a) Immunohistochemical staining of
tumor-bearing brains following tumor generation in ntv-a/p53fl/fl mice. Anti-PARP1, anti-Ki67
(proliferation), and H&E staining for morphological evaluation were carried out on adjacent
sections. (b) Quantification of PARP1 staining in juvenile and adult tumor-bearing mice. ROIs
were placed on tumor (Tu) regions and anatomically defined brain regions (Co, cortex; Po,
pons; Ce, cerebellum; Th, thalamus; n ≥ 3 animals/4–7 ROIs per region). (c)
Tumor-to-brain area ratios. N = 4 for the juvenile brain; n = 3 for the adult brain.
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cerebellum compared with pons and thalamus. While lower than what we found for tumor
tissues, physiological PARP1 expression was observed in the Purkinje cell layer in the
cerebellum and the dentate gyrus (Figure A.5.1b). When we quantified the PARP1-positive area
of the regions of interest (ROI) in tumor and nontumor affected brain areas of healthy animals in
the juvenile model, we found a PARP1-positive area of 35.9% ± 7.1% in the tumor, compared
with 7.4% ± 1.2% in the cortex, 3.8% ± 1.1% in the pons, 3.1% ± 0.9% in the thalamus, and
5.9% ± 1.5% in the cerebellum (P < 0.01, t test, vs. cortex, pons, thalamus, cerebellum; Figure
5.3.1b). When tumors were induced in the cerebral hemisphere of adult mice, very similar
PARP1 staining (Figure A.5.1c) and expression values were found (33.6% ± 4.8% PARP1positive area). Expression in different brain areas was significantly lower (2.1% ± 0.15% in the
cortex, 1.0% ± 0.1% in the pons, 0.8% ± 0.3% in the thalamus, and 2.1% ± 0.6% in the
cerebellum (P < 0.01, t test, vs. cortex, pons, thalamus, cerebellum; Figure 5.3.1b). Ratios of
PARP1 expression in tumor tissue compared with healthy brain areas were generally high. In
the juvenile model, they ranged from 5.0 ± 0.6 to 13.8 ± 2.4 (tumor/ cortex and tumor/thalamus,
respectively) and in the adult model from 16.1 ± 2.2 to 35.8 ± 10.4 (tumor/cortex and tumor/
thalamus, respectively; Figure 5.3.1c). Overall, PARP1 expression levels in tumors were found
to be statistically indistinguishable between the juvenile and adult model applying a random
effects model and using a Likelihood Ratio Test (X2 = 1.57, P = 0.21). Our GEMM PARP1
expression data corresponds to PARP1 expression in human DIPG biospecimens that showed
grade IV histopathology (Figure 5.2.1).
5.4:

DIPG Localization with [18F]PARPi

As a next step, and analogous to what we have seen for the fluorescent PARP1 tracer
PARPi-FL, we tested whether the fluorescent agent's PET active counterpart [18F]PARPi could
be used for noninvasive DIPG imaging. We injected the radiolabeled imaging agent
intravenously in tumor-bearing juvenile ntva/p53fl/fl mice. Correlation of autoradiography images
with H&E histology showed that at 2 hours p.i. of [18F]PARPi, the PET signal originated from
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Figure 5.4.1. PARPi-FL microscopy and [18F]PARPi autoradiography. Mice were injected with
PARPi-FL or [18F]PARPi upon occurrence of symptoms of tumor growth (gait instability, weight
loss, crouching, head swelling). Mice were sacrificed and brains were processed for
cryoconservation 2 hours p.i. of PARPi-FL. Adjacent sections were stained for PARP1
expression and H&E. (a) PARPi-FL microscopy. Cryosections were costained with Hoechst
DNA stain. n = 5. (b) High magnification images. (c) [18F]PARPi autoradiography. (d)
Quantification of autoradiography where ROIs were placed on activity hotspots, tumor-adjacent
brain, and corresponding sections in healthy brains (n = 3–8 ROIs per specimen). (e)
Quantification of autoradiography where ROIs were placed on entire sections. (f) Signal ratios
for autoradiography. t, tumor; n, normal brain; ta, tumor adjacent; h, hotspot; s, section.
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areas infiltrated by tumor cells (Figure 5.4.1c), identifying tumor activity hotspots, and even
tumors of less than 1.5 mm diameter showed uptake of [18F]PARPi with clear contrast to
background. In mice that did not receive an injection of virus carrying DF1 cells, no activity
hotspots or histological signs of malignant growths were found, indicating that the uptake is
connected to PARP1 expression and, consequently, tumor specific (Figure 5.4.1c).
Quantification of the signal intensity showed clearly higher signal in DIPG than in normal brain
of tumor bearing and control animals (Figure 5.4.1d). When size and number of hotspots was
not considered and average signal intensity of tumor-bearing brains was compared with normal
brains, there was also a clear, statistically significant cutoff value between the groups with no
overlap (Figure 5.4.1e; P < 0.0001, Student unpaired t test). To evaluate the strength of contrast
ratios between the different groups, we calculated mean values for each group. The average
signal in entire sections containing tumor hotspots was 7 times higher than healthy brain
sections. The average signal in ROIs focusing on tumor hotspots was 15-fold higher than in
tumor-adjacent areas of the same sections and 47-fold higher than randomly assigned areas of
the same size in healthy brains (Figure 5.4.1f).
Encouraged by the robustness of our PET imaging tracer, we decided to use the juvenile DIPG
mouse model to noninvasively probe the specificity of [18F]PARPi accumulation in vivo, using
both animals that showed symptoms of tumor presence and agematched healthy controls. For
tumor-bearing mice, PET/CT images 2 hours p.i. revealed an accumulation of [18F]PARPi in the
pons of animals that could be correlated to the presence of tumor on H&E and PARP1
histological slides (Figure 5.4.2a). Probing the selectivity of [18F]PARPi, we injected 1 mg
olaparib before injection of the tracer. This was done in an attempt to saturate available binding
sites, and consequently block the uptake of the tracer. For this cohort of mice, no accumulation
of the probe could be observed, irrespective of tumor tissue being present in the pons, as
confirmed by H&E- and PARP1-stained slides (Figure 5.4.2a). [18F]PARPi PET/CT imaging of
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Figure 5.4.2. PET/CT images. (a) Representative PET/CT images of the brainstem region
compared with H&E and PARP1 staining of the same animals. White arrow = tumor location. (b)
Quantification of %ID/g of the entire brain was derived from the PET/CT data set using the CT
as reference for creating VOIs. (c) Similarly, the %ID/g was analyzed for the brainstem region
using the CT as reference for creating VOIs.
healthy mice looked similarly negative. For quantification, volumes of interest (VOIs) were
created to encompass either the entire brain or the pons of each animal using the CT images for
anatomical reference. Calculation of the percentage of injected dose per gram (%ID/g) revealed
that the average %ID/g was significantly increased to 0.45 ± 0.07 %ID/g in tumor-bearing brains
injected with [18F]PARPi, compared with healthy animals and animals receiving a preinjection of
olaparib (0.25 ± 0.03 %ID/g and 0.23 ± 0.02 %ID/g, respectively; P < 0.05; Figure 5.4.2b). The
differences were even more pronounced when only the pons was considered (0.63 ± 0.19
%ID/g vs. 0.25 ± 0.01 and 0.22 ± 0.03 %ID/g, respectively; P < 0.05; Figure 5.4.1c). Hence,
binding specificity could be confirmed by statistically significant reduction of [18F]PARPi uptake
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by preinjection of excess PARP1 inhibitor olaparib. No statistically significant differences were
found between healthy animals and animals receiving olaparib (P = 0.3 when considering the
whole brain and P = 0.1 when considering the pons; Student unpaired t test).
5.5:

Comparison with MRI, CT and Histology

Next, we compared the ability of different in vivo imaging modalities to spatially resolve the
growth pattern of DIPG, using histology as a gold standard. We could confirm that the location
and extent of the tumor as determined using [18F]PARPi PET accurately represents the tumor
volume and the area of increased PARP1 expression (white arrow, Figure 5.5.1). In the adult
model of DIPG, we were also able to delineate tumors in T2-weighted MRI. Increased interstitial
edema caused a strong MRI signal change, which was not seen in [18F]PARPi-PET images
(orange arrow, Figure 5.5.1). Using CT alone, tumors did not show contrast due to absence of
soft tissue contrast in small animal CT. Outside of the brain, [18F]PARPi generated a strong

Figure 5.5.1. Comparison with MRI. Top (left to right): CT, PET, and PET/CT 1 hour p.i. of
[18F]PARPi. Bottom (left to right): T2-weighted 1.05T MRI image, PARP1 IHC (brown staining),
and H&E. All images are from the same animal. PET/CT and MRI were conducted on the same
day and the animal was sacrificed immediately after MRI to preserve the brain for histology.
White arrow, tumor location. Orange arrow, an accumulation of cerebrospinal fluid, which
causes a strong MRI signal, but is not seen in [18F]PARPi imaging.
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signal in the gut, due to its hepatobiliary excretion (Figure A.5.3). Beyond the gut, it specifically
localizes only to PARP1-expressing tissues, which can be seen by comparing PARP1 IHC of a
range of tissues and organs (Figure A.5.4) to biodistribution data of [18F]PARPi with and without
blocking using olaparib (Figure A.5.5), revealing the spleen, lymph nodes, salivary gland, and
pancreas as tissues with PARP1 expression.
5.6:

Comparison with Other PET Brain Tracers

To determine whether PARP1 expression and [18F]PARPi uptake in the brain coincides with the
elevated metabolism and DNA synthesis rate typically seen for aggressively growing malignant
cells, we subjected tumor-bearing animals to [11C]Choline and [18F]FLT PET/CT in addition to
[18F]PARPi PET/CT. All animals (n = 5) also received noncontrast-enhanced MRI scans (Figure
5.6.1a). Unequivocal tumor detection with [11C]Choline imaging (10 minutes p.i. of 378 ± 343
µCi) led to a visible tumor to background contrast in 3/5 animals. The mean %ID/g in tumor was
2.74 ± 0.71 and in nontumor tissue 1.96 ± 0.34 %ID/g). [18F]PARPi and [18F]FLT were both
conducted at 2 hours p.i. of comparable amounts of activity (162 ± 22 mCi and 147 ± 19 mCi for
[18F]PARPi and [18F]FLT, respectively). The mean uptake in tumor was 0.3 ± 0.12 %ID/g for
[18F]PARPi and 1.27 ± 1.19 %ID/g for [18F]FLT, showing higher overall uptake, but also higher
variability in probe uptake, yielding less consistent uptake values (Figure 5.6.1b). The
background uptake in nontumor brain tissue was lower for [18F]PARPi than [18F]FLT (0.08 ± 0.04
%ID/g vs. 0.18 ± 0.15 %ID/g, respectively. Although both [18F]PARPi and [11C]Choline showed
statistically significant differences in mean %ID/g comparing tumor and nontumor areas (P =
0.02 and P = 0.04, respectively, paired two-tailed t test), [18F]FLT did not (P = 0.1). However, we
observed a high variability of the signal and the number of animal studies was rather small.
Tumors were also visible in T2-weighted MRI images acquired on a 1.05T MRI; however, strong
variations of the T2 signal within animals was observed. Histological evaluation of all tumors
confirmed presence of PARP1 overexpression within tumor tissue (Figure 5.6.1a). We
confirmed that [18F]PARPi is able to delineate brain tumors with a clear contrast with normal
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brain tissue, and uptake location is in agreement with metabolic PET tracers. Although these,
together with MRI, are also able to delineate tumors, they cannot provide information on PARP1
expression, target engagement, and treatment eligibility monitoring, which is a unique feature of
[18F]PARPi.

Figure 5.6.1. Comparison with other PET imaging agents. (a) Representative PET/CT images
of the same tumor-bearing animal (adult model, right hemisphere) using [18F]PARPi (2 hours
p.i.), [11C]Choline (5 minutes p.i.), [18F]FLT (2 h p.i.), and MRI (T2 weighted) compared with
PARP1 IHC and H&E histology. [18F]FLT and MRI were conducted 48 hours after the
[18F]PARPi and [11C]Choline imaging. Calibration bar represents %ID/g. (b) Quantification of the
mean %ID/g of a VOI in the tumor area compared with a control area in the back region of the
brain.
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5.7:

Monitoring Tumor Progression

We further evaluated the capability of [18F]PARPi to monitor tumor growth by performing weekly
imaging using ntv-a/p53fl/fl mice injected with DF1 cells in the right hemisphere at 4–6 weeks of
age. We were able to detect focal accumulation of [18F]PARPi in week 5 p.i., showing hotspots
of activity of 1.5–2.0 mm in size. These hotspots showed considerably increased mean and max
%ID/g within one week (Figure 5.7.1a and Figure A.5.6a). The hotspots in the PET/CT imaging
could be confirmed to correlate with tumor tissue using histology. The [18F]PARPi retention was
quantified using a retrospective approach, where the confirmed tumor location in week 6 was

Figure 5.7.1. Tumor growth monitoring. (a) Tumor development was followed over the course of
6 weeks. H&E and PARP1 histology were conducted after the last imaging time point. (b) VOIs
were created in the tumor region and control region using the PET/CT and histologically
confirmed tumor location. These were then applied to earlier imaging time points. (c) Mean and
(d) max %ID/g for 3 to 6 weeks post-tumor inoculation.
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used to draw a VOI in the same region of all scans recorded in previous weeks (Figure 5.7.1b).
Quantification of mean and maximum %ID/g in the tumor area showed that an increase in
uptake was observed in week 5, which strongly increased in week 6, whereas the uptake in
nontumorous tissue and the entire brain remained unchanged over the course of the experiment
(Figure 5.7.1c and Figure 5.7.1d). Tumor-bearing animals began showing symptoms such as
weight loss, crouching, gait-instability and scruffy fur in week 6 of the experiment and had to be
sacrificed by week 7. One animal showed no uptake of [18F]PARPi over 7 weeks and was
histologically confirmed to have no tumor growth (Figure A.5.6b).
5.8:

Conclusion

In summary, our radiolabeled small-molecule [18F]PARPi efficiently targets PARP1, in vitro and
in vivo, a biomarker that is highly expressed in DIPG. To date, no biomarkers are used as the
standard of care in diagnosis or treatment of DIPG. Our results indicate that not only does
[18F]PARPi allow serial imaging, but histological slides also show that PARP1 expression might
correlate to different types of CNS neoplasms (including benign lesions), inflammation, and
radiation induced necrosis. Notably, quantification of [18F]PARPi in the brain indicates that it
might be possible to determine the presence of tumor by looking at the average total brain
uptake. Because PET imaging only requires miniscule amounts of radiolabeled tracer, the
imaging technology we present here would not interfere with therapeutic treatment protocols
and might provide robust treatment criteria for patients—even before the progression/regression
of tumor tissue is observed. In conclusion, our preclinical results indicate a strong rationale for
further investigating [18F]PARPi, and clinical translation of our small molecule is within reach.
5.9:

Experimental

Human biospecimens. Formalin-fixed paraffin-embedded tissue (FFPE; n = 4 surgical biopsies
and n = 1 autopsy specimen of diffuse midline glioma) were obtained from the tissue archives at
Weill Cornell Medicine. The use of archival tissues was approved by the Institutional Review
Board (IRB) at Weill Cornell Medical College and consent was waived as by the IRB approval.
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In vivo tumor generation. DIPG development was modeled using a glioma model based on
the RCAS/tv-a system where tumors are initiated by somatic gene transfer of oncogenes into
genetically engineered mice carrying oncogenic driver mutations23. Specifically, we used p53
deficient nestin/tv-a mice (ntv-a/p53fl/fl mice), which express the retroviral receptor for the RCAS
vector in neuroglial progenitor cells. In vivo tumor development was initiated by the delivery of
two oncogene-expressing RCAS vectors (RCAS-PDGFB and RCAS-Cre), which were
transfected into immortalized chicken fibroblasts using the Fugene 6 transfection kit (no.
11814443001; Roche) according to the manufacturer’s recommendations (DF-1 cells)24. DF1
cells were obtained from ATCC (ATCC® CRL12203™) in 2014. Cells were expanded
immediately and all experiments were conducted on the same batch of cells frozen as Passage
2. Cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) with 4.5 g/L glucose,
L-glutamine, and sodium pyruvate with 10% FBS and 2% normocin at 39°C, 5% (vol/vol) CO2,
and passaged every 3-4 days under sterile conditions.
To generate tumors, RCAS-PDGFB and RCAS-Cre DF1 were mixed in a 1:1 ratio and diluted to
a concentration of 100,000 cells/µl before injection of 1 µl of cell suspension. To generate a
pediatric tumor model, newborn pups aged 2-4 days were injected. Pups were held with a light
grip on the ears to ensure the skull sutures were visible. Using a beveled needle on a 10 µl
Hamilton syringe, the needle was lowered 2 mm deep into the brain from an approximate
location of 2 mm posterior to lambda to target the pons. After 1 µl of cells was pushed free hand
into the brain, the needle was held in the brain for a few seconds. A similar strategy was used in
adult mice (4-6 weeks at time of injection). Injections were made using a stereotactic frame
(David Kopf Instruments Model 900) and a micro4 injection pump and controller (World
Precision Instruments). Mice were anesthetized using 2% isoflurane. The skull was exposed
and the injection site at coordinates 2 mm right and 0.5 mm anterior from Bregma, and 3.5 mm
deep from the skull surface, was identified. A small hole was drilled into the skull surface, and
the syringe (World Precision Instruments Nanofil Syringe) was lowered into the brain. One µl of
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cell suspension was infused at a rate of 100 nl per minute. The syringe was left in the skull to
settle for 5 minutes before and after the infusion. Animals were continuously monitored for
common symptoms including weight loss, gait instability, hunched bodies, and scruffed fur. In
juvenile and adult mice, symptoms started showing around 4-5 weeks post-inoculation. All
animal experiments were performed in accordance with institutional guidelines and approved by
the IACUC of MSK, and followed NIH guidelines for animal welfare.
Immunohistochemical staining. Staining was carried out using primary antibodies against
PARP1 (sc-7150, Santa Cruz Biotechnology), Ki67 (proliferation; AB16667, Abcam), and CD31
(endothelial cells; DIA-310, Dianova) using formalin-fixed, paraffin-embedded sections (FFPE).
If we aimed to detect i.v. injected PARPi-FL fluorescence in adjacent sections, frozen samples
were used.
PARP1 immunohistochemistry of human and mouse FFPE sections was carried out using the
automated Discovery XT processor (Ventana Medical Systems). Three-µm sections were
deparaffinized with EZPrep buffer, antigen retrieval was performed with CC1 buffer (both
Ventana Medical Systems), and sections were blocked for 30 minutes with Background Buster
solution (Innovex). Anti-PARP1 antibody (0.2 µg/ml) was incubated for 5 h, followed by 1 h of
incubation with biotinylated goat anti-rabbit IgG (PK6106, Vector Labs) at a 1:200 dilution. For
IHC detection, a DAB detection kit (Ventana Medical Systems) was used according to the
manufacturer’s instructions. Sections were counterstained with hematoxylin and cover-slipped
with Permount (Fisher Scientific).
CD31 and Ki67 staining of FFPE or frozen sections were carried out using the Leica Bond RX
(Leica Biosystems). FFPE sections were deparaffinized and frozen sections were baked for 1 h
at 50°C. Then sections were pretreated with Leica Bond ER2 Buffer (Leica Biosystems) for 20
min at 100°C before each staining. For Ki67, sections were incubated with 1 µg/ml Ki67 rabbit
polyclonal for 1 h followed by either 10 min 1:200 Tyramide AlexaFluor 488, for IF, or protocol F
(default from manufacturer), for IHC. For CD31 staining, sections were incubated with 1 µg/ml
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CD31 rat monoclonal for 1 h and a linker antibody—1.5 µg/ml biotinylated rabbit anti-rat
Vectastain ABC kit (Vector Laboratories) for 8 min, followed by 10 min 1:200 Tyramide
AlexaFluor 488 (for IF) or protocol F (default from manufacturer), for IHC. Adjacent sections
were stained for H&E for morphological evaluation.
Multicolor immunofluorescence staining. To evaluate co-localization of PARPi-FL, PARP1,
CD31, and Ki-67, multicolor immunofluorescence (IF) staining on cryosection was conducted
following a manual staining protocol using the same antibodies as mentioned above. IF
detection was performed with Streptavidin-HRP D (from DABMap Kit, Ventana Medical
Systems), followed by incubation with Tyramide Alexa Fluor 488 (T20932, Invitrogen), Alexa
Fluor 568 (T20935, Invitrogen), or Alexa Fluor 594 (T20935, Invitrogen) prepared according to
the manufacturer’s instructions, to allow for simultaneous detections of all markers. Sections
were counterstained with 4’,6-diamidino-2-phenylindole (DAPI) for 10 minutes and cover-slipped
with Mowiol® mounting medium (Sigma-Aldrich). Incubating with a nonspecific IgG from the
same species as the primary antibody instead of the primary antibody controlled for non-specific
binding of the secondary antibody. For morphological evaluation of tissue characteristics, H&E
staining was performed on adjacent sections. Fluorescence images were captured using a
Leica (Buffalo Grove, IL) SP5-upright confocal microscope equipped with suitable lasers and
emission filters.
Synthesis of PARPi-FL. Synthesis of the optical imaging agent PARPi-FL was carried out as
previously described18. Briefly, the NHS-ester of the green fluorescent dye BODIPY-FL
(Invitrogen, Carlsbad, CA) was conjugated to 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)
phthalazin-1(2H)-one for 4 h at room temperature. The product PARPi-FL was purified by
preparative HPLC (Waters’ XTerra C-18 5 µm column, 7 ml/min, 5% to 95% of acetonitrile in
15 min) with a yield of 70-79% as a red solid and its identity was confirmed using ESI-MS
(MS(+) m/z = 663.4 [M+Na]+). Analytical HPLC analysis (Waters’ Atlantis® T3 C18 5 µm
4.6 × 250 mm column) showed high purity (>97%) of the imaging agent. For storage at -80 °C,
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PARPi-FL was formulated in polyethylene glycol (PEG300, Sigma-Aldrich) at a concentration of
1 µg (1.5 nmol)/µl. Before in vivo injection, PBS was added until a final concentration of 30%
PEG300 in PBS was reached. Intravenous injection in juvenile mice was limited to a final
volume of 50 µl (15 µg/22.4 nmol PARPi-FL).
Synthesis of [18F]PARPi. Similar to PARPi-FL, [18F]PARPi is based on the structure of olaparib
and was synthesized similar to a protocol reported before21. Specifically, a QMA cartridge
containing cyclotron-produced [18F] fluoride ion (50 mCi, 1.85 GBq) was eluted with a solution
containing

9

mg

Kryptofix

[2.2.2]

(4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8]

hexacosane), 0.08 ml 0.15 M K2CO3, and 1.92 ml MeCN into a 5 ml reaction vial. Solvents
were removed azeotropically at 120 °C under N2. Afterward, 500 µg of ethyl 4-nitrobenzoate in
100 µl of dry DMSO were added and the mixture was heated to 150 °C for 15 min. Next, 50 µl of
NaOH was added, followed by 50 µl of HCl. Then, 2 mg of 4-(4-fluoro-3-(piperazine-1carbonyl)benzyl)phthalazin-1(2H)-one in 100 µl of dry DMSO were added, followed by 10 mg of
HBTU dissolved in 100 µl of DMSO and 20 µl of Et3N. Finally, 400 µl of MeCN and 1 ml H2O
were added to the mixture and the product was purified by HPLC yielding 38.4 ± 2.5%.
Synthesis of [11C]-Choline. [11C]Choline was produced in the Radiochemistry & Molecular
Imaging Probes Core Facility at MSKCC by the on-site PETtrace800 cyclotron and GMP
production facility using an established workflow25,26. In brief, [11C]Choline was synthesized by
11

C-methylation of dimethylethanolamine (DMEA, 40 µl) in acetone and the reaction mixture was

incubated at room temperature in a GE FXM synthesizer (GE, Fairfield, CT). Next, the product
was isolated and extracted using a cation-exchange cartridge (CM light, Milford, MA) previously
rinsed with ethanol. The final product was eluted with sterile saline (dcY > 30% in a 15-minute
total synthesis time) through a sterilization filter for further imaging studies.
Synthesis of 3’-deoxy-3’[18F]-fluorothymidine ([18F]FLT). Synthesis of [18F]FLT was carried
out as described before27,28. Briefly, a QMA cartridge containing cyclotron-produced [18F] fluoride
ion (50 mCi, 1.85 GBq) was eluted with a solution containing 9 mg Kryptofix [2.2.2]
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(4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane), 0.08 ml 0.15 M K2CO3, and
1.92 ml MeCN into a 5 ml reaction vial. Solvents were removed azeotropically at 120 °C under a
slight flow of nitrogen. Thereafter, 5 mg of precursor 3-N-Boc-5’-O-dimethoxytrityl-3’-O-nosylthymidine (6.02 µmol) in 500 µl dry acetonitrile were added, then the reaction mixture was
heated to 150 °C for 10 min. After cooling to room temperature, 1 N hydrochloric acid (400 µl)
was added and the reaction mixture was heated to 90 °C for 10 min. The reaction mixture was
neutralized by the addition of 2 M sodium acetate solution (1.3 ml) and purified by HPLC
yielding 16.7% (21.7% decay-corrected) of pure [18F]FLT.
Autoradiography. To determine the localization of [18F]PARPi in the brain after i.v. injection, we
conducted autoradiography on tumor-bearing (n=4) and healthy (n=2) animals (juvenile
ntv-a;p53fl/fl mice, injected with DF1 cells at postnatal day 2-4). Animals were injected with 150170 µCi [18F]PARPi via retroorbital injection and sacrificed at 2 h p.i. The brains were extracted
without perfusion, embedded in OCT compound (Sakura Finetek), and immediately frozen on
dry ice. 20 µm serial cryosections were sliced from frontal to caudal using a cryostat (Vibratome
Ultra Pro 5000). Nine coronal sections, selected in an equidistant fashion to cover all brain
areas, were selected for autoradiography and adjacent sections were H&E stained for
morphological correlation of tissue pathology and radiotracer localization. A storage phosphor
autoradiography plate (Fujifilm, BAS-MS2325, Fiji Photo Film) was exposed to the tissue slices
overnight at -20 °C and read the following day. Relative count intensities were determined using
ImageJ 1.47u processing software (source: http://rsbweb.nih.gov/ij/). Regions of Interest (ROIs)
included entire brain sections and activity hotspots, which were identified as tumor on H&E. To
calculate count ratios between groups (tumor hotspot/normal adjacent brain, tumor-bearing
brain/normal brain), the mean value of each group was used.
PET/CT imaging—general. PET/CT images were acquired on an Inveon PET/CT (Siemens)
and reconstructed scans were analyzed using the Inveon Research Workplace Software. To
acquire PET/CT images, animals were anesthetized with 2% isoflurane and positioned on the
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scanner bed. For [18F]PARPi imaging, animals were intravenously injected with 120–180 mCi of
the tracer 2 hours before PET/CT imaging, if not indicated otherwise. Typically, PET data were
collected for 5–10 minutes, followed by CT. Correction for partial volume effects was not carried
out, due to the lack of availability of a reference standard for tumor volume.
Specificity of [18F]PARPi accumulation in vivo. To determine specificity of in vivo
accumulation of [18F]PARPi, juvenile ntv-a;p53fl/fl mice with tumors located in the brainstem (n .
6) or control mice without tumors (n = 3) were divided into three groups. Tumor-bearing and
healthy (=control) animals were injected with [18F]PARPi (n = 3/group) or tumor-bearing animals
were injected with 1 mg olaparib 30 minutes before injection of [18F]PARPi (n = 3) to occupy
specific binding sites ("Block"). We calculated the percentage of injected dose/gram (%ID/g) for
the entire brain or the pons region of all three groups. Therefore, we created three-dimensional
volumes of interest (VOI) using the CT data acquired together with the PET images.
Subsequently, animals were submitted to intracardiac perfusion and preservation of brains for
histology as described above. H&E staining and PARP1 IHC (methodology described above)
were used to compare localization of [18F]PARPi to the presence of tumors.
Comparison of [18F]PARPi, [18F]FLT, and [11C]Choline in PET/CT using adult mice. The
PET contrast agents [18F]FLT and [11C]Choline, which are clinically used for imaging
malignancies of the brain, as well as MRI, were compared with [18F]PARPi imaging. Here, we
used ntva;p53fl/fl mice injected with DF1 cells in the right hemisphere at 4- to 6-weeks-old (n =
5). Each animal underwent all four imaging procedures. Five weeks after tumor inoculation, we
first imaged [11C]-Choline and [18F]PARPi on the same day, followed by [18F]FLT and MR
imaging 48 hours later. For [11C]Choline imaging, we injected 100–900 mCi per animal. Imaging
was started 10 minutes after intravenous injection of [11C]Choline for 10 minutes, followed by
CT. Five hours later, 100–200 mCi [18F]PARPi was injected into the same animals and imaged 2
hours p.i. using a 5-minutes scan protocol followed by CT. Two days later, we imaged the same
animals using [18F]FLT after injection of 120–180 mCi. Images were acquired at 2 hours p.i.
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using a 10-minutes scan followed by CT. Later on the same day, we acquired MR images of the
same animals.
PET/CT imaging in adult mice using [18F]PARPi to follow tumor Growth. To monitor tumor
growth rate and determine minimum required tumor volumes for imaging, we conducted an
imaging study over the course of 6 weeks using ntv-a;p53fl/fl mice injected with DF1 cells in the
right hemisphere at 4- to 6-weeks-old (n = 4). At 3 weeks after tumor inoculation, we started a
weekly imaging schedule. Every 7 days, we injected 100–200 mCi [18F]PARPi and conducted
PET/CT imaging 2 hours p.i. using a 5-min PET scan, followed by CT. At the end of the study,
we conducted an MRI. Intracardiac perfusion was carried out as described above and brains
were submitted for H&E and PARP1 histology. Quantification of the %ID/g was carried out
retrospectively. VOIs were created after tumor development was confirmed using the PET/CT
and MRI images from week 6 and placed in the same brain areas in the PET/CT images of the
previous weeks. Furthermore, the %ID/g of the entire brain, independent of tumor presence or
size, was analyzed.
Magnetic resonance imaging. MRI was performed on a 1.05 T small animal imaging system
(NanoScan, Mediso Inc.). The imaging protocol included localizer gradient-echo images used to
plan sequential high-resolution T2-weighted, pre-contrast T1-weighted image, and post-contrast
T1-weighted images. The axial slice FOV was 32 ⨉ 32 mm, 2 mm slice thickness (no slice gap),
with 8 slices sufficient for full brain coverage. The matrix size was 128 ⨉ 128. A NEX of 4
provided sufficient SNR. For the T2-weighted images, TR was 4377 ms, effective TE was 90
ms, and ETL was 32.
Statistical analysis. For histological analysis, we evaluated at least 3 different stained samples
with more than 5 analyzed fields-of-view before statistical analysis was carried out. In vivo, a
minimal animal number per group of 3 mice was required for statistical analysis and was
extended to 5 where possible. Unless otherwise stated, data points represent mean values and
error bars represent standard deviations of biological replicates. Statistical analysis was carried
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out using Prism 6.0c (GraphPad Software) and R. To evaluate differences between groups we
used the unpaired Student t test, assuming populations with an equal SD, unless otherwise
stated. If more than two groups were compared, we corrected for multiple comparisons using
the Holm-Sidak method. Cutoffs for statistically significant differences between groups were
chosen at P values smaller than 0.05 and discrete P values are reported in the respective
locations.
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CHAPTER 6: [18F]PARPI-SMALL CELL LUNG CANCER
This chapter is an adaptation of another work, and is reproduced in part, from Carney, B.,
Kossatze S., Lok B.H., Schneeberger, V., Gangangari K.K., Pillarsetty, N.V.K., Weber W.A.,
Charles C.M., Poirier J.T., Reiner T.. Target Engagement Imaging of PARP Inhibitors in Small
Cell Lung Cancer. (under revision)

6.1:

Introduction

While the diagnosis and treatment of many malignancies have seen significant improvements
over recent decades1, the 5-year survival rates of small cell lung cancer (SCLC), a subset of the
general lung cancer population (13%, 29,000 of 221,000 patients in US annually) remain around
5% and are below 1% for the over 60% of patients that are diagnosed with extensive stage
disease. The standard of care for advanced SCLC has essentially remained stagnant for more
than 30 years.
The lack of progress, in part, can be attributed to the aggressive nature of this disease, which is
exceptionally proliferative and rapidly develops resistance to chemotherapy. Therefore, novel
treatment approaches are needed. Therapeutics that are targeted against a tumor specific
biomarker have gained large interest because they can specifically act against tumor cells
without the systemic toxicity and side effects of chemo- or radiotherapy. In the clinical reality,
however, only a subset of patients responds well to targeted therapies. A better understanding
of the spatial distribution and quantification of the target as well as the intratumoral drug-target
interaction could strongly improve targeted therapy approaches by identifying particularly
sensitive or resistant patient sub-populations, and by allowing ongoing monitoring of emerging
resistance, enabling rapid change in chemotherapy regimens.
A radiolabelled, non-invasive imaging tracer would be an ideal candidate for such a diagnostic
tool, because it would allow unlimited “sampling” of all metastases in an individual patient and
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provide contemporaneous uptake values, allowing quantitative measurements before, during
and after treatment cycles.
One class of therapeutics that are being investigated as new treatment options for SCLC, are
poly ADP-ribose polymerase (PARP) inhibitors. PARP inhibition, and the associated
perturbation of the single-stranded DNA repair pathway, has been shown to be a promising
therapeutic approach in both preclinical and clinical research settings2. The combination of
PARP inhibitors and DNA damaging agents, such as temozolomide, has seen recent success
and sufficient delivery of both drug classes potentiates their therapeutic effects2,3. One reason
for this is that DNA damage repair plays an important role in the sensitivity of SCLC to
chemotherapeutic agents, and consequently, current standard of care therapies for SCLC
contain at least one DNA damaging agent. This sensitivity can be attributed in part to the
genetics of this disease: nearly all patients have loss of the tumor suppressor genes TP53 and
RB1, which are critical to the normal function of multiple DNA damage response pathways and
G1/S checkpoint maintenance, respectively4,5. Critically, there is not only consistent protein
overexpression of PARP1 in SCLC, but also increased sensitivity to PARP1/2 inhibitors, despite
of intact BRCA6. Based on these observations and the underlying genetics of the disease,
PARP inhibition is gaining considerable attention as a novel systemic treatment for SCLC (i.e.,
NCT02289690, NCT02734004, NCT01286987).
“One-size-fits-all” flat dosing regimens, or weight-based dosing regimens, have generally been
used for members of this drug class, several of which have advanced to phase III trials. While
this may be sufficient for some clinical applications, many patients – and in particular SCLC
patients – may benefit from an immediate readout for determining the degree of on-target
intratumoral PARP inhibition and, consequently, an imaging probe that can monitor and quantify
PARP1/2 inhibition success.
In light of the expanding clinical relevance of PARP therapeutics, and the diversity of novel
agents in this area, we became interested in exploring in vivo pharmacodynamic monitoring of
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PARP inhibitor target engagement in SCLC. A number of PARP therapeutics have entered late
phase clinical research (niraparib, talazoparib, veliparib) or are already FDA approved
(rucaparib, olaparib). While all of these small molecules possess unique pharmacokinetic
profiles and therapeutic indices, they share one common binding motif: the NAD+ active site
pocket of PARP. Therefore, while the development of an imaging tracer for each individual
therapeutic would require considerable preclinical and clinical resources, we hypothesized that
a single imaging tracer may be used to quantify target engagement for a broad group of PARP
inhibitors, unlike other classes of drugs.
To test this hypothesis, we designed a series of experiments central to clinical translation of
PARP target engagement imaging, which that addresses 3 fundamental questions: 1) What is
the range of PARP expression in SCLC and will this range support quantitative assessment of
PARP imaging? 2) Are the putative imaging reagents, [18F]PARPi and PARPi-FL, selective
binders of PARP and do they have the same binding profile as their therapeutic counterparts?
3) Can target inhibition of PARP be quantified for PARP therapeutics generally and can our
PARP imaging agents non-invasively predict target engagement in vivo?
We believe that finding and validating [18F]PARPi as a widely applicable, easy-to-use general
PARP target engagement imaging agent is of high value for optimizing SCLC treatment. Such
an agent would not only serve as a “companion imaging agent” for one individual molecularly
targeted drug, but rather a whole class of therapeutics, dramatically expanding and amplifying
its potential utility in clinical practice. Here, using patient-derived xenograft models of SCLC, we
present a highly sensitive and accurate technology for quantifying PARP inhibitors and target
engagement in vivo in support of the clinical relevance of [18F]PARPi for treatment monitoring
and prediction.
6.2:

PARP Family Cross Reactivity

PARP enzymes are a family of 17 proteins that share the same catalytic PARP domain7. PARP
inhibitors have been shown to exhibit a wide range of pharmacologic specificity within this
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Figure 6.2.1. Cross family reactivity. Heat map visualizing enzymatic activity screening of 10
small molecules against 12 PARP enzymes at 100 nM concentration (for additional
concentrations, see Figure A.6.1).
family7. For SCLC in particular, upregulation and overexpression of PARP1 has been
demonstrated, and is proposed as a therapeutic target6. In developing PARP targeted imaging
agents, we first wanted to ensure that the modifications made for imaging did not substantially
alter target engagement with the key PARP enzymes. To determine the specificity of our
imaging agents within this family of enzymes, and to compare their inhibition profile to clinically
relevant PARP therapeutics, we conducted an enzyme activity inhibition screening across all
available enzymes. Included in the study were 5 inhibitors in phase III clinical trials or FDA
approved: olaparib, veliparib, talazoparib, niraparib, and rucaparib, together with our imaging
agents [18F]PARPi and PARPi-FL. We also included AG14361, (Ki(PARP1) < 5 nM)8, UPF1069
(IC50(PARP2) = 0.3 ± 0.1 µM)9, and iniparib as negative control. We assessed the inhibitory
activities of the PARP therapeutic agents and our imaging agents across 12 PARP enzymes
including tankyrases TNKS1 and TNKS2 (Figure 6.2.1 and Figure A.6.1). The imaging agents
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generally exhibited comparable or higher specificity for PARP1/2 compared to the therapeutic
molecules. At 100nM, all therapeutic molecules, except niraparib, inhibited activity in PARP3 as
well as PARP1/2 (>35% for PARP3, >90% for PARP1 and PARP2). Talazoparib also exhibited
inhibition for both tankyrase enzymes, TNKS1 and TNKS2.

19

F-PARPi (the non-radioactive

analogue to [18F]PARPi) and PARPi-FL showed very low inhibition of TNKS1 and TNKS2 (≤5%)
and PARP3 (≤30%). Inhibition of PARP1 and PARP2 was strong (both >90%), overlapping with
the therapeutic clinical candidates – and providing a rational basis for using our imaging agents
as general sensors for PARP1/2 target engagement. Further comparison of all inhibitors used in
this study showed similar binding affinities for all inhibitors including the imaging agents, with
low nanomolar IC50 values reported for both PARP1 and PARP2 (see Chapter 1: Table 1.5.1).
One notable difference is in the trapping ability reported for each inhibitor, a mode of efficacy
whereby the inhibitor traps the PARP enzyme at the site of DNA damage, leading to further
DNA damage and ultimately cell death10,11. It has been reported that talazoparib is the most
effective PARP trapping agent12, as well as the most potent PARP inhibitor in SCLC clinical
testing13.
6.3:

PARP1 Expression in SCLC PDX Models

In order to better understand the possible benefit of PARP targeted therapy and imaging for
SCLC, we investigated PARP1 expression in 8 different PDX lines and tissues from 6 different
mouse organs (Figure 6.3.1). Using PARP1 specific antibody staining on tissue microarrays, we
found that all SCLC PDX exhibited elevated PARP1 expression compared to lung, kidney,
muscle, liver and brain. All 7 PDX SCLC lines exhibited greater than 60% PARP1 positive area
(between 64 ± 6% PARP1 positive area for JHU-LX92 and 86 ± 3% PARP1 positive area for
JHU-LX102), while all organs, except for spleen, exhibited lower than 5% PARP1 positive area
(Figure A.6.2), emphasizing the quantitative difference in PARP1 density for binding of PARP1
targeted agents. Spleen showed higher PARP1 expression than the other organs, with a 26 ±
1% PARP1 positive area. The lowest PARP1 expression was seen in lung squamous cell PDX
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Figure 6.3.1. PARP expression in PDX cell lines. PARP1 expression was assessed via
immunohistochemistry staining on tissue microarrays (TMAs) in 8 PDX lines and 5 normal
control tissues. Scale bar represents 200 µm (whole core) and 20 µm (inset). All PDX cell lines
are SCLC, except JHU-LX88, which is squamous cell lung cancer. (See Figure A.6.2 for
quantification).
line, JHU-LX88, with 18 ± 6% PARP1 positive area. JHU-LX22 and JHU-LX48 (subsequently
used for in vitro and in vivo studies), expression was 85 ± 4% and 78 ± 6% PARP1 positive
area, respectively.
6.4:

Pharmacokinetics

In order to map the pharmacokinetics of [18F]PARPi in the JHU-LX48 PDX model, and to identify
the time point that provides ideal tumor/background ratios, we injected tumor bearing mice with
[18F]PARPi and imaged the mice at 30, 60 and 120 min post injection (Figure 6.4.1a). At 30 min,
the tumor was visible above the background signal of muscle (1.34 ± 0.28 %ID/g and 0.90 ±
0.06 %ID/g, respectively), but the differences were not statistically significant (n = 3, P = 0.1016;
Figure 6.4.1b). However, at the 60 min time point, the muscle uptake had begun to clear and
activity had fallen sharply to 0.44 ± 0.03 %ID/g, while the tumor signal was retained (0.94 ± 0.04
%ID/g), yielding P = 0.0002 (Figure 6.4.1b). This trend continued to the 120 min time point, with
uptake at 0.12 ± 0.02 %ID/g for the muscle, while tumor uptake remained constant at 0.87 ±
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Figure 6.4.1. In vivo kinetics of [18F]PARPi. Tumor bearing mice (n=3) were injected with
[18F]PARPi and imaged at 30, 60 and 120 min p.i. (a) Representative MIPs. (b) Quantification
for tumor and muscle grouped by time point (left) and grouped by organ (right). (c) Two phase
decay curve showing wash out of the tracer from the muscle while the tumor site remains
relatively constant after 60 min (left). Also shown are tumor to muscle ratios (right).
0.21 %ID/g (Figure 6.4.1b). The PARP1/2 imaging agent [18F]PARPi is therefore well suited to
image in PARP1-expressing tumors, quickly clearing from non-target tissue while binding
strongly to tumor over the course of 2 h resulting in a tumor/muscle ratio of 7.6 ± 2.7 in JHULX48 bearing animals (P = 0.0072; Figure 6.4.1c).
6.5:

Tumor Size Studies

In order to obtain quantitative data on how tumor size correlates with tracer uptake, we
performed repeated [18F]PARPi imaging studies in a cohort of JHU-LX48 PDX mice over the
course of eight weeks (n = 6; Figure 6.5.1a). We evaluated the quantitative performance of the
imaging probe over tumor volumes ranging from <25 mm3 to >1000 mm3. Once tumors reached
a size greater than 50 mm3, tumor size had no statistically significant effect on the mean
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Figure 6.5.1. Tumor size to [18F]PARPi uptake correlation. Tumor bearing mice (n=6) were
injected [18F]PARPi and imaged once a week over 8 consecutive weeks starting one week after
xenografting. (a) Representative MIPs from the same mouse over 8 weeks. (b) Quantification
(n=6) of mean uptake (top) and max uptake (bottom) tumors grouped by tumor size. The figure
includes the standard deviation as indicated by the shaded area.
[18F]PARPi signal. Mean signal remained steady at 0.86 ± 0.22 %ID/g for sizes ranging 50 mm3
to 1300 mm3 with the highest single value at 1.24 %ID/g and the lowest single value at 0.47
%ID/g (Figure 6.5.1b). Separating the data into groups organized by tumor size, we observed
that at very low tumor volumes (<50 mm3) uptake values appear lower, presumably because of
the partial volume effect14 and the associated detection limit of the small animal PET/CT used
for these experiments. The highest mean uptake values (0.97 ± 0.18 %ID/g) were observed for
tumor sizes between 100 and 200 mm3. With larger tumor sizes, mean signal decreased slightly
until reaching a minimum of 0.71 ± 0.22 %ID/g for tumor sizes between 400 and 800mm3,
presumably due to an increasing fraction of necrotic tissue in larger tumors. Necrotic tissue
does not retain [18F]PARPi, and therefore reduces the mean uptake. This was confirmed by the
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maximum uptake values (Figure 6.5.1b). Organized into groups, the maximum uptake showed a
continuous increase as tumor size increased in this range, from 2.62 ± 0.27 %ID/g for 50-100
mm3 to 3.06 ± 0.61 %ID/g for 800-1300 mm3 (Figure 6.5.1b). Maximum uptake across tumors
sizes 50-1300mm3 was 2.85 ± 0.49 %ID/g.
6.6:

Biodistribution

We also conducted a biodistribution study and found differences in organ uptake compared to
other immunocompromised mouse models from previous studies15 (Figure 6.6.1). Uptake in the
tumor was 0.74 ± 0.24 %ID/g, similar to the quantification of PET images. SCID mice showed a
greatly reduced signal in the lymph nodes (0.74 ± 0.24 %ID/g) and spleen (0.74 ± 0.24 %ID/g)
compared to nude mice (Figure 6.6.1). Additional studies were performed in healthy mice in
order to verify that this difference was not due to the differing disease models (Figure A.6.3).
SCID mice lack mature T cells, B cells, and NK cells compared to the athymic nude mice which
only lack T cells. It has previously been shown that [18F]PARPi uptake in these organs
correlates with areas of high PARP1 expression as measured by immunohistochemistry16 (see

Figure 6.6.1. Biodistribution study in selected tissues. Tumor bearing mice (n=5/group) were
injected either with [18F]PARPi alone, or with a previous injection of olaparib (50 mg/kg) 30 min
prior to [18F]PARPi.
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Chapter 4: Figure 4.7.1). These areas also correlate with internal anatomical structures with
high B cell concentration such as the follicles of the lymph nodes. In addition to this, we found in
this study that a high concentration of the bone uptake seen in the previous study is actually
attributable to bone marrow (12.64 ± 2.04 %ID/g) instead of the bone proper (Figure A.6.3). This
marrow uptake was also substantially reduced in the SCID mice (1.24 ± 0.13 %ID/g), although
the uptake remained high compared to other organs. The marrow uptake in SCID mice,
however, was still specific insofar as is was nearly completely eliminated by preinjection of
olaparib (0.58 ± 0.19 %ID/g).
6.7:

Autoradiography

In the preclinical setting, olaparib is administered at dosing levels of 50 mg/kg, whereas
talazoparib is used at much lower doses (e.g. 0.3 mg/kg)17. These trends are also reflected in
the

clinical

setting

(protocols:

NCT02032823,

NCT02184195,

NCT01945775).

Target

engagement studies using olaparib and talazoparib showed that both molecules were capable
of reducing [18F]PARPi signal in tumor and muscle tissue when administered 30 min prior to the
tracer (Figure 6.7.1a-c). Using PARP1 IHC staining, we could show comparably high PARP1
expression in tumors of all groups, while expression in muscle was very low, confirming validity
of the autoradiography findings (Figure 6.7.1d). Target engagement was not equivalent for
olaparib and talazoparib at their respective therapeutically active doses. Autoradiography
demonstrated that doses of olaparib were capable of completely blocking tumor uptake (96% of
[18F]PARPi uptake blocked), while talazoparib was only capable of blocking tumor uptake by
45% (Figure 6.7.1e). A significant reduction of [18F]PARPi was also observed in muscle tissue
despite the low PARP1 expression.
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Figure 6.7.1. Autoradiography. Tumor bearing mice (n=3/group) were injected either with
[18F]PARPi alone, or with a previous injection of talazoparib (0.3 mg/kg) or olaparib (50 mg/kg)
30 min prior to [18F]PARPi. (a) [18F]PARPi alone: tumor (top) and muscle (bottom) were
collected sliced and either exposed overnight (left), stained with H&E (middle) or stained for
PARP1 (right). (b) [18F]PARPi with a prior injection of talazoparib. (c) [18F]PARPi with a prior
injection of olaparib (d) Sections scaled to show nuclear targeted stain. (e) Quantification of
autoradiography and PARP1 stain.
6.8:

In Vivo Therapeutic Dosing Characterization

Since we saw that talazoparib, at the therapeutic doses used preclinically17, does not exhibit
complete target engagement we next aimed to study different doses of olaparib and talazoparib
and to correlate these doses to the level of target engagement as shown by [18F]PARPi blocking
(Figure 6.8.1). A positive control cohort (receiving vehicle control instead of PARP inhibitor)
showed a mean [18F]PARPi uptake of 0.87 ± 0.21 %ID/g.
The results for olaparib showed that the therapeutic dose level is much higher than required to
achieve near-quantitative target engagement. Doses of 50 mg/kg showed 78% blocking with a
mean uptake of 0.19 ± 0.03 %ID/g, and 15 mg/kg resulted in similar 75% blocking with a mean
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Figure 6.8.1. Variable dose blocking study. JHU-LX48 SCLC PDX bearing mice (n=3/group)
were injected first with olaparib (0-50 mg/kg) or talazoparib (0-15 mg/kg). Mice were then
injected with [18F]PARPi 30 min later, and imaged 120 minutes later. (a) Representative MIPs
from 4 different doses each, for olaparib (left) and talazoparib (right). (b) Quantification of PET
images for tumor uptake at each of 4 different doses of olaparib (left) and talazoparib (right), as
well as value for mice not dosed. (c) Curve fitting analysis for olaparib (left) and talazoparib
(right) showing calculated 50% blocking doses. (d) Comparison of olaparib and talazoparib at
equal doses (left) and at the relative therapeutic doses (right).
uptake of 0.22 ± 0.01 %ID/g (P > 0.25) (Figure 6.8.1b). When we reduced the dose to 5 mg/kg
we saw a significant reduction to 59% target engagement (0.36 ± 0.03 %ID/g, P < 0.005),
compared to the control cohort. At 1.5 mg/kg target engagement was further reduced to 34%
(0.57 ± 0.06 %ID/g, P < 0.001). This value is not statistically different from the control values (P
> 0.1). We fit a single phase decay curve (R2 = 0.8629) to this data (Figure 6.8.1c, left) to
calculate the 50% blocking dose to be 3.17 mg/kg.
For talazoparib, the therapeutic dose was found to be insufficient to achieve complete target
engagement. Doses of 0.3 mg/kg resulted in 50% target engagement (0.44 ± 0.06 %ID/g
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[18F]PARPi in tumor tissue). An increase of the administered dose to 0.9 mg/kg further
increased the target engagement to 64% (0.32 ± 0.05 %ID/g, P < 0.05). Increase in dose to 5
mg/kg resulted in 89% target engagement (0.10 ± 0.02 %ID/g, P < 0.05), while 15 mg/kg
showed no further increase in target engagement (84%, 0.14 ± 0.01 %ID/g, P > 0.05) (Figure
6.8.1b). A single phase decay curve (R2 = 0.8462) (Figure 6.8.1c, right) was used to calculate
the 50% blocking dose to be 0.36 mg/kg.
Interestingly, while target engagement was more complete for olaparib when using doses used
in preclinical therapeutic studies (78% and 50% for olaparib and talazoparib, respectively;
Figure 6.8.1d), talazoparib achieved a more quantitative target engagement at similar doses
(59% and 89% for olaparib and talazoparib at 5 mg/kg, respectively, 75% and 84% for olaparib
and talazoparib at 15 mg/kg, respectively; Figure 6.8.1d).
6.9:

In Vivo Therapeutic Kinetics Characterization

The dosing studies showed a significant difference between olaparib and talazoparib in their
ability to block [18F]PARPi signal in the tumor at a single defined time point. An important factor
in measuring the deposited effective doses, however, is how long the inhibitor occupies the
binding site. Therefore we sought to determine the residence time of olaparib and talazoparib in
vivo. We conducted experiments to measure the on-target residence time using [18F]PARPi by
varying the amount of time (1 to 48 h) between administration of the drug and administration of
the tracer (Figure 6.9.1).
For olaparib, we found that, at 50 mg/kg, an initial scan showed 74% target engagement (0.24 ±
0.00 %ID/g) at 60 min between injection of olaparib and [18F]PARPi. Mice with longer time
intervals between injection of drug and tracer showed gradual increase in [18F]PARPi signal
(Figure 6.9.1a, top) until, at 48 h, we measured tumor uptake to be 0.88 ± 0.15 %ID/g, which
was not statistically different from the control cohort of mice which did not receive olaparib. We
fit a two phase decay curve (R2 = 0.8548) to the target engagement data and used this to
calculate a weighted half-life of 9.4 h (Figure 6.9.1b, top). This number represents the amount of
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Figure 6.9.1. In vivo kinetics of different PARP inhibitors. Tumor bearing mice (n=3/group) were
injected first with olaparib (50 mg/kg) or talazoparib (0.3 mg/kg). Mice then were injected
[18F]PARPi 1 to 48 h later, and imaged via PET/CT 120 min after that. (a) Representative MIPs
from 4 different time points after olaparib (top) and talazoparib (bottom) administration. (b)
Quantification of PET images for tumor uptake at each of 6 different time points represented as
a percentage of blocked signal. (c) Overlay of quantification curves. (d) Summary of in vivo
kinetics data for the two therapeutic inhibitors.
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time it took for half of the [18F]PARPi signal in the tumor to return after a (therapeutic) dose of 50
mg/kg olaparib. We also used this curve to calculate an area under the curve, which was 1078
%h for olaparib. This number is a measure for the target engagement of a single dose of
olaparib (50 mg/kg) over 48 h. Complete 100% target engagement over 48 hours would result in
an integral of 4800 %h.
We repeated this procedure for talazoparib and found that, at 0.3 mg/kg, the 60 min time point
showed 0.40 ± 0.02 %ID/g with 56% target engagement. Again, we found a gradual increase in
[18F]PARPi signal as we increased the interval between drug and tracer (Figure 6.9.1a, bottom).
At 48 h, we measured 0.82 ± 0.18 %ID/g, which was not statistically different from the control
cohort of mice which did not receive talazoparib. We fit a two phase decay curve (R2 = 0.6328)
to the target engagement data and used this to calculate a weighted half-life of 9.8 h (Figure
6.9.1b, bottom). This number represents the amount of time it took for half of the [18F]PARPi
signal in the tumor to return after a dose of 0.3 mg/kg talazoparib. We also used this curve to
calculate an area under the curve, which was 1021 %h. This number represents the total
amount of [18F]PARPi signal blocking a single dose of 0.3 mg/kg talazoparib provides over the
course of 48 h.
Hence, we found comparable tumor residence times for olaparib and talazoparib, despite
differences in the applied dose, differences in the initial target engagement and reported
differences in affinity and trapping potential (Figure 6.9.1d).
6.10:

Conclusion

In this study, we demonstrated the feasibility of quantitative in vivo target engagement of a
family of PARP inhibitors in SCLC PDX models using a molecularly targeted PET imaging
agent. An imaging agent like this could have important implications for PARP inhibitor treatment
planning and monitoring in the clinic. The molecular imaging oriented approach to drug
characterization and target engagement measurement presented here provides a robust and
adaptable method for answering important questions regarding the interaction of a targeted drug
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with its intended binding site in a quantifiable manner in vitro and in vivo. Imaging techniques
like this have the potential not only to revolutionize the way that drugs are prepared but also
used in the clinic, and could pave the way for more robust and successful patient selection and
treatment monitoring. More specifically, our PET imaging agent [18F]PARPi might be used to
quantify target engagement of phase III and FDA approved PARP1 inhibitors in vivo without the
need of creating individual companion imaging agents for each drug. This non-invasive, whole
body approach could potentially preclude the need for multiple temporally and spatially
separated biopsies, and would allow quantification of target engagement for each lesion in an
individual. [18F]PARPi PET may provide a robust tool for treatment and patient selection with
profound clinical-translational implications.
6.11:

Experimental

SCLC PDX Models. PDX were propagated as previously described18,19. In brief, LX lines were
derived at Johns Hopkins University from patients with treatment-naive late stage SCLC. After
PDX model establishment, serial passaging into 6- to 8-week-old female NSG mice (NOD.CgPrkdcscid Il2rgtm1Wjl/SzJ; The Jackson Laboratory) was performed for these experiments. 5 ×
10^6 viable cells/mouse were injected with a 1:1 mix of Hank’s balanced salt solution and
Matrigel basement membrane (Corning, Corning, NY, USA) as a final volume of 100 µL
subcutaneously into the right shoulder. PDX identity was confirmed by Short Tandem Repeat
analysis using the PowerPlex 18 panel (Promega, Madison, WI, USA; DDC Medical is Fairfield,
OH, USA). Because of the lines’ inherent varying preferences to grow in vitro/propagate in vivo,
we chose LX22 for all in vitro experiments, whereas LX48 was chosen for in vivo experiments.
General PET/CT Imaging. All PET/CT images (90 mice, total) were acquired on an Inveon
PET/CT (Siemens) and reconstructed scans were analyzed using the Inveon Research
Workplace Software. To acquire PET/CT images, animals were anesthetized with 2% isoflurane
and positioned on the scanner bed. Animals were intravenously injected with 200-300 µCi of
[18F]PARPi in 100-200 µL 10% EtOH in 0.9% sterile saline. The tracer was allowed to clear for 2

!

99!

h prior to PET/CT imaging. PET data were collected for 5-10 min, followed by CT. All images
were analyzed using Inveon Workspace (Siemens Healthcare Global, Erlangen, Germany).
PET/CT Imaging Agent Kinetics. JHU-LX48 SCLC PDX tumor bearing mice (n=3/group, 3
groups, 9 mice total) were administered 200-300 µCi of [18F]PARPi and imaged at 30, 60, or 120
min post injection. Different mice were used for each group to eliminate, as much as possible,
the influence of anesthesia on tracer distribution. Activity concentration was quantified by
averaging the mean values taken from VOIs drawn on the chosen organs as they appeared in
the CT and portrayed as a mean %ID/g ± SD.
Biodistribution. Healthy nude (n=6/group, 2 groups, 12 total), healthy NOD/SCID (n=6/group, 2
groups, 12 total), or tumor bearing NOD/SCID (n=6/group, 2 groups, 12 total) mice were
injected either with or olaparib as a blocking agent (50 mg/kg) 30 min prior to injections 200-300
µCi of [18F]PARPi in 100-200 uL 10% EtOH in 0.9% sterile saline. [18F]PARPi injection. Animals
were sacrificed at 2 hours post injection of the radioactive probe, and major organs were
collected, weighed, and counted in a Wizard2 automatic γ-counter (PerkinElmer, Boston, MA).
The radiopharmaceutical uptake was expressed as a percentage of injected dose per gram
(%ID/g) using the following formula: [(activity in the target organ/grams of tissue)/injected
dose]⨉100%.
PET/CT Tumor Size Study. JHU-LX48 SCLC PDX cells where implanted into NOD/SCID mice
(n=6 mice) 7 days prior to the first imaging. At this time point, and once every 7 days thereafter,
imaging was carried out as described above. This was continued for 8 consecutive weeks until
mice were sacrificed to avoid surpassing a tumor size limit of 1500 mm3. Activity concentration
was quantified by averaging the mean or max values taken from VOIs drawn over the entire
tumor as it appeared in the CT and portrayed as a mean or max %ID/g ± SD.
PET/CT Dosing Study. JHU-LX48 SCLC PDX tumor bearing mice (n=3/group, 9 groups, 27
mice total) were administered varying doses of a therapeutic inhibitor via tail vein injection to
serve as blocking agents prior to imaging. The doses administered for olaparib were 50 mg/kg,
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15 mg/kg, 5 mg/kg and 1.5 mg/kg. The doses administered for talazoparib were 15 mg/kg, 5
mg/kg, 0.5 mg/kg and 0.3 mg/kg. Imaging was performed as described above, beginning 30 min
after administration of the blocking dose. Activity concentration was quantified by averaging the
mean values taken from VOIs drawn over the entire tumor as it appeared in the CT and
portrayed as a mean %ID/g ± SD.
In Vivo Kinetics. JHU-LX48 SCLC PDX tumor bearing mice (n=3/group, 15 groups, 45 mice
total) were administered therapeutic doses of olaparib (50 mg/kg) or talazoparib (0.3 mg/kg) via
tail vein injection to serve as blocking agents prior to imaging. The amount of time in between
administration of the blocking agent and tracer was varied from 1 to 48 h. Specifically, the time
points used were 1, 2, 4, 8, 24, and 48 h. After allowing this clearance time for the blocking
agent, the imaging was performed as described above. Activity concentration was quantified by
averaging the mean values taken from VOIs drawn over the entire tumor as it appeared in the
CT and portrayed as a mean %ID/g ± SD.
Statistical Analysis. Data are expressed as mean ± SD. Statistical analyses were performed
with GraphPad Prism, Version 7.0a (La Jolla, CA). Non-parametric, two-tailed student’s t-tests
with assumption of unequal standard deviations were used to calculate statistics. P values <
0.05 were considered significant.
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CHAPTER 7: [18F]PARPI-DIFFUSE LARGE B-CELL LYMPHOMA
This chapter is an adaptation of published work, and is reproduced in part, from Tang, J.,
Salloum, D., Carney, B., Brand, C., Kossatz, S., Sadique, A., Lewis, J., Weber, W. A., HansGuido, W. & Reiner, T. A Targeted PET Imaging Strategy to Differentiate Malignant from
Inflamed Lymph Nodes in Diffuse Large B-Cell Lymphoma. PNAS (2017).

7.1:

Introduction

Diffuse large B-cell lymphoma (DLBCL) is the most common adult lymphoma, accounting for
37% of all non-Hodgkin lymphoma (NHL) cases in the United States1. The current standard-ofcare treatment, known as R-CHOP, consists of one targeted antibody against CD20 (rituximab)
and four chemotherapies (cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and
prednisone). Although R-CHOP can cure approximately 50% of patients with DLBCL, the
refractory or relapsed cases have very poor prognosis and require timely medical interventions2.
Therefore, accurate and sensitive diagnostic methods play a pivotal role in improving the clinical
outcome of DLBCL3.
At early stages, DLBCL infiltrates lymphatic tissues such as lymph nodes, spleens, and bone
marrow across the body; at advanced stages, DLBCL tend to metastasize to non-lymphatic
tissues such as brain and spinal cords, as well as many other tissues4. To address the systemic
nature of DLBCL, whole-body imaging techniques, such as positron emission tomography
(PET), computed tomography (CT), and magnetic resonance imaging (MRI), were adopted to
improve the diagnosis and disease staging of DLBCL5. PET imaging is an important imaging
modality for DLBCL diagnosis, due to its high sensitivity, short acquisition time, and the
availability of several imaging probes6,7. Particularly for DLBCL, [18F]FDG-PET imaging is the
current standard-of-care diagnosis, because the fast-proliferating lymphoma cells consume a
high level of glucose and incorporate large amounts of [18F]FDG8. The tracer has been proven

!

102!

to be a reliable diagnostic for DLBCL detection6,9, identification of bone marrow metastasis10,11,
and therapy monitoring12.
However, the reliability of [18F]FDG-PET can be affected by the imaging agent uptake of nonmalignant tissues that also consume high levels of glucose. For example, inflamed lymph nodes
are rich in immune cells with high [18F]FDG uptake, which can then produce high [18F]FDG-PET
signals and result in false positive diagnoses in DLBCL patients13,14. In addition,
immunotherapies, particularly checkpoint inhibitors15 and chimeric antigen receptor T cells16,
have shown great efficacy in refractory/relapsed DLBCL and are likely to receive clinical
approval in the near future. These immunotherapies can induce inflammation-driven
“pseudoprogression”, which cannot be easily distinguished from true tumor progression with
[18F]FDG-PET17. There is therefore an unmet clinical need for an imaging approach that can
distinguish malignant from inflammatory tissues, and such a method would reduce the
frequency of biopsies and provide accurate therapy monitoring, as well as increase the
precision of surgical interventions.
We created a PET-imaging strategy based on a potential new DLBCL biomarker. We found
DLBCL expresses much higher levels of PARP1 than all other major cancer types, as well as
healthy tissues in humans. In a mouse DLBCL model, we used a PARP1-targeted PET imaging
probe to accurately differentiate malignant from normal or inflamed lymph nodes – using both
non-invasive PET/CT imaging and ex vivo γ-counting. The clinically established [18F]FDG-PET
failed to distinguish malignancy from inflammation in the same settings. Our PARP1-targeted
PET imaging approach presents an attractive addition to PET imaging for DLBCL, particularly
when inflammation presents high risks of misdiagnosis of the disease.
7.2:

PARP1 Expression in DLBCL

In The Cancer Genome Atlas (TCGA) database18, we found that human DLBCL expresses the
highest levels of poly [ADP-ribose] polymerase 1 (PARP1) among all major cancer types (Figure
7.2.1a). Using the Cancer Cell Line Encyclopedia (CCLE)19, we also found that the average
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Figure 7.2.1. PARP1 expression in DLBCL. (a) PARP1 expression levels in biopsied tissue
measured by mRNA levels. Data from the TCGA. (b) PARP1 expression levels in immortalized
cancer cell lines measured by mRNA levels. Data from the CCLE. (c) Immunoblot assay
showing PARP1 expression in B-cell lymphoma cell lines and primary human B-cells.
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PARP1 expression of 18 DLBCL-derived human cell lines was higher than the average
expressions of cell lines from other major human cancers (Figure 7.2.1b). Finally, 7 selected
DLBCL cell lines were found to express higher levels of PARP1 protein than normal human B
cells (Figure 7.2.1c). These data suggest that PARP1 is a potential target to help differentiate
DLBCL from normal tissues in humans.
7.3:

The DLBCL Mouse Model

To evaluate PARP1 as a potential diagnostic marker for DLBCL, we created an animal model
that closely simulates the human disease. Previous studies have found that MYC and BCL2 are
two essential oncogenes to drive the pathogenesis of DLBCL20–22. In the current model, we used
retroviral infection to introduce murine Myc oncogene into hematopoietic precursor cells (HPCs)
with oncogene Bcl2 driven by the Vav promoter23. HPCs expressing Myc and Bcl2 proteins were
transplanted into sub-lethally irradiated immunocompetent C57BL/6 (B6) mice so that a disease
with an identical genetic makeup to its human counterpart could be established in the animals.
Expression of the red fluorescent protein (RFP) is linked to that of Myc to track the progeny cells
derived from the transplanted HPCs. 20 days after the HPC transplantation, the animals
exhibited about 10% loss of body weight, splenomegaly, lymphadenopathy, low blood

Figure 7.3.1. PARP1 expression in mouse model of DLBCL. (a) Immunohistochemistry shows
the lymph nodes of DLBCL mice (n = 5) are larger than those of B6 mice (n = 5) and most cells
express RFP. (b) Immunohistochemistry measurements on the adjacent slices reveal higher
PARP1 expression levels in the lymph nodes of DLBCL mice (n = 5) than those in B6 mice (n =
5).
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hemoglobin levels, elevated white blood cell counts, and decreased blood platelets, all of which
are symptoms similar to human DLBCL24 (Figure A.7.1a). Like human DLBCL (Figure 7.2.1),
lymphoma cells from DLBCL mouse spleens expressed much higher levels of PARP1 than
those from healthy B6 mice (Figure A.7.1b). In addition, over 90% of immune cells in the
lymphatic tissues of DLBCL mice expressed RFP, confirming their origin from the transplanted
HPCs (Figure A.7.1c). In DLBCL lymph nodes, over 90% area of tissue sections was stained
positive with RFP (Figure 7.2.1a) and the integrity of germinal centers was lost (Figure A.7.1d),
demonstrating massive lymphoma penetration. Finally, the area stained positive with PARP1
was significantly higher in DLBCL lymph nodes than the healthy controls (Figure 7.2.1b; P <
0.05). These data demonstrate that our animal model accurately recapitulates the
physiopathology and genetic makeup of human DLBCL, particularly the high PARP1 levels of
the disease.
7.4:

PET/CT Imaging

Figure 7.4.1. PET/CT images of DLBCL model. (a) Representative MIPs (left) and slices of
DLBCL mice (top, n = 7), B6 mice (middle, n = 4), or DLBCL mice pre-injected with olaparib
(bpttpm, n = 4). (b) Quantification of PET signal in lymph nodes.
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PET/CT imaging is the current standard-of-care approach to diagnose and monitor DLBCL25. To
test if [18F]PARPi is a feasible PET imaging probe for DLBCL, we first measured its specificity in
our DLBCL mouse model. We performed [18F]PARPi PET/CT imaging (Figure 7.4.1) on DLBCL
mice (n = 7), B6 mice (n = 4), and DLBCL mice pre-injected with olaparib (500 µg, 1.15 µmol, n
= 4). Compared to B6 mice, DLBCL mice showed a 5.6-fold increase of PET signal in their
lymph nodes (p = 0.002). Pre-injection of olaparib diminished the accumulation by 87% (p =
0.0012), demonstrating that [18F]PARPi accumulation was specific to PARP1 (Figure 7.4.1).
This PARP1-specific accumulation was found in B6 mouse lymph nodes, which express
relatively high levels of PARP1 as well (Figure A.7.3b-c). Furthermore, the ex vivo radioactivity
measurement with γ-counting linearly agreed with the in vivo PET/CT reading, demonstrating
the highly quantitative rigor of this approach (Figure A.7.2a). Finally, the total amount of
[18F]PARPi per DLBCL lymph node was 10-fold higher than that of B6 ones (p = 0.0028, Figure
A.7.2b). These data demonstrate that PARP1-targeted PET imaging can accurately differentiate
malignant DLBCL lymph nodes from the normal ones.
7.5:

Biodistribution

We then performed comparative biodistribution of [18F]PARPi in DLBCL mice, B6 mice, and
DLBCL mice pre-injected with olaparib (500 µg, 1.15 µmol). Most tissues of DLBCL mice
showed much higher [18F]PARPi retention than those from B6 mice (Figure 7.5.1). Importantly,
the high accumulation in DLBCL tissues could be blocked by pre-injection of olaparib,
demonstrating that the retention was PARP1-specific and suggesting that infiltration of B
lymphoma cells may be the cause for the higher [18F]PARPi retention (Figure 7.5.1). To confirm
this, we focused on lymph nodes, spleens, salivary glands, livers, and pancreas. In B6 mice,
only lymph nodes, spleens, and salivary glands but not livers and pancreas showed PARP1specific accumulation of [18F]PARPi (Figure A.7.3a and Figure A.7.3b). In DLBCL mice, on the
contrary, all 5 tissues displayed higher [18F]PARPi accumulation (Figure 7.5.1 and Figure
A.7.3b). In all 5 DLBCL tissues, the cells rich in PARP1 also expressed RFP, the genetic tag of
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Figure 7.5.1. Biodistribution studies. DLBCL mice injected with [18F]PARPi (n = 12), B6 mice
injected with [18F]PARPi (n = 4), and DLBCL mice injected with [18F]PARPi and blocked with
olaparib (n = 7).
B lymphoma cells, demonstrating that the high PARP1-specific accumulation of [18F]PARPi was
a direct result of B lymphoma cell infiltration (Figure A.7.3c). These data suggest that
[18F]PARPi, in addition to being an appealing PET imaging probe, can also be used to monitor
the metastatic progression of DLBCL in multiple tissues.
7.6:

Comparison to FDG in an Inflammation Model

Because of the high uptake of glucose exhibited by inflammatory immune cells in the tissues,
[18F]FDG-PET faces difficulty in distinguishing inflammation from true malignancy in lymph
nodes. Although B cells express rather high levels of PARP1 among the major immune cell
types themselves (Immunological Genome Project)26, DLBCL cells express higher levels of
PARP1 than normal B cells (Figure 7.2.1 and Figure 7.3.1). Therefore, we hypothesized that a
PARP1-targeted PET imaging could exploit this biological difference and differentiate malignant
from inflamed lymph nodes in vivo.
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Figure 7.6.1. Inflammation model immunohistochemistry. PARP1 immunostaining images of
lymph nodes from DLBCL (left), B6 with local inflammation (middle), and normal B6 mice (right).
We induced inflammation in superficial cervical lymph nodes by systemically injecting Flt3L, a
peptide that induces dendritic cell production27, and locally injecting Poly-IC around these lymph
nodes of B6 mice to induce regional inflammation. Lymph nodes derived from this mouse model
displayed bigger volumes (Figure 7.6.1) but intact structure compared to the normal ones,
demonstrating the established inflammation.
Immunostaining of lymph nodes from the DLBCL mice, the inflamed model mice, and normal B6
mice showed that DLBCL lymph nodes displayed consistently high PARP1 expression across
the whole tissue, whereas inflamed and normal lymph nodes showed much less PARP1
expression, which was confined to germinal centers (Figure 7.6.1).
We first performed [18F]FDG PET/CT imaging on DLBCL mice, B6 mice with inflamed lymph
nodes, and normal B6 mice. We found that [18F]FDG uptake in non-lymphatic tissues around the
head and neck area was higher than in lymph nodes (Figure 7.6.2a). Autoradiography
confirmed the PET imaging results by showing a high uptake of [18F]FDG in the salivary gland
and brain in mice with inflamed lymph nodes (Figure A.7.4a), consistent with ex vivo γ-counting
(Figure A.7.4c). Importantly, inflamed lymph nodes showed identical [18F]FDG uptake levels
compared to DLBCL lymph nodes, demonstrating the inability of [18F]FDG-PET to differentiate
inflammation from malignancy in DLBCL lymph nodes (Figure 7.6.2b).
We then performed [18F]PARPi-PET/CT imaging on mice with the same 3 conditions. The
PARP1-targeted imaging clearly differentiated the malignant lymph nodes from either inflamed
or normal ones (Figure 7.6.2c). Compared to the high background of [18F]FDG-PET imaging in
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Figure 7.6.2. Comparison of [18F]PARPi to FDG in an inflammation model. (a) Representative
FDG MIPs (left) and slices of DLBCL mice (top, n = 3), B6 mice (middle, n = 3), or DLBCL mice
pre-injected with olaparib (bottom, n = 3). (b) Quantification of FDG PET signal in lymph nodes.
(c) Representative [18F]PARPi MIPs (left) and slices of inflammation model mice (top, n = 5), B6
mice (middle, n = 5), or DLBCL mice pre-injected with olaparib (bottom, n = 5). (d) Quantification
of [18F]PARPi PET signal in lymph nodes.
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the head and neck area, the low uptake of [18F]PARPi in other non-lymphatic tissues highlighted
malignant lymph nodes (Figure 7.6.2c). Quantification of PET imaging revealed 76% higher
signal in malignant lymph nodes than inflamed ones (Figure 7.6.2d, P < 0.001) and 152% higher
than the normal ones (Figure 7.6.2d, P < 0.0001). Compared to normal lymph nodes, inflamed
ones only showed modest PET signal increase (Figure A.7.4b P < 0.01), and this elevation was
not significant in ex vivo γ-counting (Figure 7.6.2d, P = 0.078). Quantitative biodistribution
confirmed that lymph nodes and spleens from DLBCL mice had much higher [18F]PARPi
accumulation than those from the other two groups (Figure A.7.4d).
Altogether, these results demonstrate that PARP1-targeted PET imaging can accurately
differentiate malignant from inflamed or normal lymph nodes in DLBCL, due to the differential
expression of PARP1 in these conditions.
7.7:

Conclusion

In conclusion, we identified PARP1 as a potential diagnostic marker for DLBCL from patient
samples. We developed a PARP1-targeted PET imaging approach that displays greater
sensitivity than the current standard-of-care [18F]FDG-PET imaging in differentiating malignant
from inflamed or normal lymph nodes PARP1-targeted PET imaging could even prove useful in
assessing cancer immunotherapies for DLBCL. Cancer immunotherapies often induce massive
immune cell infiltration and consequently cause pronounced inflammation in tumors, increasing
local metabolism level28. This inflammatory phenomenon presents tremendous challenges to
the traditional therapeutic response evaluation methods, which often use high metabolic rates
as an indicator for cancer progression29,30. For DLBCL, immunotherapies such as checkpoint
inhibitors15 and CAR-T cell therapy16,31 are rapidly advancing in the clinical development. A
novel imaging method that can differentiate inflammation from malignancy is instrumental to
evaluate the clinical efficacy of these new therapies. In this case, our PARP1-targeted PET
imaging approach seems to be an appealing solution to this urgent need. This novel targeted
PET imaging approach has the potential to shift the paradigm of PET imaging in DLBCL.
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7.8:

Experimental

PARP1 expression data in human tissues and cell line. For PAPR1 expression in human
cancer samples, data were downloaded from cBioportal (http://www.cbioportal.org/)32, which
imported

the

raw

sequencing

data

from

The

Cancer

Genome

Atlas

(TCGA,

https://cancergenome.nih.gov/)18. PARP1 mRNA expression levels were analyzed in 9129
patient samples. All available PARP1 mRNA data as of June 2016 were downloaded and
transformed to a plot with Prism 6 (GraphPad). For PARP1 expression in human cancer cell
lines,

data

were

downloaded

from

Cancer

Cell

Line

Encyclopedia

(https://portals.broadinstitute.org/ccle/home). Similarly, all available PARP1 mRNA expression
data from 1036 cancer cell lines were downloaded in June 2016.
Synthesis of PARPi-FL. The synthesis was carried out as previously described33. In summary,
BODIPY-FL NHS ester (5.0 mg, 12.8 mmol, Invitrogen, Carlsbad, CA, USA) was conjugated to
4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one (9.4 mg, 25.6 mmol) in the
presence of triethylamine (4.6 µl). Purification by preparative HPLC (Waters’ XTerra C-18 5 µm
column, 7 ml/min, 5% to 95% of acetonitrile in 15 min) afforded PARPi-FL in 70-79% yield as a
red solid. Analytical HPLC analysis (Waters’ Atlantis® T3 C18 5 µm 4.6 × 250 mm column)
showed high purity (>97%) of the imaging agent. The identity of PARPi-FL was confirmed by
using ESI-MS (MS(+) m/z = 663.4 [M+Na]+). For imaging studies, PBS (115 µl) was slowly
added to an aliquot of PARPi-FL (50 µg, 78 nmol) in 50 µl of poly(ethylene glycol) (PEG300,
Sigma-Aldrich, St. Louis, MO, USA) to obtain a final injection volume of 165 µl.
Synthesis of [18F]PARPi. [18F]PARPi was synthesized by using a labeling procedure similar to
what has been reported before34. Briefly, a QMA cartridge containing cyclotron-produced [18F]
fluoride (50 mCi, 1.85 GBq) was eluted with a solution containing 9 mg Kryptofix [2.2.2]
(4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8] hexacosane), 0.08 ml 0.15 M K2CO3 and
1.92 ml MeCN into a 5 ml reaction vial. Solvents were removed azeotropically at 120 °C under
nitrogen gas. Afterwards, 500 µg of ethyl 4-nitrobenzoate (Sigma) in 100 µl of dry DMSO was
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added and the mixture was heated to 150 °C for 15 minutes. 50 µl of 1M NaOH was then added
followed by 50 µl of 1M HCl. Then, 2 mg of 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)
phthalazin-1(2H)-one in 100 µl of dry DMSO was added followed by 10 mg of HBTU dissolved
in 100 µl of DMSO and 20 µl of Et3N. 400 µl of MeCN and 1 ml H2O were then added to the
mixture and the product was purified by HPLC with a yield (non-decay corrected) of 38.4 ± 2.5%
and a specific activity of 0.97 ± 0.41 Ci/µmol.
Generation of the DLBCL animal model. All animal experiments were approved by the
Institutional Animal Care and Use Committee (IACUC) of Memorial Sloan Kettering Cancer
Center. 8-to16-week old female C57BL/6 (B6) mice were purchased from Jackson Laboratories.
We isolated vavP-Bcl2 transgenic fetal liver cells from vavP-Bcl2 heterozygous animals at
embryonic day 14.5 (E14.5). The HPCs were grown in vitro for 4 days in a specially adapted
growth medium as described previously35 and were retrovirally transduced with MSCV vectors
directing the expression of Myc-IRES-Rfp. The HPCs were transplanted into sub-lethally
irradiated wild type recipients and the onset of the disease was monitored twice per week by
palpation.
Spectrofluorimetry. DLBCL mice were intravenously injected with 50 µg of PARPi-FL, with or
without 500 µg of olaparib injected 30 min prior to PARPi-FL. Animals were sacrificed 2.5 hours
after the injection and perfused with 20 ml PBS. Lymph nodes and spleens were collected,
weighed, and stored in 500 µl of RIPA lysis buffer (Boston Bioproducts, Ashland, MA, USA) in
bead-filled homogenizing vials (Lysing Matrix D, MP Biomedicals, Cat# 6913-050). Tissues
were homogenized in a MP homogenizer (MP Biomedicals, Ashland, MA, USA). Later, 200 µl of
homogenate was transferred to a new 1.5 ml tube and 750 µl of acetonitrile, 200 µl of water,
and 50 µl of 10% Triton X-100 (volume/volume) were added to the vials. The vials were
vortexed for 60 seconds and then incubated in 4 °C for 16 hours. Afterwards, the vials were
centrifuged at 15,000 g for 20 min and 200 µl supernatant was collected for analysis. In a plate
reader (SpectraMax, Molecular Devices, CA, USA), the solution was excited at 507 nm and
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fluorescent signal was measured at 530 nm. The concentration of PARPi-FL in the solution was
calculated by comparing the readings to standards with various concentrations of PARPi-FL.
The total PARPi-FL in the original tissues was calculated and the accumulation was presented
as the percentage of injected dose of PARPi-FL per gram of tissues (%ID/g).
Histology. Lymph nodes of DLBCL or B6 mice were collected and fixed in 4%
paraformaldehyde for 2 days. The tissues were then washed with 70% ethanol and embedded
with paraffin by following a standard histology protocol. Histology slides were stained with
standard hematoxylin and eosin staining, immunostaining with antibodies specific to PARP1
(Santa Cruz, SC-7150) or specific to B220 (Abcam, clone RA3-6B2). The stained slides were
digitalized with a slide scanner (Panoramic MIDI, PerkinElmer, MA, USA) and images were
analyzed and quantified by Panoramic Viewer (PerkinElmer, MA, USA). For each animal, on
average 5 lymph node images were analyzed per DLBCL mouse (n = 5 in total) or B6 mouse (n
= 5 in total).
Biodistribution and autoradiography. Mice were injected with 300 µCi of [18F]PARPi or
[18F]FDG. Blocking with olaparib was performed by administering 500 µg 30 min before
[18F]PARPi injection. Animals were sacrificed at 2.5 hours post injection of the radioactive probe
and perfused with 20 ml PBS. Radiotracer accumulation in lymph nodes, spleens, salivary
glands, livers, pancreas, kidneys, blood, hearts, lungs, stomach, small intestines, large
intestines, muscle, bone, and brain was determined by first weighing the tissues and then
measuring their radioactivity in a gamma counter (PerkinElmer, Waltham, MA, USA). The
relative activity per tissue is presented as a percentage of injected dose per gram of tissue
(%ID/g). For autoradiography, radiotracer accumulation in spleens, lymph nodes, salivary
glands, livers, and pancreas was determined by placing the tissues in a film cassette against a
phosphor imaging plate (BASMSM-2325, Fujifilm, Valhalla, NY, USA) for approximately 30 min.
Phosphor imaging plates were read in a Typhoon 7000IP plate reader (GE Healthcare,
Pittsburg, PA, USA).
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Inflammation of lymph nodes. C57BL/6 mice with 8-to-16 weeks of age received daily
intraperitoneal injections of Flt3L (Celldex) at the dose of 30 µg for 5 days. On day 4, 100 µg of
PolyI:C (InvivoGen, cat# tlrl-pic) dissolved in 50 µl PBS was injected subcutaneously around the
superficial cervical lymph nodes. On day 5, after the injection of Flt3L, the mice were injected
with [18F]FDG or [18F]PARPi and imaged with a PET/CT scanner (Inveon, Siemens Healthcare
Global, Erlangen, Germany). After the imaging, lymph nodes, spleens, salivary glands, brains,
and tibia bones were collected, weighed, and counted with a gamma counter. Accumulation of
radioactive tracers in the tissues was presented as the percentage of injected dose per gram of
tissues (%ID/g).
Western blot. DLBCL cell lines (KARPAS422, SU_DHL_4, Su_DHL_6, DB, SU_DHL_10,
WSU_DLCL2, and DoHH2) and human primary B cells were purchased from ATCC and were
cultured in the conditions recommended by the vendor. Western blots were performed by using
the whole cell lysates or supernatant as previously described35. In brief, 30 µg protein per
sample was resolved on SDS-PAGE gels and transferred to Immobilon-P membranes
(Millipore). Antibodies specific to PARP1 (Cell Signaling Technologies #9542) and actin (Cell
Signaling Technologies #3700) were used. Enhanced chemiluminescence was used for
detection (ECL; GE Healthcare).
Confocal microscopy. PARPi-FL accumulation was correlated with PARP1 expression in
lymph nodes by immunofluorescence staining on histological sections as described before

36

.

Lymph nodes of DLBCL mice were snap-frozen 2 hours after intravenous injection of 50 µg
PARPi-FL, with or without injection of 500 µg of olaparib 30 min prior to the PARPi-FL injection.
10 µm cryosections of DLBCL lymph nodes were fixed in 4% paraformaldehyde for 8 minutes,
followed by blocking with 3% (volume / volume) goat serum (Sigma-Aldrich, St. Louis, MO).
Antibodies were diluted in 1% (weight / volume) BSA and 0.3% (volume / volume) Triton X-100
in PBS. Anti-PARP1 primary antibody (sc-7150, Santa Cruz Biotechnology, Santa Cruz, CA)
was incubated overnight at 4 °C (1 µg/ml), followed by incubation with secondary AlexaFluor®
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680 goat anti-rabbit antibody (A21076, Molecular Probes, Eugene, OR) for 1 hour at 4 °C (2
µg/ml). Sections were mounted with Mowiol® (Sigma-Aldrich, St. Louis, MO) containing Hoechst
33342 DNA Stain (Sigma-Aldrich, St. Louis, MO). Fluorescence images were captured using a
Leica (Buffalo Grove, IL) SP5-upright confocal microscope, equipped with a 405 nm laser for
detection of cell nuclei, a 488 nm laser for detection of in vivo applied PARPi-FL, and a 633 nm
laser for detection of PARP1 antibody stain, each paired with suitable emission filters.
Flow cytometry. Previous protocols were adapted to analyze the tissues in the current study37.
Briefly, at 2.5 hours after intravenous injection of PARPi-FL, blood was collected in EDTAtreated tubes, and the animals were perfused with 20 ml PBS. For PARP1 blocking
experiments, 500 µg olaparib was intravenously injected into the mice 30 min before the
injection of PARPi-FL. Afterwards, lymph nodes, bone marrow, and spleens were collected and
gently diced. A single-cell suspension was created by removing tissue aggregates, extracellular
matrix, and cell debris from the solution. Red blood cells were removed from the blood sample
using a red blood cell lysis buffer (Biolegend, Cat# 420301). PARPi-FL was detected on the
FITC channel. To identify B cells, T cells, neutrophils, and other myeloid cells, antibodies
specific to CD45 (clone 30-F11), CD11b (clone M1/70), CD11c (clone N418), B220 (cone RA36B2), and CD3 (cone 145-2C11) were used. Antibodies were purchased from eBioscience and
Biolegend. The FITC channel of the flow cytometer was calibrated by using FITC calibration
beads (Spherotech, Cat# ECFP-F1-3), and FITC channel variation was corrected by
normalizing to the beads’ signal. All samples were measured on a Fortessa flow cytometry
analyzer (BD Biosciences, San Jose, CA, USA). Results were analyzed with FlowJo (Ashland,
OR, USA) and statistics were calculated with Prism (GraphPad, La Jolla, CA USA).
Micro PET/CT imaging. Mice were injected with [18F]PARPi or [18F]FDG at doses of
approximately 300 µCi/mouse, and the mice were imaged on an Inveon small-animal micro
PET/CT scanner (Siemens Healthcare Global, Erlangen, Germany) under isoflurane-induced
(Baxter Healthcare, Deerfield, IL, USA) anesthesia 2 hours after the radioactive tracer injection.
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For PARP1 blocking experiments, 500 µg olaparib was intravenously injected into the mice 30
min before the injection of [18F]PARPi. Whole body static PET scans were recorded for 15 min
with about 50 million coincidence events. The imaging data were normalized to correct for nonuniform PET response, dead-time count losses, positron branching ratio, and physical decay to
the time of injection, but no attenuation, scatter, or partial-volume averaging correction was
applied. The counting rates in the reconstructed images were converted to activity
concentrations (percentage injected dose [%ID] per gram of tissue [%ID/g]) via a system
calibration factor derived from imaging a mouse-sized water-equivalent phantom containing

18

F.

Images were analyzed using Inveon Workspace (Siemens Healthcare Global, Erlangen,
Germany). Activity concentration was quantified by averaging the maximal values of at least 5
ROIs drawn on consecutive slices of the chosen organs.
Radioactive cell sorting. DLBCL mice were injected with [18F]PARPi at the dose of
approximately 300 µCi per animal. For PARP1 blocking experiments, 500 µg olaparib was
intravenously injected 30 min before the injection of [18F]PARPi. 2.5 hours after the [18F]PARPi
injection, mice were sacrificed and 500 µl blood was collected and stored in tubes pre-filled with
EDTA. Red blood cells were removed as described above in the flow cytometry section. The
enriched white blood cells were purified by following standard magnetic-activated cell sorting
(MACS) procedures provided by the vendor (Miltenyi Biotec, Cologne, Germany). Briefly, the
white blood cells were incubated with anti-B220 (Miltenyi Biotec, cat# 130-049-501) or antiLy6G (Miltenyi Biotec, cat# 130-092-332) antibodies conjugated with paramagnetic beads for 30
min. After wash with flow cytometry buffer, the solution was passed through a magnetic column,
followed by buffer washing. Finally, cells with bound antibodies were eluted from the columns.
The cells were then immediately stained with a cocktail of antibodies that recognize CD45,
CD11b, Ly6G, and B220. After the staining, cells were fixed (eBioscience, 00-8222-49), their
radioactivity was counted in a gamma counter (PerkinElmer, Waltham, MA, USA) and decaycorrected. After the counting, the stained cells were left in 4 °C for 24 hours (more than 10
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decay half-life times of

18

F fluorine) for the decay of

18

F. After radioactivity decay, counting

beads were added to the cell suspension, so that the purity and the numbers of cells in each
sample could be analyzed by a Fortessa flow cytometer (BD). Finally, the percentage of injected
dose per billion cells (%ID/109 cells) was calculated using the following formula: the average
percentage of injected dose of [18F]PARPi per purified billion cells in a tube (%ID/109 cells) =
percentage of decay-corrected injected dose (%ID) / the number of cells in that tube.
Statistics. PARP1 mRNA expression data of patient samples and human cancer-derived cell
lines were presented as median plus or minus the interquartile range. Other data were
presented as the mean with the standard errors of the mean (SEM) or standard deviation (SD)
as error bars. Non-parametric, two-tailed student’s t-tests with assumption of unequal standard
deviations were used to calculate statistics. P-values smaller than 0.05 was deemed as
statistically significant.
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CHAPTER 8: CONCLUSION AND FUTURE DIRECTIONS
8.1:

Development of [18F]PARPi

This work has really been about the development of a single molecule, [18F]PARPi. This
development stretched back to when Dr. Reiner first began modifying the PARP targeting
scaffolding offered by the best clinical PARP therapeutic available, olaparib1–3. One of these
molecules, the fluorescent PARPi-FL, was highly successful, and generated most, if not all, of
the fluorescent imaging research presented in Chapter 2, Section 2.2. Indeed, it is the only
foreseeable fluorescent clinical candidate, and is one of only two imaging agents to reach the
clinic (see Chapter 2, Section 2.2). However, the
18

18

F labeled PET tracer developed at this time,

F-BO, was not so successful. In retrospect, it probably suffered from the poor in vivo kinetics

caused by its relatively large size4. Naturally, the success of PARPi-FL led to the notion that if
PARPi-FL could be radiolabelled, this new PET tracer would not only benefit from the success
of the fluorescent agent, but would itself be fluorescent and so would offer a dual modality
PET/fluorescent PARP targeted imaging agent. A synthetic route was therefore devised5 and
the work presented here picks up. We were able to successfully optimize the
dual model tracer,

18

18

F labeling of the

F-PARPi-FL, but the tracer proved instable in vivo (Chapter 3)6, and so an

alternative had to be devised. We therefore designed a new, single model tracer, [18F]PARPi,
with the goal of efficient and specific in vivo PARP targeting, and high in vivo stability. This is the
main subject of this work and has proven to be as successful a PET agent as PARPi-FL is a
fluorescent agent.
8.2:

Preclinical studies with [18F]PARPi

Our first preclinical validation followed in the footsteps of PARPi-FL7 and

18

F-PARPi-FL6, we

utilized an orthotopic glioblastoma multiforme (GBM) mouse model. [18F]PARPi showed itself to
meet the criteria we had set out for it (Chapter 4), but while this model was of extreme interest
for PARPi-FL insofar as fluorescent guided surgery could prove to be of extreme value to the
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clinical treatment of GBM, we thought that it would be interesting test [18F]PARPi in a central
nervous system (CNS) disease that was not so easily delineated by magnetic resonance
imaging MRI (see Chapter 4, Figure 4.9.3). This produced a collaboration with Dr. Mark
Souweidane’s lab, which specializes in diffuse intrinsic pontine glioma. DIPG. In these
genetically engineered mouse models (GEMMs), we found that [18F]PARPi indeed provided a
more targeted contrast than MRI (or at least the 1T MRI we had available, see Chapter 5,
Figure 5.5.1)8. So, in some cases, like DIPG, [18F]PARPi might prove to be a better diagnostic
tool than MRI, or at least an important addition. In addition to this collaboration, we collaborated
with the labs Dr. Charles Rudin and Dr. John Poirier, who were looking at PARP targeted
therapies for treatment of small cell lung cancer (SCLC)9. They identified talazoparib as the
most effective PARP inhibitor for treatment of SCLC, and so we were interested to see if
[18F]PARPi could be used to detect any differences between talazoparib and other inhibitors in
vivo. This was the first time that either PARPi-FL or [18F]PARPi was used to detect PARP target
engagement of therapeutics other than its parent compound, olaparib. We found that [18F]PARPi
could indeed detect a difference between talazoparib olaparib (see especially the dosing study,
Chapter 6, Figure 6.8.1), and that this supported the conjecture that the two were operating by
two different therapeutic mechanisms. Finally, inspired by our consistently high, and extremely
specific [18F]PARPi signal from organs with high concentrations of B-cells, and also by the fact
that B-cell lymphomas present the highest PARP1 expression in both The Cancer Genome
Atlas and the Cancer Cell Line Encyclopedia, we decided to look at [18F]PARPi in diffuse large
B-cell lymphoma (DLBCL). We found that [18F]PARPi could show infiltration of lymphoma cells
in a wide variety of organs (see Chapter 7, Figure 7.5.1) and that PET quantification of the
lymph nodes in particular could even differentiate between lymphoma infiltrated lymph nodes
and inflamed lymph nodes, a distinction that the standard PET tool for DLBCL,
[18F]fludeoxyglucose (FDG) could not make.
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8.3:

Clinical studies with [18F]PARPi (Future Directions)

Although clinical studies are underway for PARPi-FL in oral squamous cell carcinoma (OSCC,
NCT03085147), clinical studies for [18F]PARPi are still in the approval process. We have
successfully transitioned the synthesis into the radiopharmacy, and the clinical trial will probably
start sometime towards the end of 2017 or the beginning of 2018, so we will have to wait until
then to discover whether [18F]PARPi will be as useful in the clinical setting as it has been in the
preclinical setting.
8.4:

Conclusion

The development of PARP imaging agents is quite an interesting subject of study, and PARP
imaging has already shown itself to be highly valuable in the preclinical setting. The ultimate
goal, however, is to create an agent that is of some utility in the clinic. It is only our sincere belief
that one day, one of our PARP imaging agents could help extend the life or improve the quality
of life for a human being. It has been our great pleasure to work on these agents with this goal
in mind.
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CHAPTER 9: OTHER PROJECTS
Section 9.3 is an adaptation of published work, and is reproduced in part, from Büchel, G. E.,
Carney, B., Shaffer, T. M., Tang, J., Austin, C., Arora, M., Zeglis, B. M., Grimm, J., Eppinger, J.
& Reiner, T. Near-Infrared Intraoperative Chemiluminescence Imaging. ChemMedChem (2016).

9.1:

Introduction

In addition to the work that has been presented on PARP PET imaging agents, several other
projects warrant mention. These projects are at various stages of completion, and are on
diverse topics that did not quite fit into the [18F]PARPi narrative. However, the work is interesting
and is presented here for the sake of completeness and to highlight the highly collaborative
nature of the work being done between the laboratories at Hunter College and Memorial Sloan
Kettering.
9.2:

Rucaparib Fluorescence

Figure 9.2.1. Comparison of PARPi-FL and rucaparib in LX22 SCLC cells (see Chapter 6).
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During the course of the work on small cell lung cancer presented in Chapter 6, it was
discovered that one of the FDA approved PARP inhibitors, rucaparib, was indeed fluorescent
without any modifications to the structure necessary (Figure 9.2.1). Rucaparib has just been
approved by the FDA in 2017 for treatment of ovarian cancer1. PARPi-FL, which our lab has
used successfully as a PARP targeted fluorescent imaging agent for several years2–5, is based
on the FDA approved drug, olaparib, but is not yet itself FDA approved. The modification which
gives the molecule its fluorescent properties also slightly alters the PARP targeting properties of
the molecule (olaparib IC50 = 5 nM6, PARPi-FL IC50=12.2 nM3, see also the PARP family binding
assay, Chapter 6 section 2 and Figure 6.2.1). Rucaparib, by virtue of the fluorescence being an
inherent property of the original FDA approved therapeutic molecule, does not have these
potential drawbacks. In addition, PARPi-FL is nearly twice the size of rucaparib in terms of
molecular weight, and rucaparib is usually administered as either a phosphate or
camphoresulfonate (CSA) salt7. These factors are likely to give rucaparib vastly different
biophysical properties compared to either olaparib or PARPi-FL. These considerations amount
to strong motivation for the development of rucaparib as not only a therapeutic inhibitor, but as a
fluorescent imaging agent as well. The one obvious drawback to rucaparib’s fluorescence is
that, while for in vivo imaging near infrared (NIR, 700-1000 nm) wavelengths are ideal for
avoiding absorption by naturally occurring biological light absorbers (especially hemoglobin)8,
rucaparib’s highest wavelength absorption/excitation peak is well below this range at 360 nm
(although PARPi-FL also has a shorter than ideal absorption/excitation peak at around 500 nm,
which generally limits it to surface imaging in vivo, see Chapter 2, Section 2). This short
excitation wavelength potentially limits the clinical utility of rucaparib, but there is still much
possible usefulness for rucaparib in the preclinical setting with in vitro and ex vivo microscopy
studies, and we therefore set out, in collaboration with Michael Drain’s group at Hunter College,
to probe the fluorescent properties of the compound.
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Figure 9.2.2. Fluorescence properties of rucaparib compared to NATA. (a) Structures and
absorbance and emission spectra for both compounds at various concentrations. (b)
Comparison of absorbance and excitation spectra for both compounds.
Rucaparib’s fluorescence properties are probably due to the indole moiety inherent to the
original structure. Rucaparib has structural elements in common with the amino acid tryptophan,
which is also fluorescent owing to a similar indole moiety. We therefore set out to measure the
photophysical

properties

of

rucaparib

using

the

tryptophan

analogue

N-acetyl-L-tryptophanamide (NATA). In summary, we found that, in phosphate buffered saline
(PBS, pH=7.4) rucaparib has excitation maxima at 245, 270 and 360 nm with a single emission
peak with a maximum at 465 nm (Figure 9.2.2a and b). The quantum yield was 30%, and
therefore was higher than NATA’s reported value of 13%9,10. This is probably due to the
additional benzene ring that is conjugated with the indole moiety in rucaparib but not in NATA.
The excitation and emission maxima for rucaparib are also significantly red shifted compared to
NATA, which is probably also due to the additional benzene ring. The fluorescence lifetime for
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Figure 9.2.3. Dependence of rucaparib fluorescence on solvent properties.
rucaparib is quite similar to that of NATA, with a value of 6.8 ns.
Another widely explored property of tryptophan fluorescence is the variation of the quantum
yield based on what solvent is being used10. We sought to explore this property in rucaparib as
well and found varying fluorescence spectra depending on what solvent conditions were being
used. Specifically, we found that quantum yield, as a function of the emission peak height (no
quantum yields were actually calculated), dropped significantly as the solvent was made more
acidic (Figure 9.2.3).
In conclusion, this molecule presents an opportunity to utilize fluorescence microscopy
techniques for the exploration of PARP biology in vitro, and does so without any modifications
whatsoever on the structure of a compound that has already received FDA approval. This not
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only represents an extraordinary opportunity for preclinical science, but also presents clinical
applications in the areas of treatment monitoring on patient samples following PARP treatment.
9.3:
89

Eu-HOPO Lanthanide Luminescence

Zr based PET imaging has been in development for several years and was originally born out

of a desire to find a suitable PET active radioisotope for antibody based imaging11. The most
prominent chelator used for

89

Zr-antibody PET imaging is desferrioxamine (DFO), a chelator

originally used for iron. An important aspect of this is that DFO is six coordinate while Zr
chemistry seems to demand eight coordinate chelation11.
Indeed, DFT calculations suggest two additional water molecules to complete the coordination
sphere12, although no crystal structure has yet been reported. Some demetallation of

89

Zr-DFO

complexes does occur, and this is noticeable in PET imaging by the increase of bone signal
over time due to the natural accumulation of free Zr4+ ions in the bone. This has lead to efforts in

Figure 9.3.1. Harnessing lanthanide luminescence for 89Zr-HOPO based immuno-PET. (a)
Comparison of the 89Zr complex and the Eu complex. (b) Luminescence spectra. Modified and
reprinted from Abergel et al. J Med Chem, 2010.
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the labs of Lynn Francesconi to develop a new chelator more suitable for Zr chemistry, and one
chelator was originally designed for actinide sequestration15, but the octadentate chelator was
shown in small animal biodistribution studies to have superior in vivo stability when compared to
the hexadentate DFO14. Another well known characteristic of the HOPO ligand is its use as an
“antenna” for lanthanide luminescence16. An antenna is a chromophore that acts to collect the
energy from an excitation source and then transfers this energy to the metal which then
performs the light emission17. We sought, in collaboration with Lynn Francesconi’s group at
Hunter College, to use this antenna effect to quantify the number of HOPO chelators per
antibody for the 89Zr-HOPO based immuno-PET imaging (Figure 9.3.1).

Figure 9.3.2. Eu-HOPO Mass Spec.
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First, we performed the coordination chemistry with the chelator alone according to the
literature16, in methanol at 50 °C. However, we soon found that the synthesis worked well even
when performed in PBS at room temperature, and these conditions are better for the eventual
work with antibodies and were used for the luminescence experiments with the plate reader.
Luminescence readings from a SpectraMax® M5 Multi-Mode Microplate Reader confirmed that
the luminescence from the complex was bright enough to be measured by the plate reader and
that the signal increased, although not entirely linearly, with concentration of material. We also
saw that the Eu by itself only had negligible background signal, and that it was feasible to
synthesize the complex without purification for the purposes of the chelator measurements. With
this in mind, free EuCl3 was used for all the background measurements with the plate reader.
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Figure 9.3.3. Eu-HOPO lanthanide luminescence as measured on a SpectraMax® M5 MultiMode Microplate Reader. Eu-HOPO luminescence is clearly higher than background EuCl3
luminescence. This is visible on both a linear scale (top) and a log scale (bottom). The signal
increases with concentration (left), though not in a linear fashion at the concentrations studied.
Also visible is the increase in signal/background afforded by the long lifetime.
Signal/background can be increased by including a delay time (middle) or extending the
integration time (right).
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We were also able to detect the reported long (805 µs16) lifetime of the luminescent signal using
the “delay time” setting on the plate reader, which delays the detection of the emission for some
period after the excitation. This eliminates the signal from fluorescent agents, which typically
have much shorter emission lifetimes. We found that at a delay time of 50 µs eliminated 95% of
the background signal while the signal from the complex only reduced by 5%. This resulted in a
four fold increase in signal to background when a 50 µs delay time was used. Another way of
utilizing the long luminescent lifetime of the complex to increase signal to background is to
increase the amount of time the detector collects the luminescent signal. This setting is called
“integration time” on the plate reader. We found that, in comparison to a 50 µs integration time,
the signal collected from the complex was 10 times higher when an integration time of 1000 µs
was used.
In summary, this method could be used for chelator quantification, but there needs to be further
study, especially in regards to the linearity of the luminescent signal. This must be correlated to
the standard methods of chelator quantification such as MALDI-MS and the isotopic dilution
assay. Isotope dilution was used in determination of HOPO chelator to antibody14.
9.4:

Ru(bpy)3 Chemiluminescence imaging

The generation of an imaging signal through chemiluminescence is fundamentally different from
fluorescence imaging, as these chemiluminescent agents emit light without requiring an
excitation light source. Typically, chemiluminescence imaging is based on the detection of
photons produced as a by-product of the reduction/oxidation of a probe molecule. In biological
systems, chemiluminescence imaging has only briefly been touched upon18. The most notable
example is the injection of luminol into mice, which generates violet photons (424 nm) upon its
oxidation by endogenous myeloperoxidase19. Transition-metal-mediated chemiluminescence
has so far remained largely untapped by the molecular imaging community. Advantages of
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Figure 9.4.1. a) Structure, reactivity and absorbance and emission spectrum of the
chemiluminescent probe [Ru(bpy)3]2+. b) Design of the automatic nebulizer. c) Position of the
spray device inside an IVIS Spectrum bioluminescence imaging system. d) Generation of near
infrared light by nebulizing and spraying on an oxidizing agent.
chemiluminescence over other methods include: 1) no excitation light necessary; 2) no tissue
penetration issues for incident light; 3) unlike in Cherenkov, no radioactivity is needed,
eliminating exposure to patients and hospital personnel; 4) there are a large number of potential
in vivo chemiluminescence imaging agents available, ranging from small organic molecules and
transition-metal complexes to nanoparticles20,21, spanning wavelengths from the visible to the
near-infrared (NIR) spectrum; and 5) these imaging agents can easily be conjugated to
biologically active targeting molecules to target specific tissues, for example, which is one of the
fundamental requirements for a molecular imaging agent22. In conjunction with the labs of Brian
Zeglis at Hunter College, we set out in this proof-of-principle study to show that high signal-tonoise ratios can be achieved by detecting the NIR photon that is emitted from the
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oxidation/reduction cycle of the reporter, that intraoperative chemiluminescence imaging
reaches detection limits suitable for in vivo use, and that the biodistribution of a transition-metalbased chemiluminescent reporter can be visualized in vivo.
Figure 9.4.1a illustrates the generation and detection of a chemiluminescence signal under
conditions suitable for chemiluminescence imaging. Because application of the required
oxidation agent to sample tissue is essential to elicit chemiluminescence, we developed the
nebulizing device outlined in Figure 9.4.1b. It is designed to fit into a commercially available IVIS
Spectrum imaging system (Figure 9.4.1c) and can be operated remotely via a cable when the
IVIS Spectrum door is closed and camera shutters are open. The spray bottle contains an
aqueous solution of the oxidizing agent (NH3)2Ce(NO3)6 and is aimed toward the tissue sample,
a histological slide, or any other analyte (Figure 9.4.1d). Once a spray burst is released, the
surface of the tissue of interest is covered in (NH3)2Ce(NO3)6, which will oxidize the
chemiluminescent reporter contained in the tissue, prompting the emission of photons.
Alternatively,

if

the

(NH3)2Ce(NO3)6

solution

is

sprayed

on

a

region

lacking

any

chemiluminescent reporters, no photons will be generated. Chemiluminescent imaging is
therefore devoid of autofluorescence and allows the mapping of the distribution of the
chemiluminescent reporter close to the tissue surface.
We tested the general feasibility of chemiluminescent imaging in fresh tissues by injecting a
solution of [Ru(bpy)3]Cl2 (8–33 nmol in 100 mL PBS) intravenously in a set of healthy mice
(n=5); 10 min after injection, the mice were sacrificed, their body cavities were opened, kidneys
cut, and chemiluminescence was generated by spraying (NH3)2Ce(NO3)6 onto the body cavities.
Not surprisingly, large amounts of signal were localized to kidneys (Figure 9.4.2a) and liver,
whereas other organs did not emit significant chemiluminescence, indicating renal clearance of
[Ru(bpy)3]2+. Kidney chemiluminescence is far greater within the tissue than the tissue surface,
and organs did not emit chemiluminescence if not treated with the (NH3)2Ce(NO3)6

agent

(Figure 9.4.2b). Biodistribution of the reporter was established from a second cohort of mice
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(n=10), which underwent similar treatment. All major organs were excised, and the
chemiluminescence in each organ was quantified individually. Comparison with signals
generated when the animals were injected with PBS alone yields signal-to-noise ratios of 27/1
for kidney and 21/1 for liver (Figure 9.4.2c), and only moderate signal intensities were observed
for other organs. This confirms the observed renal localization of the [Ru(bpy)3]2+ reporter.
ICP-MS analyses of the mouse tissues further corroborated the chemiluminescence imaging
data (Figure 9.4.2d). We found that ruthenium concentrations correlate well with photon flux
rates, with the highest deposition in the kidneys (574 000 photons s-1cm-2sr-1 and 1.24 ± 0.25
mg·g-1), followed by liver tissue (260 000 photons s-1cm-2sr-1 and 256 ± 47 ng·g-1). Overall, this
indicates that chemiluminescence might not only be useful to detect the presence of

Figure 9.4.2. a) White light (left), chemiluminescence (center), and overlay (right) images of a
mouse body cavity injected with 33 nmol of [Ru(bpy)3]2+ in 100 mL PBS. The green arrows point
toward the right kidney. b) Images of excised kidneys are clearly visible in mice injected with the
ICI agent, but not when injected with PBS. c) Quantification of the imaging results shown in
panel a, with imaging quantification performed on excised organs. d) Quantification of ruthenium
metal concentrations in various tissues using ICP-MS. e) Correlation of chemiluminescent
photon flux and ICP-MS determined ruthenium concentrations.
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[Ru(bpy)3]2+ in vivo, but that this technique might ultimately be able to quantify concentrations
noninvasively.
9.5:

Experimental

9.5.1: Rucaparib Fluorescence
Commercially available compounds were used without further purification unless otherwise
stated. Rucaparib was purchased through SelleckChem and N-Acetyl-L-tryptophanamide
(NATA) purchased from Sigma Aldrich (St. Louis, MO, USA).
Sample preparation. Stock solutions of N-Acetyl-L-tryptophanamide (NATA, Sigma-Aldrich) in
water and rucaparib (Ruc) in 1x Dulbecco’s PBS were made at 500, 400, 300, 200 and 100 µM
concentration. Three mL of the corresponding solvents were used to obtain baseline spectra for
UV-vis and fluorescence spectroscopy, and then 50 µL aliquots of the stock solutions were
added to the same cuvettes used for the baselines (final concentrations: 1.64, 3.23, 4.76, 6.25
and 7.69 µM). This procedure generated a series of 5 sets of spectra (UV-vis, fluorescence
emission and fluorescence excitation) at varying concentrations for both compounds. For Ruc,
fluorescence lifetime measurements were also performed at each concentration for two different
emission wavelengths.
UV-Vis Spectrometry. UV-visible spectra were obtained on a Perkin-Elmer Lambda 35 UV-vis
spectrometer, scanning from 200 nm to 1000 nm, in 1 nm increments with a slit width of 1 nm.
Solutions were mixed directly in 1 cm pathlength quartz cuvettes, and these same cuvettes
were used for steady-state and time correlated fluorescence measurements.
Fluorescence Spectrometry. Steady-state fluorescence emission and excitation spectra were
obtained on a HORIBA Scientific FluoroLog-3 fluorometer. All spectra were corrected by
dividing by the wavelength dependent lamp intensity reference signal, and further baseline
corrected using the spectra of the pure solvents. For both the NATA and rucaparib samples,
emission spectra were obtained using a 290 nm (1 nm slit width) excitation wavelength and
scanning from 300 to 1000 nm (5 nm slit width). For rucaparib, additional emission spectra were
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obtained under almost identical conditions, but using 350 nm and 395 nm excitation
wavelengths. The NATA excitation spectra were obtained at an emission wavelength of 400 nm
(1 nm slit width), scanning from 200 to 390 nm (5 nm slit width). Rucaparib excitation spectra
were obtained similarly, but monitoring emission wavelengths of 450 nm and 500 nm.
Quantum yield calculations. Gradient plots of emission intensity (at the primary peak
wavelength) vs. absorbance (at the excitation wavelength, 290 nm) were made from data from
the absorbance and fluorescence emission measurements. The slopes from these plots, ∇F for
rucaparib, and ∇Fstd for NATA, along with the known quantum yield for NATA in H2O, φstd into
the following equation:

! = ! !!"#

∇!
∇!!"#

Where φ represents the quantum yield of rucaparib in PBS.
Fluorescence Lifetimes. Time correlated single photon counting (TCSPC) measurements
were recorded with the FluoroHub Tau-3 module for the same fluorometer, using a diode laser
source (NanoLED-405) with a pulse duration less than 200 ps. The excitation wavelength was
set to 395 nm (slit width 5 nm) and the emission wavelength was set to 450 nm or 500 nm (both
with 5 nm slit widths) to obtain two separate measurements for each sample concentration. The
recorded decay was fit to a monoexponential function using the Decay Analysis Software (v.
6.4) provided with the instrument.
9.5.2: Eu-HOPO Lanthanide Luminescence.
Commercially available compounds were used without further purification unless otherwise
stated. EuCl3 was purchased from Sigma Aldrich (St. Louis, MO, USA). 3,4,3-(LI-1,2hydroxypyridinone) (HOPO) was prepared as reported previously13, and provided by the labs of
Lynn Francesconi. Water (>18.2 MΩcm-1 at 25 °C) was obtained from an Alpha-Q Ultrapure
water system from Millipore (Bedford, MA, USA).
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Eu-HOPO Synthesis. Eu-HOPO was first prepared as reported previously16,23,24. Briefly, 1 mg
HOPO and 1 mg EuCl3 were combined in 1mL of pure MeOH and 2µL of pyridine were added.
The MeOH was then removed via vacuum and the unpurified product was used for HPLC and
LCMS analysis. Subsequently, the reaction was performed entirely in PBS. 1mg HOPO was
combined with 5 mg EuCl3 and shaken at 500rpm at room temperature for 5-10 min. The
product was used for the luminescence measurements without purification.
Luminescence Measurements. Lanthanide luminescence was measured in a 96-well plate
(Costar black clear bottom, company) with a path length of 0.3 cm for a volume of 100 µL
respectively. Measurements were made on a SpectraMax® M5 Multi-Mode Microplate Reader.
Samples were prepared via serial dilution to a final volume of 100 µL directly on the 96 well
plate. All studies were performed with excitation wavelength 325 nm and emission wavelength
610 nm. For the mass correlation study, the final concentration varied between 5 and 0.5 mM
(5.34, 2.67, 1.34, 0.67 mM). This study was performed without a delay time (0 µs) and the
maximum integration time (1500 µs). The delay time study was performed on the highest
concentration (5.34 mM) and maximum integration time (1500 µs). The delay time was varied
between 0 and 600 µs (the maximum value available). For the integration time study, again, the
highest concentration was used, but no delay time (0 µs) was used. The integration time was
varied from the lowest value (50 µs) to the highest value possible (1500 µs).
9.5.3: Ru(bpy)3 Chemiluminescence imaging
Commercially available compounds were used without further purification unless otherwise
stated.

Tris(2,2’-bipyridyl)dichloro

ruthenium(II)

hexahydrate

([Ru(bpy)3]Cl2·6H2O)

and

ammonium cerium(IV) nitrate (NH3)2Ce(NO3)6 were purchased from Sigma Aldrich (St. Louis,
MO, USA). Water (>18.2 MΩcm-1 at 25 °C) was obtained from an Alpha-Q Ultrapure water
system from Millipore (Bedford, MA, USA). High performance liquid chromatography (HPLC)
purification and analysis was performed on a Shimadzu UFLC HPLC system equipped with a
DGU-20A degasser, a SPD-M20A UV detector, a RF- 20Axs fluorescence detector, a LC-20AB
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pump system, and a CBM-20A communication BUS module. HPLC solvents (Buffer A: 0.1%
TFA in water, Buffer B: 0.1% TFA in MeCN) were filtered before use. HPLC analysis was
performed on a reversed phase Phenomenex Gemini column (C18, 5 µm, 4.6 mm, 250 mm).
Analysis were performed with this method: flowrate: 1 mL/min; gradient: 0-15 min 5-95% B; 1518 min 95% B; 18-20 min 100%-5% B).
Mouse Models All animal experiments were done in accordance with protocols approved by the
Institutional Animal Care and Use Committee of MSKCC and followed National Institutes of
Health guidelines for animal welfare. Female nude (outbred) mice at age 5 - 6 weeks and NU/J
male mice at age 6 – 8 were purchased from Taconic Laboratories (Hudson, NY, USA) and
Jackson Laboratories (Farmington, CT, USA) respectively.
Nebulizer Components 1 Harmon Face Values 3oz mini sprayer (Bed, Bath and Beyond, New
York, NY, USA); 1 Hitech HS-82MG Mirco Servo Motor, 3.4kg/cm output torque @ 6V (Hitech
RCD USA Inc., Poway, CA, USA); 1 Energizer 9V alkaline battery (Energizer Holdings Inc., St.
Louis, USA); 2 28 cm plastic cable ties (General Electric Inc., Fairfield, CT, USA); 1 role of duct
tape (3M Inc., St. Paul, MN, USA); 1 copper speaker cable 1m (RCA Inc., New York, NY, USA);
1 pencil Papermate Classic HB (Sanford L.P., Oak Brook, IL, USA); 1 littleBits w1 wire (littleBits,
New York, NY, USA); 1 littleBits p1 power (littleBits, New York, NY, USA); 1 littleBits i2 toggle
switch (littleBits, New York, NY, USA); 1 littleBits 011 servo (littleBits, New York, NY, USA); 3
Wood parts: 12.5x2.5x1.8 cm (A), 11x2.5x1.8cm (B), 12.7x10.7x1.8cm (C); 3 wood cutting
screws (4x25 mm); 1 paper clip (Staples, New York, NY, USA); 2 20 cm plastic covered wire
twist ties (Staples, New York, NY, USA); 1 10cm of 1/16” stainless steel rod (Metals Depot Int.
Inc., Winchester, KY, USA).
Nebulizer Construction Wood part A was attached upright in the center of part C using two
screws. Wood part B was attached to the middle of part A using one screw so the B can still be
moved a bit. Two holes were drilled trough the lower tip of the spray bottle trigger. The stainless
steel rod was pushed through to form two loops one on either side of the trigger. The spray
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bottle was attached to wood part B using the two plastic cable ties. The littleBits 011 servo
motor was cut off, and the cables of the littleBits servo control unit reconnected to the HS-82MG
servo motor. The servo motor was attached to the top of wood part A using duct tape. The
pencil was attached to the servo motor lever using the paper clip. The outermost parts of the
pencil were connected tightly to the steel rod loops using plastic covered twist wires. The
littleBits servo motor control units magnetic cable connector was cut off, reattached to the
speaker cable and taped to wood part C. A littleBits w1 cable was cut in half and one part
attached to the loose end from the speaker cable. The (magnetic) littleBits parts i2 and p1 were
connected to the available w1. Figure A.9.1 shows a photograph of the nebulizer.
In vivo chemiluminescence imaging after intravenous injection
In vivo chemiluminescence imaging was performed in female nude mice. Mice received
[Ru(bpy)3]Cl2 · 6H2O (20 µg, 27 nmol, in 100 µL, in sterile PBS) via tail vein injection after
sterilizing the tail with an alcohol pad. For all intravenous injections, mice were gently warmed
with a heat lamp and placed on a restrainer. The tails were sterilized with alcohol pads, and
injection took place via the lateral tail vein. Mice were sacrificed by CO2 asphyxiation at 10 min
p.i. The mouse abdomen were opened by a longitudinal cut and the organ of interest exposed
superficially cut. The IVIS bioluminescence reader was set up by initializing the Live Image 4.2
software. After signing in to the user profile the “Initialize” button was clicked in the acquisition
control panel. In the “Imaging Mode” “Luminescent” and “Photograph” were checked, and
“Fluorescent” was unchecked. “Exposure Time” setting for “Luminescent” was changed to 20
seconds. Remaining settings for “Luminescent” were set to “Binning”: Medium; “F/stop”: 1; and
“Emission Filter”: Open. Settings for “Photograph” were set to “Exposure Time”: Auto; “Binning”:
Medium; and “F/stop”: 8. “Subject Height” was adjusted according to imaging target. In the
“Field of View” drop down menu stage position was changed to “B”. The experiment was then
set up by placing the mouse carcass on a sheet of black construction paper on the floor of the
imaging chamber. The nebulizer was prepared by detaching the plastic spray bottle from the
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wooden support and filling it with a 25mM solution of (NH3)2Ce(NO3)6 in water before
reattachment. The nebulizer was placed inside the bioluminescence reader such that the spray
flow was pointed towards the area of interest on the imaging subject, and also such that the
nebulizer was not obstructing the camera’s field of view. Small black pieces of construction
paper were placed over any potential hot spots (e.g. injection sites). At least 40 cm of the
nebulizer remote chord were placed inside the IVIS chamber such that it did not interfere with
the imaging subject, nebulizer, or the magnetic door latch. After closing the instrument door
image sequences were acquired. After the camera shutter opened, three bursts of a solution of
(NH3)2Ce(NO3)6 in water were sprayed by remotely switching the nebulizer on/off three times
(0.24 ± 0.04 mL per spray burst). Quantification was performed the same way as for the
determination of the detection limit using Live Image 4.3 software. Control animals were injected
with PBS and treated the same way.
In vivo biodistribution Biodistribution studies were performed in female nude mice (n = 5).
Mice administered with [Ru(bpy)3]Cl2 · 6H2O (20 µg, in 100 µL, in sterile PBS) via tail vein
injection. Mice were sacrificed by CO2 asphyxiation at 10 min p.i. and major organs were
collected, sliced in half and sprayed with a solution of (NH3)2Ce(NO3)6 in water (25mM), using
the same protocol and settings as described in the in vivo ICI section. All images were
quantified using Live Image 4.3 software. ROIs were drawn over regions of interest and the
average flux was reported. For background determination PBS injected control animals were
used.
ICP-MS quantification Female athymic mice (n = 3) at 10 weeks of age (Taconic, Hudson, NY,
USA) were injected with [Ru(bpy)3]Cl2 · 6H2O (20 µg, in 100 µL, in sterile PBS) through tail
veins. One mouse was injected with 100 µl PBS. Mice were sacrificed by CO2 asphyxiation at
10 min p.i. and perfused with 20 ml PBS. Kidneys, liver, lungs, spleen, brain, heart, and femur
muscle were collected from each animal, weighed, and preserved at -20 °C before ICP-MS
analysis. Ruthenium (Ru) analysis and quantification was performed using inductively coupled
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plasma-mass spectrometry (ICP-MS). Tissues were weighed and acid digested before ICP-MS
analysis. For each gram of tissue, 2 mL of nitric acid and 1 mL of hydrogen peroxide was
added. Samples were left at room temperature for 2 days and vortexed to aid tissue breakdown
before the addition of hydrogen peroxide. After dilution in Milli-Q water, samples were
centrifuged and then analyzed using an Agilent Technologies 8800 ICP-MS. Indium was used
as an internal standard, added via t-piece before the nebulizer. Calibration standards were
prepared from

a 1000 µg/mL Ru certified reference material (Inorganic Ventures,

Christiansburg, VA, USA). Blanks were inserted during the run, and all reagents used were
ultra-trace grade.
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CHAPTER 3: APPENDIX

HPLC chromatograms of crude compound (Figure A.3.1)
HPLC chromatograms of purified compound (Figure A.3.2)
Mass Spectra (Figure A.3.3)
18

F-PARPi-FL fluorescence and emission spectra (Figure A.3.4)

PARPi-FL stability and formulation (Figure A.3.5)
Blood half life and bio distribution tumor/organ ratios (Figure A.3.6)
Values for the biodistribution studies (Table A.3.1)
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Figure A.3.1. Analytical HPLC trace of (a) absorbance and (b) radioactivity for the crude

reaction mixture before semi-prep HPLC purification.
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Figure A.3.2. HPLC chromatograms for PARPi-FL (a) before and (b) after isotope exchange
(after purification).
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Figure A.3.3. Mass Spectra for PARPi-FL (a) before and (b) after isotope exchange.
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Figure A.3.4. 18F-PARPi-FL fluorescence and emission spectra. Synthesized 18F-PARPi-FL was
injected onto a HPLC equipped with a fluorescence detector and excitation/emission spectra
recorded. Excitation spectrum collected at 515nm, emission spectrum excited at 498nm.
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Figure A.3.5. PARPi-FL stability and formulation. (b) Stability of 19F-PARPi-FL was checked by
HPLC. Chromatograms were acquired at 0 minutes and 24 hours after formulation and
compared with 19F-PARPi-FL QC. (b) 30% PEG300, 10% Captisol and 0.1M HCl were tested
as formulations for PARPi-FL. HPLC chromatograms were obtained at different time points (0,
1, 2, 4, 8, 12, 16, 24 h respectively) and PARPi-FL fraction collected and plotted as % of the
area of pure compound. (n=4) P < 0.05.
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Figure A.3.6. Blood half life and bio distribution tumor/organ ratios. (a) Ex-vivo blood half-life of
18
F-PARPi-FL (n=4). Blood was collected at different time points (5, 15, 30, 60, and 120 min),
weighed, and γ-counted. Results expressed as percent injected activity/gram (%ID/g); (b)
selected tumor to non-target tissues ratio of 18F-PARPi-FL.
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Organ

Non Blocked

Blocked

%ID/g

S.D.

%ID/g

S.D.

Tumor

0.79

0.09

0.15

0.05

Heart

0.23

0.04

0.22

0.10

Lung

0.43

0.11

0.42

0.18

Blood

0.42

0.19

1.03

1.20

Liver

3.80

0.39

2.33

0.56

Spleen

3.31

0.24

1.38

1.14

Pancreas

0.62

0.13

0.27

0.16

Kidney

0.76

0.13

0.49

0.15

SI

1.70

0.95

3.17

2.51

LI

2.19

3.03

0.35

0.16

Stomach

0.43

0.18

0.44

0.17

Bone

12.08

5.14

13.48

3.68

Muscle

0.20

0.04

0.24

0.07

Brain

0.07

0.00

0.09

0.01

Table A.3.1. Values for the biodistribution studies in Figure 3.5.1
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HPLC chromatograms for crude [18F]PARPi (Figure A.4.1)
HPLC chromatogram for purified 19F-PARPi (Figure A.4.2)
MS data for 19F-PARPi (Figure A.4.3)
1

H-NMR for 19F-PARPi (Figure A.4.4)

Values for the biodistribution studies (Table A.4.1)
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Figure A.4.1. HPLC chromatograms for crude [18F]PARPi
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!

Figure A.4.2. UV (254 nm) HPLC chromatogram for 19F-PARPi.
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Figure A.4.3. MS data for 19F-PARPi
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Figure A.4.4. 1H-NMR (500 MHz) for 19F-PARPi. In CDCl3
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Organ
Tumor
Heart
Lung
Blood
Liver
Spleen
Pancreas
Kidney
SI
LI
Stomach
Bone
Muscle
Brain
Lymph

Non Blocked
%ID/g
S.D.
1.82
0.21
0.30
0.08
0.44
0.11
0.41
0.09
3.98
0.56
4.04
1.23
1.71
0.41
1.17
0.46
2.94
0.91
2.24
0.59
0.73
0.30
1.21
0.24
0.37
0.09
0.04
0.01
2.80
0.51

Blocked
%ID/g
0.23
0.12
0.38
0.45
3.61
0.26
0.48
0.47
2.35
1.73
1.05
0.21
0.19
0.04
0.13

S.D.
0.09
0.03
0.07
0.36
2.04
0.09
0.25
0.22
0.70
0.80
0.58
0.10
0.08
0.03
0.03

Nodesfor the biodistribution studies in Figure 4.7.1.
Table A.4.1. Values
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PARP1 IHC staining (Figure A.5.1)
Histological characterization of GEMM tumor model and PARPi-FL localization (Figure A.5.2)
PET/CT whole body image of [18F]PARPi 2 h p.i. (Figure A.5.3)
PARP1 IHC of brain areas and relevant tissues and organs of ntv-a;p53fl/fl mice (Figure A.5.4)
Biodistribution of [18F]PARPi in healthy ntv-a;p53fl/fl mice 2 h p.i. (Figure A.5.5)
Values for the biodistribution studies (Table A.7.1)
Monitoring tumor growth using [18F]PARPi (Figure A.5.6)
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Figure A.5.1. PARP1 IHC staining.! (a) PARP1 staining of frontal cortex autopsy tissue of a
diffuse midline glioma patient. The corresponding H&E is from the same area as the PARP1
stained image. (b) Physiological, non-tumor related PARP1 expression was observed in the
brain of ntv-a;p53fl/fl mice in the Purkinje cell layer in the cerebellum and the dentate gyrus. (c)
Example of PARP1 and H&E staining of tumor bearing ntv-a; p53fl/fl mice injected with DF1 cells
at 4-6 weeks of age.
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Figure A.5.2. Histological characterization of GEMM tumor model and PARPi-FL localization.!
(a) The GEMM model showed heterogenous morphological characteristics, representing high
grade areas (with necrotic features, high cellularity, microvascular proliferation) and lower grade
areas (less cellular, no necrosis). PARP1 expression was more pronounced in high grade areas
compared to low grade areas and very low in normal pons. (b) Immunofluorescent
characterization of high grade and low grade tumor areas and healthy brain. Tissues were
stained for Ki67, CD31 and PARP1 expression.

!

156!

Figure A.5.3. Whole body PET/CT images of tumor bearing ntv-a;p53fl/fl mice
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Figure A.5.4. PARP1 IHC of brain areas and relevant tissues and organs of ntv-a;p53fl/fl mice
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Figure A.5.5. Biodistribution of [18F]PARPi in healthy ntv-a;p53fl/fl mice 2 h p.i. Animals were
injected with [18F]PARPi 2 hours prior to the biodistribution study (n=4). One group (n=4) was
injected with 1 mg olaparib 30min prior to the [18F]PARPi injection.
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Organ

Non Blocked

Blocked

%ID/g

S.D

%ID/g

S.D

Heart

0.14

0.02

0.14

0.06

Lung

0.40

0.05

0.34

0.10

Blood

0.22

0.12

0.20

0.05

Liver

2.61

0.24

2.51

0.54

Spleen

2.92

0.40

0.35

0.05

Pancreas

0.54

0.13

0.12

0.04

Kidney

0.53

0.04

0.45

0.10

SI

1.07

0.98

2.72

2.48

LI

0.98

0.24

1.35

0.54

Stomach

0.66

0.50

1.11

0.58

Bone

0.60

0.17

0.10

0.04

Muscle

0.13

0.05

0.07

0.01

Brain

0.03

0.00

0.06

0.07

Lymph

1.73

0.37

0.21

0.06

Salivary

0.61

0.13

0.19

0.06

Table A.5.1. Values for the biodistribution studies in Figure A.5.5.
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Figure A.5.6. Monitoring tumor growth using [18F]PARPi. (a) Adult animals were imaged weekly
after DF1 cell injection. Animals were sacrificed after week 6 and tumor presence was
confirmed histologically. (b) One animal showed no increase in [18F]PARPi uptake over the
weeks and we confirmed histologically that tumor development was absent in this case.
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CHAPTER 6: APPENDIX
Additional PARP family assays (Figure A.6.1)
Quantification of PARP expression from tissue microaarays (Figure A.6.2)
Additional biodistribution studies for different genetically modified mice (Figure A.6.3)
Values for the biodistribution studies (Table A.6.1)
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Figure A.6.1. Additional PARP family assays
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Figure A.6.2. Quantification of PARP expression from tissue microaarays.
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Figure A.6.3. Additional biodistribution studies for different genetically modified mice.

!

165!

Blood
3.35

0.81

0.59

0.57

0.90

0.30

0.18

1.35

0.60

0.42

0.10

0.09

0.21

0.20

0.88

2.28

0.43

0.58

2.00

0.20

0.00

0.26

0.29

0.05

0.04

0.22

0.08

0.17

0.10

1.25

1.12

0.23

0.10

1.47

0.19

0.00

0.00

0.01

0.85

0.51

0.04

0.03

0.21

0.04

3.23

0.34

1.24

0.87

0.38

1.61

0.94

0.42

0.16

0.11

0.74

%ID/g

0.01

0.28

0.26

0.13

0.20

0.10

0.47

0.26

0.11

0.04

0.03

0.24

S.D

0.01

0.05

0.12

0.04

0.58

0.92

0.61

0.84

0.12

0.05

0.15

0.09

0.11

%ID/g

0.00

0.01

0.03

0.02

0.19

0.58

0.48

0.15

0.06

0.01

0.05

0.02

0.04

S.D

Non Blocked
Blocked
Non Blocked
Blocked
Non Blocked
Blocked LX48
Healthy Nude Healthy Nude Healthy SCID Healthy SCID
LX48

Liver
3.82
0.23
1.12
0.62

0.00

0.31

0.05

0.00

0.06

0.00

Organ

Spleen
0.92
0.11
2.57
0.00

2.08

0.00

0.02

0.01

0.01

S.D

Kidney
2.30
0.51
0.07

0.15

0.11

0.00

0.09

0.02

%ID/g

SI
2.24
0.16
0.66

0.06

0.02

0.08

0.08

S.D

LI
0.88
2.04

0.12

0.00

0.22

0.07

%ID/g

Bone
12.64
0.14

0.02

0.01

0.40

S.D

Marrow
0.36
0.00

0.08

0.03

%ID/g

Muscle
0.03

0.24

0.10

S.D

Brain
1.78

0.10

%ID/g

Lymph
0.61

Tumor

Salivary

Table A.6.1. Values for the biodistribution studies.
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CHAPTER 7: APPENDIX

Verification of DLBCL model (Figure A.7.1)
Additional quantification for PET imaging studies (Figure A.7.1)
Additional data for biodistribution studies (Figure A.7.1)
Additional data for inflammation studies (Figure A.7.1)
Values for the biodistribution studies (Table A.7.1)
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Figure A.7.1. Verification of DLBCL model. (a) Weights of various organs, white blood cell
counts and platelet counts. n = 5/group. (b) Western blot of DLBCL cells from mouse spleens
and normal B cells from B6 mouse spleens. (c) Representative flow cytometry graphs show that
most immune cells (CD45+) in DLBCL mice express RFP and therefore derive from the
transplanted hematopoietic precursor cells (HPCs). (d) Representative H&E of superficial
cervical lymph nodes showing loss of germinal center integrity.
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Figure A.7.2. Additional quantification for PET imaging studies. (a) Correlation of radioactivity
measurement between in vivo PET imaging and ex vivo γ-counting (n = 7). (b) Accumulation of
[18F]PARPi per lymph nodes in DLBCL (n = 9) and B6 mice (n = 4) as measured by ex vivo γcounting.
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Figure A.7.3. Additional data for biodistribution studies. (a) Biodistribution in B6 mice showing
PARP1-specific accumulation in the lymph nodes, spleens, and salivary glands. B6 mice were
injected with [18F]PARPi (n = 4 ) or pre-blocked with olaparib (n = 3). (b) Representative
autoradiograms show [18F]PARPi uptake in the selected tissues in DLBCL and B6 mice injected
with [18F]PARPi and with olaparib blocking. (c) Representative histological images of the 5
tissues from DLBCL (n = 5) and B6 mice (n = 5). Consecutive sections were stained with
hematoxylin and eosin (H&E), PARP1, or RFP.
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Figure A.7.4. Additional data for inflammation studies. (a) (b) (c) Biodistribution of [18F]FDG in 5
selected tissues from DLBCL mice (n = 5), B6 mice with inflamed lymph nodes (LN) (n = 5), and
normal B6 mice (n = 5). (d) Biodistribution of [18F]PARPi in the same tissues from DLBCL mice
(n = 5), B6 mice with inflamed lymph nodes (n = 5), and normal B6 mice (n = 5).
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Organ

Non Blocked DLBCL

Blocked DLBCL

Healthy B6

%ID/g

S.D

%ID/g

S.D

%ID/g

S.D

Heart

0.75

0.32

0.04

0.01

0.07

0.01

Lung

3.38

2.89

0.08

0.02

0.07

0.01

Blood

1.55

0.95

0.13

0.05

0.12

0.03

Liver

8.48

3.64

1.41

0.28

1.59

0.53

Spleen

8.89

2.96

0.11

0.08

2.07

0.34

Pancreas

3.45

1.04

0.18

0.19

0.26

0.07

Kidney

4.54

2.56

0.24

0.09

0.30

0.06

SI

11.87

3.81

4.69

1.39

2.70

2.22

LI

3.07

1.57

0.28

0.05

2.17

1.39

Stomach

1.47

0.97

0.33

0.12

1.13

1.09

Bone

1.73

0.47

0.08

0.04

0.32

0.11

Muscle

0.49

0.15

0.04

0.01

0.19

0.17

Brain

0.10

0.03

0.02

0.00

0.02

0.01

Lymph

6.32

3.84

0.07

0.03

1.11

0.30

Salivary

3.67

0.90

0.05

0.02

0.29

0.07

Table A.7.1. Values for the biodistribution studies in Figure 5.7.1.
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CHAPTER 9: APPENDIX

Photograph of the Nebulizer (Figure A.9.1)
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Figure A.9.1: Photograph of the Nebulizer. Parts used: Wooden structure parts (A, B, C), spray
bottle (D), bent steel rod (E), duct tape (F), plastic cable ties (G), 011 servo connector part (H),
servo motor (I), pencil (J) held by bent paper clip (K), plastic covered wire twist ties (L) w1 wire
connector (M) and speaker cable (N) leading to the battery.
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